0001493152-23-029788.txt : 20230822 0001493152-23-029788.hdr.sgml : 20230822 20230822110745 ACCESSION NUMBER: 0001493152-23-029788 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20230531 FILED AS OF DATE: 20230822 DATE AS OF CHANGE: 20230822 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biopower Operations Corp CENTRAL INDEX KEY: 0001510832 STANDARD INDUSTRIAL CLASSIFICATION: FINANCE SERVICES [6199] IRS NUMBER: 274460232 STATE OF INCORPORATION: NV FISCAL YEAR END: 1130 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-172139 FILM NUMBER: 231191464 BUSINESS ADDRESS: STREET 1: 5379 LYONS RD. STREET 2: SUITE 301 CITY: COCONUT CREEK STATE: FL ZIP: 33073 BUSINESS PHONE: 954-509-9830 MAIL ADDRESS: STREET 1: 5379 LYONS RD. STREET 2: SUITE 301 CITY: COCONUT CREEK STATE: FL ZIP: 33073 10-Q 1 form10-q.htm
0001510832 false --11-30 Q2 0001510832 2022-12-01 2023-05-31 0001510832 2023-08-22 0001510832 2023-05-31 0001510832 2022-11-30 0001510832 us-gaap:NonrelatedPartyMember 2023-05-31 0001510832 us-gaap:NonrelatedPartyMember 2022-11-30 0001510832 us-gaap:RelatedPartyMember 2023-05-31 0001510832 us-gaap:RelatedPartyMember 2022-11-30 0001510832 us-gaap:SeriesAPreferredStockMember 2023-05-31 0001510832 us-gaap:SeriesAPreferredStockMember 2022-11-30 0001510832 us-gaap:SeriesCPreferredStockMember 2023-05-31 0001510832 us-gaap:SeriesCPreferredStockMember 2022-11-30 0001510832 2023-03-01 2023-05-31 0001510832 2022-03-01 2022-05-31 0001510832 2021-12-01 2022-05-31 0001510832 BOPO:SaleOfTokensMember 2023-03-01 2023-05-31 0001510832 BOPO:SaleOfTokensMember 2022-03-01 2022-05-31 0001510832 BOPO:SaleOfTokensMember 2022-12-01 2023-05-31 0001510832 BOPO:SaleOfTokensMember 2021-12-01 2022-05-31 0001510832 BOPO:SaleOfTokensRelatedPartyMember 2023-03-01 2023-05-31 0001510832 BOPO:SaleOfTokensRelatedPartyMember 2022-03-01 2022-05-31 0001510832 BOPO:SaleOfTokensRelatedPartyMember 2022-12-01 2023-05-31 0001510832 BOPO:SaleOfTokensRelatedPartyMember 2021-12-01 2022-05-31 0001510832 us-gaap:NonrelatedPartyMember 2023-03-01 2023-05-31 0001510832 us-gaap:NonrelatedPartyMember 2022-03-01 2022-05-31 0001510832 us-gaap:NonrelatedPartyMember 2022-12-01 2023-05-31 0001510832 us-gaap:NonrelatedPartyMember 2021-12-01 2022-05-31 0001510832 us-gaap:RelatedPartyMember 2023-03-01 2023-05-31 0001510832 us-gaap:RelatedPartyMember 2022-03-01 2022-05-31 0001510832 us-gaap:RelatedPartyMember 2022-12-01 2023-05-31 0001510832 us-gaap:RelatedPartyMember 2021-12-01 2022-05-31 0001510832 2021-11-30 0001510832 2022-05-31 0001510832 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-02-28 0001510832 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-02-28 0001510832 us-gaap:PreferredStockMember 2022-02-28 0001510832 BOPO:CommonStockPayableMember 2022-02-28 0001510832 us-gaap:CommonStockMember 2022-02-28 0001510832 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0001510832 us-gaap:RetainedEarningsMember 2022-02-28 0001510832 2022-02-28 0001510832 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2023-02-28 0001510832 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-02-28 0001510832 us-gaap:PreferredStockMember 2023-02-28 0001510832 BOPO:CommonStockPayableMember 2023-02-28 0001510832 us-gaap:CommonStockMember 2023-02-28 0001510832 us-gaap:AdditionalPaidInCapitalMember 2023-02-28 0001510832 us-gaap:RetainedEarningsMember 2023-02-28 0001510832 2023-02-28 0001510832 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-11-30 0001510832 us-gaap:PreferredStockMember 2021-11-30 0001510832 BOPO:CommonStockPayableMember 2021-11-30 0001510832 us-gaap:CommonStockMember 2021-11-30 0001510832 us-gaap:AdditionalPaidInCapitalMember 2021-11-30 0001510832 us-gaap:RetainedEarningsMember 2021-11-30 0001510832 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-11-30 0001510832 us-gaap:PreferredStockMember 2022-11-30 0001510832 BOPO:CommonStockPayableMember 2022-11-30 0001510832 us-gaap:CommonStockMember 2022-11-30 0001510832 us-gaap:AdditionalPaidInCapitalMember 2022-11-30 0001510832 us-gaap:RetainedEarningsMember 2022-11-30 0001510832 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-03-01 2022-05-31 0001510832 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-03-01 2022-05-31 0001510832 us-gaap:PreferredStockMember 2022-03-01 2022-05-31 0001510832 BOPO:CommonStockPayableMember 2022-03-01 2022-05-31 0001510832 us-gaap:CommonStockMember 2022-03-01 2022-05-31 0001510832 us-gaap:AdditionalPaidInCapitalMember 2022-03-01 2022-05-31 0001510832 us-gaap:RetainedEarningsMember 2022-03-01 2022-05-31 0001510832 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2023-03-01 2023-05-31 0001510832 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-03-01 2023-05-31 0001510832 us-gaap:PreferredStockMember 2023-03-01 2023-05-31 0001510832 BOPO:CommonStockPayableMember 2023-03-01 2023-05-31 0001510832 us-gaap:CommonStockMember 2023-03-01 2023-05-31 0001510832 us-gaap:AdditionalPaidInCapitalMember 2023-03-01 2023-05-31 0001510832 us-gaap:RetainedEarningsMember 2023-03-01 2023-05-31 0001510832 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-12-01 2022-05-31 0001510832 us-gaap:PreferredStockMember 2021-12-01 2022-05-31 0001510832 BOPO:CommonStockPayableMember 2021-12-01 2022-05-31 0001510832 us-gaap:CommonStockMember 2021-12-01 2022-05-31 0001510832 us-gaap:AdditionalPaidInCapitalMember 2021-12-01 2022-05-31 0001510832 us-gaap:RetainedEarningsMember 2021-12-01 2022-05-31 0001510832 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-12-01 2023-05-31 0001510832 us-gaap:PreferredStockMember 2022-12-01 2023-05-31 0001510832 BOPO:CommonStockPayableMember 2022-12-01 2023-05-31 0001510832 us-gaap:CommonStockMember 2022-12-01 2023-05-31 0001510832 us-gaap:AdditionalPaidInCapitalMember 2022-12-01 2023-05-31 0001510832 us-gaap:RetainedEarningsMember 2022-12-01 2023-05-31 0001510832 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-05-31 0001510832 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-05-31 0001510832 us-gaap:PreferredStockMember 2022-05-31 0001510832 BOPO:CommonStockPayableMember 2022-05-31 0001510832 us-gaap:CommonStockMember 2022-05-31 0001510832 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001510832 us-gaap:RetainedEarningsMember 2022-05-31 0001510832 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2023-05-31 0001510832 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2023-05-31 0001510832 us-gaap:PreferredStockMember 2023-05-31 0001510832 BOPO:CommonStockPayableMember 2023-05-31 0001510832 us-gaap:CommonStockMember 2023-05-31 0001510832 us-gaap:AdditionalPaidInCapitalMember 2023-05-31 0001510832 us-gaap:RetainedEarningsMember 2023-05-31 0001510832 BOPO:BioPowerCorporationMember 2011-01-06 0001510832 BOPO:ChiefExecutiveOfficerAndDirectorMember 2010-09-12 2010-09-13 0001510832 BOPO:HyFiMember 2021-06-28 2021-06-29 0001510832 BOPO:HyFiMember BOPO:HyFiTokensMember 2021-06-28 2021-06-29 0001510832 us-gaap:SeriesCPreferredStockMember 2021-06-29 0001510832 us-gaap:CommonStockMember 2021-06-28 2021-06-29 0001510832 us-gaap:SeriesCPreferredStockMember 2021-06-28 2021-06-29 0001510832 BOPO:ChinaEnergyPartnersLLCMember BOPO:RedemptionAgreementMember us-gaap:SeriesAPreferredStockMember 2021-06-29 0001510832 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember BOPO:TwoCustomersMember 2022-03-01 2022-05-31 0001510832 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember BOPO:FiveCustomersMember 2021-12-01 2022-05-31 0001510832 2021-07-27 0001510832 2021-07-28 0001510832 BOPO:CanadianInvestorMember 2022-03-03 2022-03-04 0001510832 BOPO:CanadianInvestorMember 2022-03-04 0001510832 BOPO:DiagonalLendingMember 2023-02-17 2023-02-17 0001510832 BOPO:DiagonalLendingMember 2023-02-17 0001510832 BOPO:DemandLoansMember 2023-05-31 0001510832 BOPO:DemandLoansMember srt:MinimumMember 2023-05-31 0001510832 srt:MaximumMember BOPO:DemandLoansMember 2023-05-31 0001510832 BOPO:DemandLoansMember 2022-12-01 2023-05-31 0001510832 BOPO:ReclassificationOfAccruedCompensationToNotesPayableMember 2023-05-31 0001510832 BOPO:ReclassificationOfAccruedCompensationToNotesPayableMember 2022-12-01 2023-05-31 0001510832 BOPO:DemandLoanAgreementsMember BOPO:ThirdPartyInvestorMember 2016-07-27 0001510832 BOPO:LenderMember 2012-01-07 0001510832 BOPO:LenderMember 2011-10-28 2012-01-07 0001510832 BOPO:ConvertibleDebtAgreementMember BOPO:ThirdPartyInvestorMember 2013-12-03 0001510832 BOPO:ConvertibleDebtAgreementMember BOPO:ThirdPartyInvestorOneMember 2015-07-30 0001510832 BOPO:ConvertibleDebtAgreementMember BOPO:ThirdPartyInvestorOneMember 2015-07-29 2015-07-30 0001510832 BOPO:ConvertibleDebtAgreementMember BOPO:ThirdPartyInvestorMember 2016-05-23 0001510832 BOPO:ConvertibleDebtAgreementMember BOPO:ThirdPartyInvestorMember 2016-05-22 2016-05-23 0001510832 BOPO:ConvertibleDebtAgreementMember BOPO:ThirdPartyInvestorTwoMember 2015-07-30 0001510832 BOPO:ConvertibleDebtAgreementMember BOPO:ThirdPartyInvestorTwoMember 2015-07-29 2015-07-30 0001510832 BOPO:ConvertibleDebtAgreementMember BOPO:ThirdPartyInvestorThreeMember 2015-07-30 0001510832 BOPO:ConvertibleDebtAgreementMember BOPO:ThirdPartyInvestorThreeMember 2015-07-29 2015-07-30 0001510832 2015-07-28 0001510832 BOPO:ThirdPartiesMember us-gaap:ConvertibleDebtMember 2023-03-01 2023-05-31 0001510832 BOPO:ThirdPartiesMember us-gaap:ConvertibleDebtMember 2022-12-01 2023-05-31 0001510832 BOPO:ThirdPartiesMember us-gaap:ConvertibleDebtMember 2022-03-01 2022-05-31 0001510832 BOPO:ThirdPartiesMember us-gaap:ConvertibleDebtMember 2021-12-01 2022-05-31 0001510832 srt:ChiefFinancialOfficerMember 2016-05-26 2016-05-27 0001510832 srt:ChiefFinancialOfficerMember 2016-05-27 0001510832 srt:ChiefFinancialOfficerMember 2016-06-01 2016-06-01 0001510832 srt:ChiefFinancialOfficerMember 2023-05-31 0001510832 srt:ChiefFinancialOfficerMember 2022-11-30 0001510832 srt:ChiefFinancialOfficerMember 2022-12-01 2023-05-31 0001510832 BOPO:DirectorOfBusinessStrategyMember 2016-05-26 2016-05-27 0001510832 BOPO:DirectorOfBusinessStrategyMember 2016-05-27 0001510832 BOPO:DirectorOfBusinessStrategyMember BOPO:ThreeNotesMember 2016-05-27 0001510832 BOPO:DirectorOfBusinessStrategyMember 2016-06-01 2016-06-02 0001510832 BOPO:DirectorOfBusinessStrategyMember 2016-06-01 2016-06-01 0001510832 BOPO:DirectorOfBusinessStrategyMember 2023-05-31 0001510832 BOPO:DirectorOfBusinessStrategyMember 2022-11-30 0001510832 BOPO:DirectorOfBusinessStrategyMember 2022-12-01 2023-05-31 0001510832 us-gaap:RelatedPartyMember us-gaap:InvestorMember 2016-11-30 0001510832 us-gaap:RelatedPartyMember us-gaap:InvestorMember 2016-11-29 2016-11-30 0001510832 srt:ChiefOperatingOfficerMember 2016-03-31 0001510832 srt:ChiefOperatingOfficerMember 2016-03-01 2016-03-31 0001510832 srt:ChiefOperatingOfficerMember 2016-03-02 0001510832 srt:ChiefOperatingOfficerMember 2016-05-18 0001510832 BOPO:ThirdPartyInvestorMember 2016-05-23 0001510832 BOPO:ThirdPartyInvestorMember 2016-05-23 0001510832 srt:ChiefOperatingOfficerMember 2016-05-23 0001510832 srt:ChiefOperatingOfficerMember 2016-05-31 0001510832 srt:ChiefOperatingOfficerMember 2016-05-31 2016-05-31 0001510832 srt:ChiefOperatingOfficerMember 2016-07-31 0001510832 srt:ChiefOperatingOfficerMember 2016-07-31 2016-07-31 0001510832 BOPO:RobertKohnMember 2021-06-29 0001510832 BOPO:RobertKohnMember 2023-05-31 0001510832 BOPO:RobertKohnMember 2022-11-30 0001510832 BOPO:HyFiTokensMember BOPO:TechnologyMember us-gaap:RelatedPartyMember 2020-12-01 2021-11-30 0001510832 BOPO:TechnologyMember us-gaap:RelatedPartyMember 2021-11-30 0001510832 BOPO:HyFiTokensMember BOPO:TechnologyMember BOPO:TroyMacDonaldMember 2020-12-01 2021-11-30 0001510832 BOPO:TechnologyMember us-gaap:RelatedPartyMember 2020-12-01 2021-11-30 0001510832 us-gaap:RelatedPartyMember 2021-11-30 0001510832 BOPO:SecuritiesPurchaseAgreementMember us-gaap:ConvertibleDebtMember BOPO:DiagonalLendingMember 2022-05-31 0001510832 BOPO:SecuritiesPurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember BOPO:DiagonalLendingMember 2022-08-05 0001510832 BOPO:SecuritiesPurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember BOPO:DiagonalLendingMember 2022-09-26 0001510832 BOPO:SecuritiesPurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember BOPO:DiagonalLendingMember 2022-05-31 0001510832 BOPO:SecuritiesPurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember BOPO:DiagonalLendingMember 2022-05-31 2022-05-31 0001510832 BOPO:PrepaymentPeriodOneMember 2023-05-31 0001510832 BOPO:PrepaymentPeriodTwoMember 2023-05-31 0001510832 BOPO:PrepaymentPeriodThreeMember 2023-05-31 0001510832 BOPO:ChinaEnergyPartnersNoteAmendmentMember 2021-06-29 0001510832 BOPO:ConsultantMember 2021-08-04 2021-08-05 0001510832 BOPO:ConsultantMember 2021-08-05 0001510832 BOPO:BaruchHalpernMember 2021-08-04 2021-08-05 0001510832 BOPO:BaruchHalpernMember 2021-08-05 0001510832 BOPO:RobertKohnMember 2021-08-04 2021-08-05 0001510832 BOPO:RobertKohnMember 2021-08-05 0001510832 BOPO:BonnieNelsonMember 2021-08-04 2021-08-05 0001510832 BOPO:BonnieNelsonMember 2021-08-05 0001510832 BOPO:HyFiMember us-gaap:SeriesCPreferredStockMember 2021-06-28 2021-06-29 0001510832 BOPO:MrComptonMember 2022-03-03 2022-03-05 0001510832 BOPO:RestrictedCommonStockMember 2022-06-25 2022-06-26 0001510832 BOPO:RestrictedCommonStockMember 2022-06-26 0001510832 us-gaap:SeriesCPreferredStockMember 2023-04-21 2023-04-21 0001510832 us-gaap:ShareBasedCompensationAwardTrancheOneMember us-gaap:SeriesCPreferredStockMember 2023-04-21 2023-04-21 0001510832 us-gaap:ShareBasedCompensationAwardTrancheTwoMember us-gaap:SeriesCPreferredStockMember 2023-04-21 2023-04-21 0001510832 us-gaap:ShareBasedCompensationAwardTrancheThreeMember us-gaap:SeriesCPreferredStockMember 2023-04-21 2023-04-21 0001510832 BOPO:ShareBasedCompensationAwardTrancheFourMember us-gaap:SeriesCPreferredStockMember 2023-04-21 2023-04-21 0001510832 BOPO:DigitalArtMember BOPO:SanctumAgreementMember 2022-04-05 2022-04-06 0001510832 BOPO:DigitalArtMember BOPO:SanctumAgreementMember 2022-04-04 2022-04-04 0001510832 BOPO:DigitalArtMember BOPO:SanctumAgreementMember 2022-05-19 2022-05-19 0001510832 BOPO:DigitalArtMember BOPO:SanctumAgreementMember 2022-07-01 2022-07-01 0001510832 BOPO:ILOAndMultiAgreementMember 2022-06-26 2022-06-26 0001510832 BOPO:ExclusiveLicenseOptionsYearOneMember BOPO:PIPAgreementMember 2022-06-26 0001510832 BOPO:ExclusiveLicenseOptionsYearFiveMember BOPO:PIPAgreementMember 2022-06-26 0001510832 BOPO:PIPAgreementMember 2022-06-26 2022-06-26 0001510832 BOPO:PIPAgreementMember 2022-06-26 0001510832 BOPO:PIPAgreementMember BOPO:RestrictedCommonStockMember 2022-06-25 2022-06-26 0001510832 BOPO:PIPAgreementMember BOPO:RestrictedCommonStockMember 2022-06-26 0001510832 BOPO:GenerationPowerGroupLimitedMember 2022-11-10 2022-11-11 0001510832 2022-11-10 2022-11-11 0001510832 2023-04-21 2023-04-21 0001510832 BOPO:MrWaltonMember srt:MinimumMember 2023-04-21 2023-04-21 0001510832 BOPO:MrWaltonMember 2023-03-01 2023-05-31 0001510832 BOPO:MrWaltonMember 2023-05-31 0001510832 us-gaap:ShareBasedCompensationAwardTrancheOneMember us-gaap:SeriesCPreferredStockMember BOPO:MrWaltonMember 2023-04-21 2023-04-21 0001510832 us-gaap:ShareBasedCompensationAwardTrancheTwoMember us-gaap:SeriesCPreferredStockMember BOPO:MrWaltonMember 2023-04-21 2023-04-21 0001510832 us-gaap:ShareBasedCompensationAwardTrancheThreeMember us-gaap:SeriesCPreferredStockMember BOPO:MrWaltonMember 2023-04-21 2023-04-21 0001510832 BOPO:ShareBasedCompensationAwardTrancheFourMember us-gaap:SeriesCPreferredStockMember BOPO:MrWaltonMember 2023-04-21 2023-04-21 0001510832 us-gaap:SubsequentEventMember BOPO:DiagonalLendingMember 2023-06-21 2023-06-22 0001510832 us-gaap:SubsequentEventMember BOPO:DiagonalLendingMember 2023-06-22 0001510832 us-gaap:SubsequentEventMember BOPO:DiagonalLendingMember 2023-06-26 2023-06-27 0001510832 us-gaap:SubsequentEventMember BOPO:DiagonalLendingMember 2023-06-27 0001510832 us-gaap:SubsequentEventMember BOPO:DiagonalLendingMember 2023-07-11 2023-07-12 0001510832 us-gaap:SubsequentEventMember BOPO:DiagonalLendingMember 2023-07-12 0001510832 us-gaap:SubsequentEventMember BOPO:DiagonalLendingMember 2023-07-13 2023-07-14 0001510832 us-gaap:SubsequentEventMember BOPO:DiagonalLendingMember 2023-07-14 0001510832 us-gaap:SubsequentEventMember BOPO:SecuritiesPurchaseAgreementMember BOPO:DiagonalLendingMember 2023-07-27 2023-07-28 0001510832 us-gaap:SubsequentEventMember BOPO:SecuritiesPurchaseAgreementMember BOPO:DiagonalLendingMember 2023-07-16 2023-07-17 0001510832 us-gaap:SubsequentEventMember BOPO:SecuritiesPurchaseAgreementMember BOPO:DiagonalLendingMember 2023-08-20 2023-08-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares BOPO:Integer xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended May 31, 2023

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____________ to ______________

 

Commission file number: 000-53274

 

BioPower Operations Corporation

(Exact name of registrant as specified in its charter)

 

Nevada   27-4460232
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

 

20801 Biscayne Blvd., Suite 403

Aventura, FL. 33180

 
  (Address of principal executive offices) (Zip Code)  

 

Registrant’s telephone number, including area code: (786) 923-0272

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No

 

As of August 22, 2023, the registrant had 47,538,859 shares of common stock outstanding.

 

Explanatory Note

 

 

 

 

 

 

BIOPOWER OPERATIONS CORPORATION

FORM 10-Q

 

TABLE OF CONTENTS

 

 

PAGE

NO.

PART I FINANCIAL INFORMATION  
       
  Item 1. Financial Statements  
    Consolidated Balance Sheets as of May 31, 2022 and November 30, 2021 (Unaudited) F-1
    Consolidated Statements of Operations for the Three Months ended May 31, 2022 and the Three Months ended May 31, 2021 (Unaudited) F-2
    Consolidated Statements of Cash Flows for the Three Months ended May 31, 2022 and the Three Months ended May 31, 2021 (Unaudited) F-3
    Consolidated Statements of Changes in Stockholders’ Deficit for the Three Months ended May 31, 2022 and November 30, 2021 (Unaudited) F-4
    Consolidated Notes to the Unaudited Financial Statements as of May 31, 2022 F-5
       
  Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 3
       
  Item 3. Quantitative and Qualitative Disclosures About Market Risk 7
       
  Item 4. Controls and Procedures 7
       
PART II OTHER INFORMATION 8
       
  Item 1. Legal Proceedings 8
       
  Item 1A. Risk Factors 8
       
  Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 8
       
  Item 3. Defaults Upon Senior Securities 8
       
  Item 4. Mine Safety Disclosures 8
       
  Item 5. Other Information 8
       
  Item 6. Exhibits 9
       
  SIGNATURES 10

 

2

 

 

BioPower Operations Corporation and Subsidiaries

Consolidated Balance Sheets

 

   May 31,   November 30, 
   2023   2022 
   (Unaudited)     
Assets          
Current assets          
Cash and cash equivalents  $-   $825 
Accounts receivable   331    331 
Inventory   12,893    12,893 
Total assets  $13,224   $14,049 
           
Liabilities and Stockholders’ Deficit          
Current liabilities          
Cash overdraft  $245   $- 
Accounts payable and accrued expenses   1,275,421    451,846 
Accounts payable and accrued expenses - related party   2,300,788    2,295,213 
Deferred revenue   375,000    375,000 
Notes payable   130,671    130,671 
Convertible debt variable priced conversion   211,750    157,167 
Convertible debt   368,031    368,031 
Convertible debt - related parties,   399,447    399,447 
Notes payable   193,667    193,667 
Notes payable - related parties   1,320,700    1,320,700 
Derivative liability   313,464    262,050 
Total current liabilities   6,889,184    5,953,792 
           
Commitments and Contingencies (Note 9)   -    - 
           
Stockholders’ deficit          
Preferred stock - Series A, $1.00 par value: 10,000 authorized, 0 and 1 shares issued and outstanding on May 31, 2023 and November 30, 2022, respectively   -    - 
Preferred stock - Series C, $.001 par value: 5,000,000 authorized, 900,000 and 0 shares issued and outstanding on May 31, 2023 and November 30, 2022, respectively   900    900 
Common Stock owed   125,000    125,000 
Common stock, $.0001 par value: 500,000,000 authorized;45,867,915 and 45,625,000 issued and outstanding on May 31 2023 and November 30, 2022, respectively   4,588    4,564 
Additional paid-in capital   8,730,014    4,279,317 
Accumulated deficit   (15,736,462)   (10,349,524)
Total stockholders ‘deficit   (6,875,960)   (5,939,743)
Total liabilities and stockholders’ deficit  $13,224    14,049 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-1

 

 

BioPower Operations Corporation and Subsidiaries

Consolidated Statements of Operations

(Unaudited)

 

   2023   2022   2023   2022 
   For the three Months Ended
May 31,
   For the Six Months ended
May 31,
 
   2023   2022   2023   2022 
Revenue:                    
Sale of Tokens   -    136,000    -    336,000 
Sale of Tokens - related party   -    110,700    -    110,700 
Total Revenue  $-   $246,700   $-   $446,700 
                     
Operating expenses                    
Development expense   248,773    -    681,139    - 
Selling, general and administrative expenses   4,446,448    212,443    4,497,298    363,868 
Total operating expenses   4,695,221    212,443    5,178,437    363,868 
                     
Income / (Loss) from operations   (4,695,221)   34,257    (5,178,437)   82,832 
                     
Other expenses                    
Loss on derivative   (16,900)   -    (66,590)   - 
Interest expense   (24,021)   (11,248)   (99,533)   (22,495)
Interest expense -related party   (21,189)   (36,147)   (42,378)   (72,295)
Total other expenses   (62,110)   (47,395)   (208,501)   (94,790)
                     
Net loss  $(4,757,331)  $(13,138)  $(5,386,938)  $(11,958)
                     
Net loss per common share: basic and diluted  $(0.10)  $(0.00)  $(0.12)  $(0.00)
                     
Weighted average common shares outstanding: basic and diluted   45,867,915    45,597,826    45,762,474    45,302,198 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-2

 

 

BioPower Operations Corporation and Subsidiaries

Consolidated Statements of Cash Flows

(Unaudited)

 

   2023   2022 
   For the Six Months ended May 31, 
   2023   2022 
Cash flows from operating activities          
Net loss  $(5,386,938)  $(11,958)
Adjustments to reconcile net loss to net cash used in operating activities          
Stock based compensation   4,423,545    - 
Amortization of debt discount   66,583    - 
Loss on derivative   66,590    - 
Adjustments to reconcile net loss to net          
Changes in operating assets and liabilities          
Increase in accounts receivable   -    (331)
Increase in prepaid expenses   -    (77,593)
Increase in inventory        (12,983)
Accounts payable and accrued expenses   823,575    (191,071)
Accounts payable and accrued expenses - related party   5,575    470,238 
Net cash used in operating activities   (1,070)   176,302 
           
           
Cash flow from financing activities          
Bank overdraft   245    - 
Proceeds from issuance of common stock   -    249,991 
Net cash provided by financing activities   245    249,991 
           
Net increase in cash and cash equivalents   (825)   426,293 
Cash and cash equivalents at beginning of period   825    95,973 
Cash and cash equivalents at end of period  $-   $522,266 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $-   $- 
Cash paid for income taxes  $-   $- 
           
Supplemental disclosure of cash flow information:          
Non-cash investing and financing activities:          
Conversion of Convertible debentures to common stock  $12,000   $- 
Derivative resolution  $15,176   $- 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-3

 

 

BioPower Operations Corporation and Subsidiaries

Consolidated Statements of Changes in Stockholders’ Deficit

For the Three and Six Months Ended May 31, 2023 and 2022

(Unaudited)

 

   Shares   Par   Shares   Par   Shares   Par   Shares   Par   Paid-in   Accumulated     
   Preferred Series C   Preferred Stock   Common Stock payable   Common Stock   Additional         
   Shares   Par   Shares   Par   Shares   Par   Shares   Par   Paid-in   Accumulated     
   Outstanding   Amount   Outstanding   Amount   Issuable   Amount   Outstanding   Amount   Capital   Deficit   Total 
Balance February 29, 2022        -          - -  900,000      900        -   $     -    45,000,000   $4,500   $4,140,411   $(9,555,809)  $(5,409,998)
Sale of common stock   -    -    -    -    -    -    625,000    63    249,928    -    249,991 
Net loss, for three months ended May 31, 2022   -    - -  -    -    -    -    -    -    -    (13,138)   (13,138)
Balance May 31, 2022   -   $- 1  900,000   $900    -   $-    45,625,000   $4,563   $4,390,339   $(9,568,948)  $(5,173,145)

 

   Preferred Series C   Preferred Stock   Common Stock payable   Common Stock   Additional         
   Shares   Par   Shares   Par   Shares   Dollar   Shares   Par   Paid-in   Accumulated     
   Outstanding   Amount   Outstanding   Amount   Issuable   Amount   Outstanding   Amount   Capital   Deficit   Total 
Balance February 29, 2023            -   $      - -  900,000   $900    500,000    125,000    45,867,915   $4,588   $4,306,469   $(10,979,131)  $(6,542,174)
Stock based compensation   -    -    -    -    -    -    -    -    4,423,545    -    4,423,545 
Net loss, for the three months ended May 31,2022   -    - -  -    -    -    -    -    -    -    (4,757,331)   (4,757,331)
Balance May 31, 2023   -   $- -  900,000   $900    500,000   $125,000    45,867,915   $4,588   $8,730,014   $(15,736,462)  $(6,875,960)

 

   Outstanding   Amount   Outstanding   Amount   Issuable   Amount   Outstanding   Amount   Capital   Deficit   Total 
   Preferred Stock - Series A   Preferred Stock   Common Stock payable   Common Stock   Additional         
   Shares   Par   Shares   Par   Shares   Dollar   Shares   Par   Paid-in   Accumulated     
   Outstanding   Amount   Outstanding   Amount   Issuable   Amount   Outstanding   Amount   Capital   Deficit   Total 
Balance November 30, 2021         1   $      1 -  900,000   $900    -   $-    45,000,000   $4,500   $4,140,411   $(9,556,990)  $(5,411,178)
Sale of common stock   -    -    -    -              625,000    63    249,928    -    249,991 
Net loss, six months ended May 31, 2022   -    - -  -    -    -    -    -    -    -    (11,958)   (11,958)
Balance May 31, 2022   1   $1 -  900,000   $900    -   $-    45,625,000   $4,563   $4,390,339   $(9,568,948)  $(5,173,145)
                                                        
Balance November 30, 2022   -    - -  900,000    900    500,000    125,000    45,625,000    4,564    4,279,317    (10,349,524)   (5,939,743)
Conversion of notes payable   -    -    -    -    -    -    242,915    24    11,976    -    12,000 
Derivative resolution   -    -    -    -    -    -    -    -    15,176    -    15,176 
Stock based compensation                                           4,423,545         4,423,545 
Net loss, Six months ended May 31, 2023   -    - -  -    -    -    -    -    -    -    (5,386,938)   (5,386,938)
Balance May 31, 2023   -   $- -  900,000   $900    500,000   $125,000    45,867,915   $4,588   $8,730,014   $(15,736,462)  $(6,875,960)

 

F-4

 

 

BioPower Operations Corporation and Subsidiaries

Notes to Unaudited Consolidated Financial Statements

May 31, 2023

 

Note 1. Organization

 

BioPower Corporation (“BioPower” or the “Company”) was incorporated in the State of Florida on September 13, 2010. On January 5, 2011, the Company re-domiciled to Nevada and formed BioPower Operations Corporation, a Nevada corporation. On January 6, 2011, the shareholders of BioPower Corporation contributed their shares of BioPower Corporation to BioPower Operations Corporation and BioPower Corporation became a wholly owned subsidiary.

 

On October 24, 2014, the Company executed a Share Exchange Agreement (“SEA”) with Green3Power Holdings Company (“G3P”) to acquire G3P and its wholly owned subsidiaries Green3Power Operations Inc., a Delaware corporation (“G3P OPS”), and Green3Power International Company, a Nevis corporation (“G3PI”). This transaction was a stock for stock exchange (the “Exchange”), which was accounted for as an acquisition and recorded as an expense based on the fair value of the Company’s common stock as of the date of the exchange. Also exchanged was one share of the Company’s Series B preferred stock, which is convertible into common shares two years from the date of the SEA, if certain milestones are met as required by the SEA. No value was attributed to the preferred share. We conduct all of our operations through G3P and its subsidiaries which are primarily engaged in the development of waste-to-energy projects and services including design, permitting, equipment procurement, construction management and operations and maintenance of the intended facilities. We intend to hold equity interests in the waste-to-energy facilities on a global basis and operate and maintain the facilities. A second business unit is focused on providing waste remediation services globally.

 

The Company’s fiscal year end is November 30.

 

On January 6, 2011, we acquired 100% of BioPower Corporation (“BC”), a Florida corporation incorporated on September 13, 2010, by our then-CEO and Director contributing 100% of the outstanding shares to the Company. As a result, BC became a wholly owned subsidiary of the Company.

 

On October 24, 2014, the Company entered into the SEA with G3P to acquire G3P and its wholly owned subsidiaries, G3P OPS and G3PI through the Exchange.

 

By October 24, 2016, G3P had failed to meet the provisions of the SEA that would allow G3P to take over control of the Company. As a result, the Company’s Board of Directors tried to come to an arrangement to separate BioPower from its subsidiaries, but in the end, decided that it would be in the best interests of the Company’s shareholders to move forward looking for a new acquisition. From October 24, 2016 until February 2017, the Company continued project development of waste-to-energy projects with extremely limited funds. In February 2017, the Company ceased all operations. At that time, we became a shell company.

 

On June 29, 2021, we entered into an Asset Purchase Agreement (the “APA”) with Rafael Ben Shaya, Troy MacDonald, Adam Benchaya, Thomas Perez, Tom Saban and Edouard Pouchoy (collectively, Messrs. Ben Shaya, MacDonald, Benchaya, Perez, Saban and Pouchoy are referred to herein as the “Sellers”).

 

Pursuant to the terms of the APA, the Company agreed to acquire from the Sellers, and the Sellers agreed to sell to the Company, certain assets comprised of the goodwill, intellectual property, business proprietary know-how and trade secrets, intangible property and other assets of Sellers’ business with respect to HyFi, and any and all rights of Sellers in and to the foregoing (the “Assets”), and certain governance/utility virtual tokens (collectively, the “HyFi Tokens”) expected to be used as a means of payment on the HyFi Platform, as hereinafter defined (the “Acquisition”). The “HyFi Platform” refers to the HyFi Decentralized Finance (“DeFi”) exchange marketplace using blockchain platform technology. The DeFi principles are based on an ecosystem of financial services utilizing tokenization and non-fungible tokens (“NFTs”) in connection with qualifying products, licenses and projects.

 

F-5

 

 

In addition, the Sellers agreed to (i) pay to the Company, on the closing date of the Acquisition, $300,000 (the “Cash Consideration”), and (ii) transfer to the Company, on the closing date of the Acquisition, 400,000,000 HyFi Tokens (the “HyFi Token Consideration”). The Company used the Cash Consideration to bring the Company into a fully reporting status with the Securities and Exchange Commission (the “SEC”) and for public company operating expenses.

 

Pursuant to the terms of the APA, the Company agreed to file with the State of Nevada the certificate of designation for the Series C preferred stock on or before the date that is 60 calendar days after the closing of the Acquisition. In exchange for the sale of the Assets and the Cash Consideration, the Company agreed to issue to the Sellers an aggregate of 900,000 Series C preferred shares within 30 calendar days after the State of Nevada provides written confirmation of filing of the certificate of designation for the Series C preferred stock.

 

Pursuant to the terms of the APA, the parties agreed that the Series C preferred stock will have the following terms, among others:

 

1. Authorized Shares of Series C Preferred Stock. The number of authorized shares of Series C preferred stock will be 900,000.

 

2. Conversion. Subject to the other terms and conditions in the certificate of designation, a Series C preferred stockholder will have the right from time to time and at any time following the date that is one year after the date on the signature page of the certificate of designations to convert each outstanding share of Series C preferred stock into 450 shares of Company common stock. Based on the number of shares of common stock issued and outstanding as of June 29, 2021, if all of the 900,000 shares of Series C preferred stock are issued and subsequently converted, the holders of the converted stock will hold 90% of the issued and outstanding shares of common stock.

 

3. Voting. Except as otherwise set forth in the certificate of designation, each share of Series C preferred stock will, on any matter submitted to the holders of Company common stock, or any class thereof, for a vote, vote together with the common stock, or any class thereof, as applicable, as one class on such matter, and each share of Series C preferred stock will have 450 votes.

 

4. Dividends. The Series C preferred stock is not entitled to receive dividends or distributions.

 

The Acquisition closed on June 29, 2021 (the “Closing Date”). On the Closing Date, the Sellers delivered the Cash Consideration and the HyFi Token Consideration.

 

On August 27, 2021, the Company filed with the State of Nevada a certificate of designations for the Series C preferred stock.

 

Series A Preferred Stock Redemption Agreement & Senior Promissory Note

 

Also on the Closing Date, the Company and CEP entered into a share redemption agreement (the “Redemption Agreement”), dated as of June 29, 2021, pursuant to which the Company redeemed one share of the Company’s Series A preferred stock from CEP (the “Series A Share”). On the Closing Date, as provided in the Redemption Agreement, the Company issued to CEP a senior promissory note (the “Note”) in the principal amount of $1,000,000. The Series A Share will be held in escrow. If an Event of Default (as defined in the Note) occurs under the Note, then the Company will direct the escrow agent to release the Series A Share to CEP; provided, however, that CEP will also retain all rights and privileges under the Note (and the Company will remain bound to all obligations under Note) even if the Series A Share is required to be released by the escrow agent to CEP as provided in the Redemption Agreement. For the avoidance of doubt, CEP will regain all rights, title, and interest in and to the Series A Share upon the occurrence of an Event of Default under the Note, regardless of the amount of the outstanding balance owed under the Note at the time of the occurrence of an Event of Default under the Note.

 

F-6

 

 

On October 7, 2021, the Company filed a certificate of amendment (the “Certificate of Amendment”) to its amended and restated articles in the State of Nevada and with FINRA, in order to change its corporate name from BioPower Operations Corporation. to HyFi Corp (the “Name Change”). The State of Nevada has officially changed the name of the Company to HYFI Corp. The Name Change and stock symbol change will be effective for Securities and Exchange Commission or trading purposes until it is cleared by the Financial Industry Regulatory Authority (FINRA).

 

Note 2. Summary of Significant Accounting Policies

 

Management’s Representation of Interim Financial Statements

 

The accompanying unaudited consolidated financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the SEC. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These consolidated financial statements include all of the adjustments, which in the opinion of management are necessary to a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements filed as part of the Company’s Annual Report on Form 10-K with the SEC on June 15, 2023.

 

Principles of Consolidation

 

All inter-company accounts and transactions have been eliminated in consolidation.

 

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (the “ASC”) which is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with GAAP.

 

Going Concern

 

The accompanying unaudited consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these financial statements. The Company has incurred significant operating losses since inception. As of May 31, 2023, the Company had an accumulated deficit of $15,736,462 and stockholders’ deficit of $6,875,960.

 

Because the Company does not expect that existing operational cash flow will be sufficient to fund presently anticipated operations, this raises substantial doubt about the Company’s ability to continue as a going concern. Therefore, the Company will need to raise additional funds and is currently exploring alternative sources of financing. Historically, the Company has raised capital through private placements, as an interim measure to finance working capital needs and may continue to raise additional capital through the sale of common stock or other securities and obtaining some short-term loans. The Company will be required to continue to so until its operations become profitable. Also, the Company has, in the past, paid for consulting services with its common stock to maximize working capital, and intends to continue this practice where feasible.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

 

F-7

 

 

Accounts Receivable

 

Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. If market conditions decline, actual collection experience may not meet expectations and may result in decreased cash flows and increased bad debt expense.

 

The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made.

 

Inventory

 

Inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out basis and net realizable value. Net realizable value is defined as sales price less cost of completion, disposition and transportation and a normal profit margin. As of May 31, 2023 and November 30, 2022, inventory amounted to $12,893 and $12,893, respectively, which consisted of finished goods.

 

Revenue Recognition

 

On July 1, 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Results for reporting periods beginning after January 1, 2018, are presented under ASC 606.

 

On June 29, 2021, the Sellers agreed to (i) pay to the Company, on the closing date of the Acquisition, $300,000 (the “Cash Consideration”), and (ii) transfer to the Company, on the closing date of the Acquisition, 400,000,000 HyFi Tokens (the “HyFi Token Consideration”). The Company used the Cash Consideration to bring the Company into a fully reporting status with the SEC and for public company operating expenses.

 

Concentration

 

Two customers, including one related party, account for 100% of sales during the three months ended May 31, 2022.

 

Five customers, including two related parties, account for 100% of sales during the six months ended May 31, 2022.

 

Cash and cash equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On May 31, 2023 the Company had a cash overdraft of $245 and on November 30, 2022, the Company’s cash equivalents totaled $825.

 

Income taxes

 

The Company accounts for income taxes under FASB ASC 740, “Accounting for Income Taxes”. Under FASB ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. FASB ASC 740-10-05, “Accounting for Uncertainty in Income Taxes,” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.

 

F-8

 

 

The amount recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company assesses the validity of its conclusions regarding uncertain tax positions quarterly to determine if facts or circumstances have arisen that might cause it to change its judgment regarding the likelihood of a tax position’s sustainability under audit.

 

Stock-based Compensation

 

The Company accounts for stock-based compensation using the fair value method following the guidance outlined in Section 718-10 of the ASC for disclosure about stock-based compensation. This section requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). That cost will be recognized over the period during which an employee is required to provide service in exchange for the award- the requisite service period (usually the vesting period). No compensation cost is recognized for equity instruments for which employees do not render the requisite service.

 

Net Loss per Share

 

Net loss per common share is computed by dividing net loss by the weighted average common shares outstanding during the period as defined by ASC Topic 260, “Earnings per Share.” Basic earnings per common share calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

 

Recent Accounting Pronouncements

 

In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which establishes a new lease accounting model for lessees. The updated guidance requires an entity to recognize assets and liabilities arising from financing and operating leases, along with additional qualitative and quantitative disclosures. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, with early adoption permitted. In March 2019, the FASB issued ASU 2019-01, Codification Improvements, which clarifies certain aspects of the new lease standard. The FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases in July 2018. Also in 2018, the FASB issued ASU 2018-11, Leases (Topic 842) Targeted Improvements, which provides an optional transition method whereby the new lease standard is applied at the adoption date and recognized as an adjustment to retained earnings. The amendments have the same effective date and transition requirements as the new lease standard.

 

We adopted ASC 842 on July 1, 2021. The adoption of ASC 842 did not have any impact on our financial statements.

 

Stockholders’ Equity

 

On July 28, 2021, the Company amended and restated its articles of incorporation, as amended, in order to, among other things, (i) increase the number of authorized shares of common stock from 100,000,000 to 500,000,000, (ii) increase the number of authorized shares of preferred stock from 10,000 to 5,000,000, and (iii) change the par value of the preferred stock from $1.00 par value per share to $0.0001 par value per share. As of November 30, 2021, the Company had authorized 500,000,000 shares of common stock, $0.0001 par value per share, and 5,000,000 shares of preferred stock, $0.0001 par value per share.

 

On March 4, 2022, the Company issued 625,000 shares of restricted common stock to a Canadian investor for $0.40 per share for a total purchase price of $250,000.

 

F-9

 

 

On February 17, 2023 Diagonal converted $12,000 of principal into 242,915 shares of common stock at the price of $0.0494. The Company recorded a dividend resolution of $15,176.

 

As of May 31, 2023, and November 30, 2022, respectively, there were 45,867,915 and 45,625,000 shares of common stock issued and outstanding, respectively, and 900,000 and 1 shares and 0 shares of preferred stock issued and outstanding, respectively.

 

Note 3. Notes Payable and Convertible Debt

 

Notes payable consists of the following:

 

   Balance   Interest Rate   Maturity 
Demand loans  $551,167    4% to 8%   Various
Reclassification of accrued compensation to notes payable  143,031    8%   December 1, 2017  
Balance –May 31, 2023 and November 30, 2022  $694,198           

 

As of May 31, 2023 and November 30, 2022, all loans are past due and in default.

 

On July 27, 2016, the Company entered into demand loan agreements with a third-party investor totaling $193,667 at 4% interest, payable upon demand.

 

Between October 28, 2011 and January 7, 2012, the Company issued a total of $70,000 in notes payable, due May 31, 2012. Interest on the notes is payable at 4%. The lender may elect to convert the loan before maturity at a conversion price of $0.25 per share. The loans are currently past due.

 

On December 3, 2013, the Company entered into convertible debt agreements with a third-party investor totaling $62,500 at 8% interest, payable upon demand. The debt is convertible into shares of common stock at a conversion price of $0.10 per share, for any amount up to 50% of the original amount of the notes. As of May 31, 2023 and November 30, 2022, the note was in default.

 

On July 30, 2015, the Company entered into convertible debt agreements with a third-party investor totaling $200,000 at 8% interest, due on December 31, 2015. The debt is convertible into shares of common stock at a conversion price of $0.15 per share. As of May 31, 2023 and November 30, 2022, the note was in default.

 

On May 23, 2016, the Company entered into convertible debt agreements with a third-party investor totaling $25,000 at 8% interest, due on May 23, 2018. The debt is convertible into shares of common stock at a conversion price of $0.10 per share. As of May 31, 2023 and November 30, 2022, the note was in default.

 

On July 30, 2015, the Company entered into convertible debt agreements with a third-party investor totaling $15,000 at 8% interest, due on May 23, 2018. The debt is convertible into shares of common stock at a conversion price of $0.15 per share. As of May 31, 2023 and November 30, 2022, the note was in default.

 

On July 30, 2015, the Company entered into convertible debt agreements with a third-party investor totaling $15,000 at 8% interest, due on May 23, 2018. The debt is convertible into shares of common stock at a conversion price of $0.15 per share. As of May 31, 2023 and November 30, 2022, the note was in default.

 

Between December 3, 2014 and July 28, 2015, the Company issued a total of $113,031 in notes payable. Interest on the notes is payable at 8%. The loans were due prior to December 31, 2015 and are past due.

 

Accrued interest on notes payable and convertible debt at May 31, 2023 and November 30, 2022 amounted to $365,107 and $275,071, respectively, which is included as a component of accounts payable and accrued expenses.

 

Interest expense on notes payable and convertible debt with third parties amounted to $11,247, $22,494, $11,247 and $22,494 for the three and six months ended May 31, 2023 and May 31, 2022 respectively.

 

F-10

 

 

Note 4. Related Party Transactions

 

On May 27, 2016, the former Chief Executive Officer, now our Chief Financial Officer, agreed to reduce his accrued compensation by $206,250 as a contribution to additional paid in capital. He also agreed to reclassify $874,000 in accrued compensation to long term debt upon the issuance of a non-convertible 4% interest bearing note with a maturity date of December 1, 2017. The compensation included was accrued during the period from January 2, 2011 to February 29, 2016. This compensation will be paid as bonuses out of future income only and is further subject to a cap of 20% of operating net cash flow in any given period. If bonuses are paid, accrued compensation will be paid with an amount decided by the Board. On June 1, 2016, he agreed to reduce his accrued compensation by $25,000 as a contribution to additional paid in capital. He also agreed to reduce his long term note by $214,000 as a contribution to additional paid in capital. As the Company was not funded prior to December 1, 2016, the Board of Directors reversed the contribution of accrued salaries. As of May 31, 2023 and November 30, 2022, the Chief Financial Officer was owed $445,250 and $445,250, respectively, of accrued compensation and accrued salary was reduced by $15,722.47. As of May 31, 2023 and November 30, 2022, the Chief Financial Officer was owed $805,637 and $805,637, respectively, of notes payable and accrued interest.

 

On May 27, 2016, the Director of Strategy agreed to reduce her accrued compensation by $206,250 as a contribution to additional paid in capital. She also agreed to reclassify $660,000 in accrued compensation to long term debt upon the issuance of a non-convertible 4% interest bearing note with a maturity date of December 1, 2017. The total principal amount of $710,000 included three different notes totaling $50,000@ 8% interest. The compensation included was accrued during the period from January 2, 2011 to February 29, 2016. This compensation will be paid as bonuses out of future income only and is further subject to a cap of 20% of operating net cash flow in any given period. If bonuses are paid, accrued compensation will be paid with an amount decided by the Board. On June 1, 2016, she agreed to reduce her accrued compensation by $225,000 as a contribution to additional paid in capital. She also agreed to reduce her long term note by $9,583 as a contribution to additional paid in capital. As the Company was not funded prior to December 1, 2016, the Board of Directors reversed the contribution of accrued salaries. As of May 31, 2023 and November 30, 2022, the Director was owed a total of $440,833 and $440,833, respectively, of accrued compensation. As of May 31, 2023 and November 30, 2022, the Director was owed a total of $883,791 and $883,791, respectively, of notes payable and accrued interest. There was a reduction in the liability by share issuance of $27,308.

 

As of November 30, 2016, a related party investor advanced a total of $99,448 due on or before June 15, 2016. Pursuant to the agreement, the investor is allowed to convert 100% of the debt at a share price of $0.15. As of May 31, 2023 and November 30, 2022, the note was in default.

 

In March 2016, the Chief Operating Officer loaned to the Company $100,000. The loan bears interest at 8% and is due on or before March 2, 2018. Pursuant to the agreement, the investor is allowed to convert 100% of the debt on the maturity date at a share price of $0.15. The Company accounted for the conversion of loan in accordance with ASC 470, “Debt with Conversion and Other Options”. The fair market value of the shares on March 2, 2016 was $0.10 per share and, accordingly, there was deemed to be no Beneficial Conversion Factor. On May 18, 2016, the Chief Operating Officer loaned the Company an additional $50,000 with conversion rights at $0.10 per share. Therefore, effective May 18, 2016, $50,000 of the Chief Operating Officer’s note payable had conversion rights of $0.10 per share. The Company accounted for the conversion of loan in accordance with ASC 470, “Debt with Conversion and Other Options”. The fair market value of the shares on May 18, 2016 was $0.10 per share and accordingly there was deemed to be no Beneficial Conversion Factor. On May 23, 2016, a third-party investor loaned the Company $25,000 with conversion rights at $0.10 per share. Therefore, effective May 23, 2016, an additional $25,000 of the Chief Operating Officer’s $100,000 note payable had conversion rights of $0.10 per share. The Company accounted for the conversion of loan in accordance with ASC 470, “Debt with Conversion and Other Options”. The fair market value of the shares on May 18, 2016 was $0.10 per share and accordingly, was deemed to have no Beneficial Conversion Factor. As of May 31, 2023 and November 30, 2022, the note was in default.

 

In May 2016, the Chief Operating Officer made a loan of $50,000, bearing interest at 8% and due on or before May 18, 2018. The debt is convertible into shares of common stock at a conversion price of $0.10 per share. As of May 31, 2023 and November 30, 2022, the note was in default.

 

F-11

 

 

In July 2016, the Chief Operating Officer made a loan of $50,000 as collateral, bearing interest at 8% and due on or before July 31, 2018. The debt is convertible into shares of common stock at a conversion price of $0.10 per share. As of May 31, 2023 and November 30, 2022, the note was in default.

 

On June 29, 2021 the Company entered into an employment agreement with Robert Kohn. The Company agreed to an annual salary of $150,000 beginning on September 30, 2021. Mr. Kohn resigned on November 15, 2022. As of May 31, 2023 and November 30, 2022 the Company accrued $168,750 and $168,750, respectively.

 

During the year ended November 30, 2021 the Company issued 17,500,000 HyFi Tokens to related parties for the purchase of technology. The Technology has a historical value of $0. In addition, the Company issued Troy MacDonald 175,000 HyFi Tokens as consideration for his sale of HyFi tokens at 5% of the related token sales.

 

Accrued interest on related party notes payable and convertible debt at May 31, 2023 and November 30, 2022, amounted to $611,290 and $568,912, respectively, and is a component of accounts payable and accrued expenses – related parties.

 

The Company has separated accounts payable and accrued expenses on the balance sheet to reflect amounts due to related parties primarily consisting of officer compensation, health insurance, interest on notes and reimbursable expenses to officers for travel, meals and entertainment, vehicle and other related business expenses.

 

Convertible Loans – variable priced conversion

 

Note 5. Convertible loans

 

Diagonal Lending Securities Purchase Agreement & Convertible Note

 

On May 31, 2022, the Company entered into a Securities Purchase Agreement (the “Diagonal Lending SPA”) by and between the Company and 1800 Diagonal Lending LLC (“Diagonal Lending”). Pursuant to the terms of the Diagonal Lending SPA, the Company agreed to sell, and Diagonal Lending agreed to purchase, a convertible note of the Company in the aggregate principal amount of $90,000. On August 5, 2022 the Company borrowed an additional $78,750 with similar terms. On September 26, 2022 the Company borrowed an additional $55,000 with similar terms

 

On May 31, 2022 ,August 5, 2022 and September 26, 2022, pursuant to the terms of the Diagonal Lending SPA, the Company issued to Diagonal Lending a convertible promissory note (the “Diagonal Lending Note”) in the principal amount of $90,000, $78,750 and $55,000, respectively. The Diagonal Lending Note was funded on June 23, 2022, August 5th, 2022 and November 6, 2022. The Diagonal Lending Note bears interest at a rate of 10% per annum and matures 180 days after issuance. The Diagonal Lending Note may not be prepaid in whole or in part except as otherwise explicitly set forth in the Diagonal Lending Note. Any amount of principal or interest which is not paid when due will bear interest at a rate of 22% per annum.

 

Diagonal Lending has the right from time to time, and at any time following November 27, 2022 and ending on the earlier of (i) payment of all amounts due under the Diagonal Lending Note, (ii) May 31, 2023, if all amounts are repaid in full at such time, or (iii) the date full repayment of all indebtedness to convert all or any part of the indebtedness into common stock subject to the terms of the Digital Lending Note at the Conversion Price (as hereinafter defined). The “Conversion Price” means 65% multiplied by the lowest trading price for the Company’s common stock during the 10 trading day period ending on the latest complete trading day prior to the conversion date, subject to a 4.99% equity blocker and subject to the terms of the Diagonal Lending Note.

 

The Diagonal Lending Note may be prepaid; provided, however, that if the Company exercises its right to prepay, the Company will make payment to Diagonal Lending of an amount in cash equal to the percentage as set forth in the table below, multiplied by the sum of: (w) the then outstanding principal amount of the Diagonal Lending Note, plus (x) accrued and unpaid interest on the unpaid principal amount of the Diagonal Lending Note, plus (y) default interest, if any, on the amounts referred to in clauses (w) and (x) plus (z) certain other amounts owed to Diagonal Lending pursuant to the terms of the Diagonal Lending Note.

 

F-12

 

 

Prepayment Period  Prepayment Percentage 
May 31, 2022 to July 30, 2022   120%
July 31, 2022 to October 28, 2022   125%
October 29, 2022 to November 27, 2022   130%

 

After November 27, 2022, prepayment will be subject to agreement of the parties with respect to the applicable prepayment percentage.

 

On February 17, 2023 Diagonal converted $12,000 of principal into 242,915 shares of common stock at the price of $0.0494. The Company recorded dividend resolution of $15,176.

 

Note 6. Senior Promissory Note – related party

 

On June 29, 2021, the Closing Date, the Company and CEP entered into the Redemption Agreement, dated as of June 29, 2021, pursuant to which the Company redeemed the Series A Share. On the Closing Date, as provided in the Redemption Agreement, the Company issued to CEP the Note in the principal amount of $1,000,000 with an interest rate of 6% per annum. The Series A Share will be held in escrow. If an Event of Default (as defined in the Note) occurs under the Note, then the Company will direct the escrow agent to release the Series A Share to CEP; provided, however, that CEP will also retain all rights and privileges under the Note (and the Company will remain bound to all obligations under Note) even if the Series A Share is required to be released by the escrow agent to CEP as provided in the Redemption Agreement. For the avoidance of doubt, CEP will regain all rights, title, and interest in and to the Series A Share upon the occurrence of an Event of Default under the Note, regardless of the amount of the outstanding balance owed under the Note at the time of the occurrence of an Event of Default under the Note.

 

On June 22, 2022, the Company entered into the Addendum and Amendment of Promissory Note (the “Note Amendment”) by and between the Company and China Energy Partners, LLC (“China Energy”). Pursuant to the terms of the Note Amendment, the Company and China Energy agreed to amend the Senior Promissory Note issued by the Company to China Energy on June 29, 2021 (the “China Energy Note”) such that (i) the principal amount and accrued interest under the China Energy Note will be repaid in full on or before June 28, 2022, with $800,000 to be paid in cash and $200,000 to be paid via the transfer to China Energy of tokens to an electronic wallet; and (ii) the parties agree that $60,000 in interest previously accrued under the China Energy Note was satisfied via the transfer by the Company to China Energy of 53 HyFi NFT Athena vaults.

 

On June 28, 2022, the China Energy Note, as amended by the Note Amendment, was paid in full.

 

Note 6. Stockholders’ deficit

 

On August 5, 2021, Company effected the following share issuances:

 

The Company issued 50,000 shares of common stock valued at $2,500 ($0.05 per share) to a consultant.

 

The Company issued 750,000 shares of common stock valued at $37,500 ($0.05 per share) to Baruch Halpern for severance compensation.

 

The Company issued 546,160 shares of common stock valued at $27,307 ($0.05 per share) to Robert Kohn for partial conversion of accrued compensation.

 

The Company issued 546,160 shares of common stock valued at $27,307 ($0.05 per share) to Bonnie Nelson for partial conversion of accrued compensation.

 

On the Closing Date, the Company and CEP entered into the Redemption Agreement, dated as of June 29, 2021, pursuant to which the Company redeemed the Series A Share. On the Closing Date, as provided in the Redemption Agreement, the Company issued to CEP the Note in the principal amount of $1,000,000 with an interest rate of 6% per annum. The Series A Share will be held in escrow. If an Event of Default (as defined in the Note) occurs under the Note, then the Company will direct the escrow agent to release the Series A Share to CEP; provided, however, that CEP will also retain all rights and privileges under the Note (and the Company will remain bound to all obligations under Note) even if the Series A Share is required to be released by the escrow agent to CEP as provided in the Redemption Agreement. For the avoidance of doubt, CEP will regain all rights, title, and interest in and to the Series A Share upon the occurrence of an Event of Default under the Note, regardless of the amount of the outstanding balance owed under the Note at the time of the occurrence of an Event of Default under the Note.

 

F-13

 

 

On June 29, 2021, the Sellers agreed to (i) pay to the Company, on the closing date of the Acquisition, $300,000 (the “Cash Consideration”), and (ii) transfer to the Company, on the closing date of the Acquisition, 400,000,000 HyFi Tokens (the “HyFi Token Consideration”). The Company used the Cash Consideration to bring the Company into a fully reporting status with the SEC and for public company operating expenses.

 

In exchange for the sale of the Assets and the Cash Consideration, the Company agreed to issue to the Sellers an aggregate of 900,000 Series C preferred shares within 30 calendar days after the State of Nevada provides written confirmation of filing of the certificate of designation for the Series C preferred stock.

 

Pursuant to the terms of the APA, the parties agreed that the Series C preferred stock will have the following terms, among others:

 

1. Authorized Shares of Series C Preferred Stock. The number of authorized shares of Series C preferred stock will be 900,000.

 

2. Conversion. Subject to the other terms and conditions in the certificate of designation, a Series C preferred stock holder will have the right from time to time and at any time following the date that is one year after the date on the signature page of the certificate of designations to convert each outstanding share of Series C preferred stock into 450 shares of Company common stock. Based on the number of shares of common stock issued and outstanding as of November 30, 2021, if all of the 900,000 shares of Series C preferred stock are issued and subsequently converted, the holders of the converted stock will hold 90% of the issued and outstanding shares of common stock.

 

3. Voting. Except as otherwise set forth in the certificate of designation, each share of Series C preferred stock will, on any matter submitted to the holders of Company common stock, or any class thereof, for a vote, vote together with the common stock, or any class thereof, as applicable, as one class on such matter, and each share of Series C preferred stock will have 450 votes.

 

4. Dividends. The Series C preferred stock is not entitled to receive dividends or distributions.

 

On August 27, 2021, the Company filed with the State of Nevada a certificate of designations for the Series C preferred stock.

 

On July 28, 2021, the Company amended and restated its articles of incorporation, as amended, in order to, among other things, (i) increase the number of authorized shares of common stock from 100,000,000 to 500,000,000, (ii) increase the number of authorized shares of preferred stock from 10,000 to 5,000,000, and (iii) change the par value of the preferred stock from $1.00 par value per share to $0.0001 par value per share. As of November 30, 2021, the Company had authorized 500,000,000 shares of common stock, $0.0001 par value per share, and 5,000,000 shares of preferred stock, $0.0001 par value per share. As of May 31, 2022, and November 30, 2021, respectively, there were 45,625,000 and 45,000,000 shares of common stock issued and outstanding, and 900,000 and 1 shares and 0 shares of preferred stock issued and outstanding, respectively.

 

On March 5, 2022, the Company entered into a Stock Purchase Agreement (the “Compton SPA”) by and between the Company and Clarke Compton. Pursuant to the terms of the Compton SPA, the Company agreed to sell, and Mr. Compton agreed to purchase 625,000 shares of the Company’s common stock for a total purchase price of $250,000.

 

On June 26, 2022 PIP agreed to purchase, and the Company agreed to sell 500,000 shares of restricted common stock at a purchase price of $0.25 per share. As of May 31, 2023 and November 30, 2022 the shares have not been issued by the transfer agent

 

F-14

 

 

On April 21, 2023 the Company awarded 112,346 of the Company’s ‘C’ class preference shares to an employe the vesting schedule is :

 

On signing this agreement (April 21, 2023)   28,088 ‘C’ class preference shares
After 6 months (October 21, 2023)   28,086 ‘C’ class preference shares
After 12 months (April 21, 2024)   28,086 ‘C’ class preference shares
After 18 months (October 21, 2024)   28,086 ‘C’ class preference shares

 

During the three months ended May 31, 2023 the Company recorded an expense of $4,423,545 for the vested portion of the awards. The remaining unamortized amount of $7,709,607 will be amortized over the vesting period.

 

Note 8. Commitments and Contingencies

 

Commitments

 

On April 6, 2022, the Company entered into an agreement (the “Sanctum Agreement”) with Sanctum Studios (“Sanctum”) relating to The Athena Project. Pursuant to the terms of the Sanctum Agreement, Sanctum agreed to conceptualize, create and produce a collection of 20,000 digital art assets based on the Greek Goddess Athena, in exchange for payment by the Company of $121,000 and certain variable rate payments depending on the number of vaults sold by the Company. The $121,000 is payable by the Company in three equal installments of $40,333.33 due on April 4, 2022, May 19, 2022 and July 1, 2022. The Company paid all installments due through August 31, 2022. The Sanctum deliverables are due by July 1, 2022 or earlier, as set forth in the Sanctum Agreement. The Company announced this material definitive agreement and associated Press Release, incorporated by reference, on a Current Report on Form 8-K which was filed with the SEC on April 7, 2022.

 

PIP North America ILO and Multi-Agreement

 

On June 26, 2022 , the Company entered into an ILO and Multi-Agreement (the “PIP Agreement”) with PIP North America Inc. (“PIP”). Pursuant to the terms of the PIP Agreement, the parties agreed as follows:

 

1. The Company agreed to provide PIP the exclusivity to list the first initial license offering (“ILO”) for a minimum of 90 days. PIP can mutually agree to allow the Company to list another ILO during this period and PIP will receive 50% of gross revenues.

 

2. PIP will not pay any listing fee for its first three ILOs, and the Company will provide free consulting services to help structure the ILOs.

 

3. The Company agreed to provide services necessary from Super How for the customization of the HyFi technology for the first three PIP ILOs, including smart contracts for each listing.

 

4. The Company agreed to provide, at the Company’s cost, Prime Trust for anti-money laundering (AML) and know your customer (KYC) services, including processing of the payments, conversion of tokens to fiat currency for the use by the ILO issuer and all other services necessary for any ILOs, projects or bridge loans that PIP agrees to list on HyFi marketplaces to raise capital.

 

5. The Company agreed to provide PIP with Exclusive License options for one-year $1 million an option for an additional year for $10 million for the agriculture category on the HyFi DeFi marketplaces. Whoever brings the issuer will receive 75% of the gross revenues and whoever does not bring the issuer will receive 25% of the gross revenues. The option for the one-year exclusive must be exercised while the first PIP ILO is listed on the HyFi ILO marketplace and, once exercised, will last for one year. Within 90 days of the expiration of the one-year exclusive license, PIP must exercise the license for the second year.

 

F-15

 

 

6. PIP agreed to pay the Company 5% of gross sales of PIP vaults plus usual and customary percentages charged by third party vendors for the vault program.

 

7. PIP agreed to purchase, and the Company agreed to sell 500,000 shares of restricted common stock at a purchase price of $0.25 per share. As of November 30, 2022 the shares have not been issued by the transfer agent.

 

8. PIP agreed to purchase, and the Company agreed to sell 3,125,000 HyFi tokens at a purchase price of $0.04 per token for $125,000. The HyFi tokens can be used as utility tokens in conjunction with HyFi DeFi marketplace fees and services, HyFi vaults, HyFi memberships and any other HyFi fees and services. As of November 30, 2022 the HyFi tokens have not been delivered.

 

9. The Company agreed to grant PIP an option to purchase up to 50 HyFi vaults for $1,000. The option will expire on August 30, 2022.

 

10. The Company agreed to provide a license for the HyFi Vault Program, a blockchain promotional and marketing program, and services necessary from third party vendors, including Super How and Sanctum Studios.

 

11. In exchange for the above, PIP agreed to pay to the Company $500,000. The Company agreed to use this payment as part of the payments to retire the China Energy Note, as amended.

 

On November 11, 2022, the Company entered into an agreement with Generation Power Group Limited. The Company agreed to act as a non-exclusive placement agent in connection with an offering to investors of up to an aggregate of $100,000,000 of securities. The Company will receive the following:

 

  (a) Company Onboarding & Due Diligence Fee. The Company will receive a non-refundable Onboarding fee of $125,000 upon execution of this Agreement.

 

  (b) Placement Fee. The Company will receive a cash placement fee equal to 4% of the aggregate gross proceeds received from Investors that the Company originated. The Company will receive placement fee equal to 2% of the aggregate gross proceeds received from Investors that Generation Power Group Limited originate.

 

  (c) Expenses. The Company will receive promptly reimburse upon request for reasonable out-of-pocket expenses incurred by the Company in connection with the services provided hereunder, including, without limitation, travel costs, Site maintenance, and other customary expenses for this type of engagement, including, without limitation, out-of-pocket legal or regulatory fees, costs and expenses (including without limitation, any Offering-related regulatory filing fees and reasonable out-of-pocket counsel or consultant fees, related to the review of Offering Materials for compliance with applicable SEC/FINRA rules).

 

  (d) All fees and expenses payable hereunder are net of all applicable withholding and similar taxes.

 

The term of this Agreement shall be from the date hereof until the earlier of: (i) 12 months from the date hereof; or (ii) the date of the closing of the Offering as agreed by HYFI and the Company. The engagement hereunder will commence upon the execution of this Agreement by both parties, and shall be terminable by either party, with or without cause, on 30 days’ prior written notice to the other.

 

As of November 30, 2022, the Company has recorded the Onboarding & Due Diligence Fee as deferred revenue.

 

On November 15, 2022, Robert Kohn resigned as Chief Financial Officer of the Company and as a member of the Company’s Board of Directors, effective immediately. Mr. Kohn’s resignation was not because of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Effective November 15, 2022, the Board appointed Paul Christopher Walton to serve as the Company’s Chief Operating Officer, as well as the Company’s principal financial officer and principal accounting officer.

 

F-16

 

 

Mr.Walton, Since September 2022, Mr. Walton has served as Chief Operating Officer of HyFi, helping to review its security token and renewable green energy financing business. He is responsible for developing the regulated financial infrastructure which will enable HyFi to raise capital for its clients, as well as attending to key operational responsibilities.

 

For the past five years Mr. Walton advised several start-up fintech businesses to raise capital, arrange operations and develop business invest management and alternative investing markets. This work involved regulated blockchain and cryptocurrency businesses as well as style-based investment technology. At Optimal Asset Management, Mr. Walton grew assets and helped to develop a business which was eventually sold to BNY Mellon.

 

Prior to this, Mr. Walton advised on a substantial portion of new technology and new product development at the London Stock Exchange’s New York operation, FTSE Russell for two periods between 2009 and 2017. Mr. Walton also ran business development for renowned economist, Mr. Stephen Ross, at his Ross, Jeffrey and Antle hedge fund, for a four-year period, helping to grow assets substantially.

 

Mr. Walton worked for a number of leading investment banks in London over three decades from the 1980s to the early 2000’s. In this work, Mr. Walton was a highly rated financial analyst and investment strategist at the Warburg’s private bank, Schroders private bank, Goldman Sachs, Schroder Salomon Smith Barney, and Merrill Lynch.

 

Mr. Walton received a Master’s Degree in Economics from the University of London and Bachelor’s Degree in Economics from the Victoria University of Manchester. Mr. Walton studied advanced management principles at the UK-based Ashridge Business School. For most of his career, Mr. Walton held regulatory qualifications administered by the then UK supervisory body, Financial Services Authority.

 

Effective April 21, 2023 The Company and Paul Walton entered into a one year employment agreement.

 

The Company shall pay the Executive as compensation for his services during the first twelve (12) months of his Employment a base salary at a gross annual rate of $180,000. Such salary shall be payable either when:

 

i.the Company receives net investment of at least $1,000,000 or,
ii.the Company receives net income of at least $1,000,000.

 

Mr. Walton shall be awarded 112,346 of the Company’s ‘C’ class preference shares on signing this agreement according to the following vesting schedule:

 

On signing this agreement (April 21, 2023)   28,088 ‘C’ class preference shares
After 6 months (October 21, 2023)   28,086 ‘C’ class preference shares
After 12 months (April 21, 2024)   28,086 ‘C’ class preference shares
After 18 months (October 21, 2024)   28,086 ‘C’ class preference shares

 

During the three months ended May 31, 2023 the Company recorded an expense of $4,423,545 for the vested portion of the awards. The remaining unamortized amount of $7,709,607 will be amortized over the vesting period.

 

Contingencies

 

From time to time, the Company may be involved in legal matters arising in the ordinary course of business. While the Company believes that such matters are currently not material, there can be no assurance that matters arising in the ordinary course of business for which the Company is, or could be, involved in litigation, will not have a material adverse effect on its business, financial condition or results of operations.

 

Note 9. Subsequent Events

 

On June 22, 2023 Diagonal converted $25,000 of principal into 253,036 shares of common stock at the price of $0.0988.

 

On June 27, 2023 Diagonal converted $25,000 of principal into 300,120 shares of common stock at the price of $0.0833.

 

On July 12, 2023 Diagonal converted $22,000 of principal into 637,019 shares of common stock at the price of $0.0416.

 

On July 14, 2023 Diagonal converted $20,000 of principal into 480,769 shares of common stock at the price of $0.0416.

 

On June 28, 2023, the Company entered into a Securities Purchase Agreement by and between the Company and Fast Capital LLC. Pursuant to the terms of the Diagonal Lending SPA, the Company agreed to sell, and Diagonal Lending agreed to purchase, a convertible note of the Company in the aggregate principal amount of $75,000. The Note is convertible at 65% of the lowest trading price of the Common Stock as reported on the National Quotations Bureau OTC.

 

On July 17, 2023, the Company entered into a Securities Purchase Agreement by and between the Company and 1800 Diagonal Lending LLC. Pursuant to the terms of the Diagonal Lending SPA, the Company agreed to sell, and Diagonal Lending agreed to purchase, a convertible note of the Company in the aggregate principal amount of $55,000. See note 5 for terms.

 

On August 21, 2023, the Company entered into a Securities Purchase Agreement by and between the Company and 1800 Diagonal Lending LLC. Pursuant to the terms of the Diagonal Lending SPA, the Company agreed to sell, and Diagonal Lending agreed to purchase, a convertible note of the Company in the aggregate principal amount of $10,000. See note 5 for terms.

 

F-17

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the fiscal year ended November 30, 2021 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in the Company’s Annual Report on Form 10-K for the fiscal year ended November 30, 2021, filed with the Securities and Exchange Commission (the “SEC”) on February 17, 2022.

 

Forward-Looking Statements

 

The information in this discussion contains forward-looking statements and information. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “should,” “could,” “predicts,” “potential,” “continue,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements. All forward-looking statements in this Quarterly Report on Form 10-Q are made based on our current expectations, forecasts, estimates and assumptions, and involve risks, uncertainties and other factors that could cause results or events to differ materially from those expressed in the forward-looking statements. In evaluating these statements, you should specifically consider various factors, uncertainties and risks that could affect our future results or operations. These factors, uncertainties and risks may cause our actual results to differ materially from any forward-looking statement set forth in this Quarterly Report on Form 10-Q. You should carefully consider these risk and uncertainties described and other information contained in the reports we file with or furnish to the SEC before making any investment decision with respect to our securities. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

 

Businesses

 

We have focused our business to become a U.S.-based green finance and renewable energy company. Our target markets need to access traditional capital markets via structured finance and ESG project consultancy supporting green, environmental and infrastructure related initiatives. Our unique relationship with WPP Energy and its multinational distributor network provides a tremendous deal flow for projects seeking capital. Adding structured finance creates a very scalable, fast moving new business unit capable of handling billions of dollars in volume. While we are not currently a Broker Dealer in the U.S, or any other jurisdiction, we are working with regulated entities to obtain funding for our clients.

 

HYFI had developed an innovative hybrid Centralized and Decentralized Finance (“CeDeFi”) blockchain technology called “HYFI”, “HYFI Tokens” to be used as utility tokens, an NFT investments utilizing both. Subsequently this platform and the investments it supported was not launched given increased uncertainty on the outlook for cryptocurrencies and the legal standing of the platforms which support them. We are reviewing the future of these projects within the new and ever-changing SEC regulated environment.

 

3

 

 

New services

 

BOPO/ HYFI is not a registered Broker Dealer but will rely upon third-party regulated services provided by Signet Capital, LLC. Signet is a boutique investment banking and structured finance services firm with extensive structuring and distribution capabilities for debt and equities securities. We have formed relationships with traditional institutions that are wholesale capital providers established in the U.S. bond and promissory note markets. As a result, our clients can reap the benefits, as this new business unit can accept projects with capital funding requests from $10 million to several billions of dollars in value as follows:

 

1. Structured Finance/Bond Market: Capital supplied by the U.S. bond market, with deal sizes typically in the range of $100 million to over $1 billion.
2. Structured Finance/Promissory Notes: Capital supplied by insurance and pension funds via a promissory note model, with deal sizes ranging from $10 million to $100 million or more.
3. Securities offerings through third party Broker Dealers: Capital supplied by accredited investors via a Regulation D, Rule 506(c) offering, with deal sizes ranging from $1 million to $100 million.

 

Our ESG project consultancy division reviews projects, makes recommendations on funding partners for projects, addresses any missing elements which would disqualify a project from being financed, such as absent or unsatisfactory offtake agreements, and helps source and negotiate the missing elements for clients.

 

Key projects

 

Currently, we have a number of very large business opportunities in the renewable energy market. One particular venture is a partnership with Powgex South Africa to support the introduction of solar and wind power into South Africa to address that country’s electricity crisis. BOPO has executed multiple agreements, including the formation of a joint venture with Powgex South Africa, to build, own and operate renewable electricity generating facilities for the next 45 years.

 

BioPower/HYFI will own up to 19.99% of the Powgex/HYFI joint venture in exchange for various deliverables, including providing structured finance for green infrastructure and our OEM relationships. BioPower/HYFI has put together a consortium of banks, investment banks and institutions approved to provide structured project finance for the build out of as much as 300 gigawatts (GW) of utility scale and rooftop solar electricity, onshore and offshore wind, true green hydrogen production and atmospheric water generation.

 

The projects are confirmed to be guaranteed by Power Purchase Agreements from established key off-takers. In the first year it is contemplated that installations will begin in the fourth quarter for approximately 1 (GW) of power at a cost of approximately $2.25 Billion per GW, and subsequent years will target up to 6 GW of installed capacity, per year, with the help of world class OEM’s and leaders in the renewable energy industry such as large co-developers and EPC’s. BioPower/HYFI will arrange the structured finance for these renewable energy facilities and will also receive project development fees.

 

Subject to certain terms and conditions, including the amount of funds that BioPower/HYFI is able to arrange for investment in Powgex South Africa, Powgex South Africa will buy up to 15% of BioPower Common Stock for up to $50 Million, currently equal to 7,500,000 million shares at $6.67 per share. BioPower Operations Corporation will appoint one of Powgex South Africa’s officers to its board of directors and another of Powgex South Africa’s officers one year from the date of the Joint Venture Agreement. BioPower/HYFI will appoint one director and Powgex South Africa will appoint two directors to the POWGEX-HYFI Board of Directors.

 

Under the terms of the contracts, BioPower/HYFI will receive approximately $40 million in fees in year 1 and is projected to receive over $120 million in fees in year 2. In year 3 revenues are expected to scale up further, with the addition of revenues derived from PPA’s for installations completed in year 2. Each installed GW is expected to generate no less than $150,000 per hour in revenue for the POWGEX-HYFI Joint Venture. Subject to conditions, BioPower/HYFI owns 19.99% of Powgex/HYFI joint venture and is expected to receive a minimum of 19.99% of the net income for 45 years

 

4

 

 

Going Concern

 

Our unaudited financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The unaudited financial statements do not include any adjustments that might result from the outcome of this uncertainty. We have a minimal operating history and minimal revenues or earnings from operations. We have no significant assets or financial resources. We will, in all likelihood, sustain operating expenses without corresponding revenues for the immediate future.

 

There is substantial doubt that we can continue as an ongoing business for the next 12 months unless we obtain additional capital to pay our expenses or revenues. We must raise cash from sources other than revenues generated, such as from the proceeds of loans, public or private equity sales, and/or advances from related parties. There is no guarantee that any revenues or loans will be received, any equity sales will be made, and/or any related parties will advance funds to us or that such funds will be available on favorable terms.

 

Plan of Operation

 

We were dormant from February 2017 to June 29, 2021.

 

We have initiated our Structured Finance Program and launched our ESG project consultancy phase in the last quarter of 2023. We have executed major agreements to build out electricity facilities in Africa and other countries.

 

Our new structured finance division has three funding models:

 

  1. Structured Finance/Bond Market: Capital supplied by the U.S. bond market, with deal sizes typically in the range of $100 million to over $1 billion.
  2. Structured Finance/Promissory Notes: Capital supplied by insurance and pension funds via a promissory note model, with deal sizes ranging from $10 million to $100 million or more.
  3. Securities offerings through third party Broker Dealers: Capital supplied by accredited investors via a Regulation D, Rule 506(c) offering, with deal sizes ranging from $1 million to $100 million.

 

We have formed relationships with institutions and traditional wholesale capital providers established in the U.S. bond and promissory note markets. As a result, our clients can reap the benefits, as this new business unit can accept projects with capital funding requests from $10 million to several billions of dollars in value.

 

There can be no assurance that any of the above market segments will materialize, produce customers or revenue, or that the Company will achieve profitability.

 

Limited Operating History; Need for Additional Capital

 

We cannot guarantee we will be successful in our business operations. We have generated limited revenue since inception. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources and possible cost overruns due to the price and cost increases in supplies and services.

 

If we are unable to meet our needs for cash from either our operations, or possible alternative sources, then we may be unable to continue, develop, or expand our operations.

 

Liquidity and Capital Resources

 

For the three months ended February 28, 2023, we had $0 in revenue over $200,000 in revenue for the three months ended February 28, 2022. Our Net loss from operations at Feb 28, 2023, was $147,578, resulting from $0 in revenue, $50,856 in selling, general and administrative expenses and $47,395 in interest expenses which resulted in an increased loss of $148,758 versus a Net gain of $1,180 for the three months ended Feb 28, 2022 when we had $200,000 in revenue and 151,425 in selling, general and administrative expenses, and 47,395 in interest expenses.

 

5

 

 

   For the three months ended Feb 28, 
   2023   2022 
Revenue  $0   $200,000 
           
Operating expenses          
Development expense   432,366      
Selling, general and administrative expenses   50,850    151,425 
           
Total operating expenses   483,216    151,425 
           
Income / (Loss) from operations   (483,216)   48,575 
           
Other expenses          
Loss on Derivative   (46,690)   (11,247)
Interest expense   75,512      
Interest expense -related party   (21,189)   (36,148)
Total other expenses   (146,391)   (47,395)
           
Net income / (loss)  $(627,607)  $1,180 

 

On June 29, 2021 (“Closing Date”), the Company entered into an Asset Purchase Agreement (the “APA”) with Rafael Ben Shaya, Troy MacDonald, Adam Benchaya, Thomas Perez, Tom Saban and Edouard Pouchoy (collectively, Messrs. Ben Shaya, MacDonald, Benchaya, Perez, Saban and Pouchoy are referred to herein as the “Sellers”).

 

Pursuant to the terms of the APA, the Company agreed to acquire from the Sellers, and the Sellers agreed to sell to the Company, certain assets comprised of the goodwill, intellectual property, business proprietary know-how and trade secrets, intangible property and other assets of Sellers’ business with respect to HyFi, and any and all rights of Sellers in and to the foregoing (the “Assets”), and certain governance/utility virtual tokens (collectively, the “HyFi Tokens”) expected to be used as a means of payment on the HyFi Platform, as hereinafter defined (the “Acquisition”). The “HyFi Platform” refers to the HyFi Decentralized Finance (“DeFi”) exchange marketplace using blockchain platform technology. The DeFi principles are based on an ecosystem of financial services utilizing tokenization and non-fungible tokens (“NFTs”) in connection with qualifying products, licenses and projects.

 

In addition, on the Closing Date, the Company acquired 400,000,000 HyFi Tokens and a cash consideration of $300,000 in exchange for an aggregate of 900,000 of the Company’s Series C preferred shares (“Series C Preferred Stock”) within 30 calendar days after the State of Nevada provides written confirmation of filing of the certificate of designation for the Series C preferred stock. On August 27, 2021, the Company filed with the State of Nevada a certificate of designations for the Series C preferred stock. The shares of Series C Preferred Stock issuable upon exercise thereof have not been registered under the Securities Act, nor qualified under applicable state securities laws. The Company used the Cash Consideration to ensure the Company reaches full reporting status with the SEC and for public company operating expenses.

 

Also, on the Closing Date, the Company and China Energy Partners, LLC (“CEP”) entered into a share redemption agreement (the “Redemption Agreement”), dated as of the Closing Date, pursuant to which the Company redeemed one share of the Company’s Series A preferred stock from CEP (the “Series A Preferred Stock”). On the Closing Date, as provided in the Redemption Agreement, the Company issued to CEP a senior promissory note (the “Note”) in the principal amount of $1,000,000. The Series A Preferred Stock will be held in escrow. If an Event of Default (as defined in the Note) occurs under the Note, then the Company will direct the escrow agent to release the Series A Preferred Stock to CEP; provided, however, that CEP will also retain all rights and privileges under the Note (and the Company will remain bound to all obligations under Note) even if the Series A Preferred Stock is required to be released by the escrow agent to CEP as provided in the Redemption Agreement. For the avoidance of doubt, CEP will regain all rights, title, and interest in and to the Series A Preferred Stock upon the occurrence of an Event of Default under the Note, regardless of the amount of the outstanding balance owed under the Note at the time of the occurrence of an Event of Default under the Note. The shares of Series A Preferred Stock redeemable in accordance with the Redemption Agreement thereof have not been registered under the Securities Act, nor qualified under applicable state securities laws. This Note has been paid in full.

 

6

 

 

There is no historical financial information about us upon which to base an evaluation of our performance. We have generated revenues from operations of $175,000 for the year ending November 30, 2022, $446,700. We cannot guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources, possible delays in the launching of our structured finance and ESG divisions. We do not believe we have sufficient funds to operate our business for the next 12 months.

 

We have no assurance that future financing will be available to us on acceptable terms, or at all. If financing is not available on satisfactory terms, we may be unable to continue, develop or expand our operations. Equity financing could result in additional dilution to existing shareholders. If we are unable to raise additional capital to maintain our operations in the future, we may be unable to carry out our full business plan or we may be forced to cease operations.

 

Critical Accounting Policies

 

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our financial statements is critical to an understanding of our financial statements.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements

 

Our company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not required for smaller reporting companies.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of disclosure controls and procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in company reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

 

7

 

 

As required by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of May 31, 2022. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective as of Feb 28, 2023.

 

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

Change in internal control over financial reporting

 

There has been no change in our internal control over financial reporting that occurred during the quarterly period ended Feb 28, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

PART II: OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We are not involved in any pending legal proceeding nor are we aware of any pending or threatened litigation against us.

 

ITEM 1A. RISK FACTORS

 

Not required for smaller reporting companies.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

  (a) None
     
  (b) There have been no material changes to the procedures by which security holders may recommend nominees to the Company’s Board of Directors since the filing with the SEC of the Company’s Annual Report on Form 10-K for the year ended November 30, 2022.

 

8

 

 

ITEM 6. EXHIBITS

 

Exhibit No.   Exhibit Description
     
31.1   Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2   Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1   Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS   Inline XBRL Instance Document
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Document
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

9

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BioPower Operations Corporation
     
Date: August 22, 2023 By: /s/ Troy MacDonald
    Troy MacDonald
    Chief Executive Officer
    (principal executive officer)
     
  By: /s/ Troy MacDonald
    Troy MacDonald
    Chief Financial Officer
    (principal financial officer and principal accounting officer)

 

10

 

EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Troy MacDonald, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q for the quarterly period ended February 28, 2023 of BioPower Operations Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 22, 2023 /s/ Troy MacDonald
  Troy MacDonald
  Chief Executive Officer (principal executive officer)

 

 

 

EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Troy MacDonald, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q for the quarterly period ended February 28, 2023 of BioPower Operations Corporation;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 22, 2023 /s/ Troy MacDonald
  Troy MacDonald
  Chief Financial Officer (principal financial officer)

 

 

 

EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report on Form 10-Q of BioPower Operations Corporation (the “Company”) for the quarter ended February 28, 2023 as filed with the Securities and Exchange Commission (the “Report”), each of the undersigned, Troy MacDonald, Chief Executive Officer of the Company, and Troy MacDonald, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: August 22, 2023 /s/ Troy MacDonald
  Troy MacDonald, Chief Executive Officer (principal executive officer)
   
Date: August 22, 2023 /s/ Troy MacDonald
  Troy MacDonald, Chief Financial Officer (principal financial officer)

 

 

 

EX-101.SCH 5 bopo-20230531.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Notes Payable and Convertible Debt link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Convertible loans link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Senior Promissory Note – related party link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stockholders’ deficit link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Notes Payable and Convertible Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Convertible loans (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stockholders’ deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Organization (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Schedule of Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Notes Payable and Convertible Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Schedule of Amount Owed on Prepayment of Diagonal Lending Note (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Convertible loans (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Senior Promissory Note – related party (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Schedule of Preference Shares Awarded to an Employee (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Stockholders’ deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Schedule of Preference Shares Awarded (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 bopo-20230531_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 bopo-20230531_def.xml XBRL DEFINITION FILE EX-101.LAB 8 bopo-20230531_lab.xml XBRL LABEL FILE Related Party, Type [Axis] Nonrelated Party [Member] Related Party [Member] Class of Stock [Axis] Series A Preferred Stock [Member] Series C Preferred Stock [Member] Product and Service [Axis] Sale of Tokens [Member] Sale of Tokens - Related Party [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock Payable [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Investment, Name [Axis] BioPower Corporation [Member] Chief Executive Officer and Director [Member] Business Acquisition [Axis] HyFi [Member] Financial Instrument [Axis] HyFi Tokens [Member] Legal Entity [Axis] China Energy Partners LLC [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Redemption Agreement [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Customer [Axis] Two Customers [Member] Five Customers [Member] Title of Individual [Axis] Canadian Investor [Member] Diagonal Lending [Member] Debt Instrument [Axis] Demand Loans [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Reclassification of Accrued Compensation To Notes Payable [Member] Demand Loan Agreements [Member] Third Party Investor [Member] Lender [Member] Convertible Debt Agreement [Member] Third Party Investor One [Member] Third Party Investor Two [Member] Third Party Investor Three [Member] Third Parties [Member] Short-Term Debt, Type [Axis] Convertible Debt [Member] Chief Financial Officer [Member] Director Of Business Strategy [Member] Three Notes [Member] Investor [Member] Chief Operating Officer [Member] Robert Kohn [Member] Long-Lived Tangible Asset [Axis] Technology [Member] Troy Mac Donald [Member] Securities Purchase Agreement [Member] Long-Term Debt, Type [Axis] Convertible Notes Payable [Member] Award Type [Axis] May 31, 2022 to July 30, 2022 [Member] July 31, 2022 to October 28, 2022 [Member] October 29, 2022 to November 27, 2022 [Member] China Energy Partners Note Amendment [Member] Consultant [Member] Baruch Halpern [Member] Bonnie Nelson [Member] Mr. Compton [Member] Restricted Common Stock [Member] Vesting [Axis] Share-Based Payment Arrangement, Tranche One [Member] Share-Based Payment Arrangement, Tranche Two [Member] Share-Based Payment Arrangement, Tranche Three [Member] Share-Based Compensation Award Tranche Four [Member] Indefinite-Lived Intangible Assets [Axis] Digital Art [Member] Sanctum Agreement [Member] ILO and Multi Agreement [Member] Exclusive License Options Year One [Member] PIP Agreement [Member] Exclusive License Options Year Five [Member] Generation Power Group Limited [Member] Mr Walton [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] Assets Current assets Cash and cash equivalents Accounts receivable Inventory Total assets Liabilities and Stockholders’ Deficit Current liabilities Cash overdraft Accounts payable and accrued expenses Deferred revenue Notes payable Convertible debt variable priced conversion Convertible debt Notes payable Derivative liability Total current liabilities Commitments and Contingencies (Note 9) Stockholders’ deficit Preferred stock , value Common Stock owed Common stock, $.0001 par value: 500,000,000 authorized;45,867,915 and 45,625,000 issued and outstanding on May 31 2023 and November 30, 2022, respectively Additional paid-in capital Accumulated deficit Total stockholders ‘deficit Total liabilities and stockholders’ deficit Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Revenue: Total Revenue Operating expenses Development expense Selling, general and administrative expenses Total operating expenses Income / (Loss) from operations Other expenses Loss on derivative Interest expense Total other expenses Net loss Net loss per common share: basic Net loss per common share: diluted Weighted average common shares outstanding: basic Weighted average common shares outstanding: diluted Statement of Cash Flows [Abstract] Cash flows from operating activities Net loss Adjustments to reconcile net loss to net cash used in operating activities Stock based compensation Amortization of debt discount Loss on derivative Adjustments to reconcile net loss to net Changes in operating assets and liabilities Increase in accounts receivable Increase in prepaid expenses Increase in inventory Accounts payable and accrued expenses Accounts payable and accrued expenses - related party Net cash used in operating activities Cash flow from financing activities Bank overdraft Proceeds from issuance of common stock Net cash provided by financing activities Net increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for income taxes Non-cash investing and financing activities: Conversion of Convertible debentures to common stock Derivative resolution Balance Balance, shares Sale of common stock Sale of common stock, shares Stock based compensation Conversion of notes payable Conversion of notes payable, shares Derivative resolution Balance Balance, shares Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization Accounting Policies [Abstract] Summary of Significant Accounting Policies Debt Disclosure [Abstract] Notes Payable and Convertible Debt Related Party Transactions [Abstract] Related Party Transactions Convertible Loans Convertible loans Senior Promissory Note Related Party Senior Promissory Note – related party Equity [Abstract] Stockholders’ deficit Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Principles of Consolidation Basis of Presentation Going Concern Use of Estimates Accounts Receivable Inventory Revenue Recognition Concentration Cash and cash equivalents Income taxes Stock-based Compensation Net Loss per Share Recent Accounting Pronouncements Stockholders’ Equity Schedule of Notes Payable Schedule of Amount Owed on Prepayment of Diagonal Lending Note Schedule of Preference Shares Awarded to an Employee Schedule of Preference Shares Awarded Ownership, percentage Outstanding shares, percentage Cash consideration, acquisition Number of consideration shares Business combination description Stock conversion, issued shares Preferred stock, conversion basis Preferred stock, voting rights Debt instrument, principal amount Schedule of Product Information [Table] Product Information [Line Items] Accumulated deficit Stockholders' deficit Concentration risk, percentage Cash equivalents Restricted common stock issued, shares Share issued price per share Restricted common stock issued Debt principal amount converted Common stock issued in conversion Debt conversion price Dividend resolution Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Balance Interest rate Maturity date Notes payable Debt instrument, interest Debt Instrument, Maturity Date Conversion price per share Convertible debt Debt instrument, original percentage Accrued interest Interest expense Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Reduction in accrued compensation Long term debt Debt instrument, interest rate Debt instrument, maturity date Debt instrument, description Reduction in long term debt Accrued compensation Decrease in accrued salaries Debt instrument, face amount Reduction in liability insurance Debt instrument, conversion rate Debt instrument, conversion price Loans payable Share price Accrued salary Number of tokens, issued Value of purchased assets Related party token sales, rate Accrued interest Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Prepayment, rate Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Debt instrument, term Debt default, interest rate Principal amount Debt instrument, interest rate Debt transfer amount Accurued interest Schedule of Stock by Class [Table] Class of Stock [Line Items] Vesting schedule Number of shares awarded Number of shares issued Value of shares issued Issue price per share Value of shares issued Value of shares issued Cash consideration, acquisition Number of shares issued as consideration Conversion of stock, description Conversion of stock shares issued Preferred stock voting rights Number of shares issued Share purchase price Shares of restriced common stock Share-based compensation expense Unamortized expense amount Product Liability Contingency [Table] Product Liability Contingency [Line Items] Number of assets Payment of exchange Gross revenue, description Exclusive license Amount Gross sales percentage Shares issued, shares Tokens issued during period shares Token price Tokens issued during period value new issues Purchase of vaults, description Debt payment amount Offering to investors Onboarding fee Cash placement fee rate Base salary annual rate Net investment threshold limit for salary payment Net income threshold limit for salary payment Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Subsequent Event [Table] Subsequent Event [Line Items] Debt principal amount, conversion rate Convertible debt variable priced conversion current. Common stock owed value. Derivative resolution. Common Stock Payable [Member] Bio power corporation [Member] Chief Executive Officer and Director [Member] HyFi [Member] China Energy Partners LLC [Member] Redemption Agreement [Member] Going Concern Policy [TextBlock] Canadian investor [Member] Demand Loans [Member] Reclassification Of Accrued Compensation To Notes Payable [Member] Demand Loan Agreements [Member] Third Party Investor [Member] Lender [Member] Convertible Debt Agreement [Member] Third Party Investor One [Member] Third Party Investor Two [Member] Third Party Investor Three [Member] Third Parties [Member] Director Of Business Strategy [Member] Three Notes [Member] Reduction in liability share issurance. Number of tokens issued to purchase assets. HyFi Tokens [Member] Technology [Member] Troy Mac Donald [Member] Securities Purchase Agreement [Member] Schedule of Amount Owed on Prepayment of Diagonal Lending Note [TableTextBlock] Senior Promissory Note Related Party [Disclosure Text Block] China Energy Partners Note Amendment [Member] Debt transfer amount. Consultant [Member]. Baruch Halpern [Member] Robert Kohn [Member] Bonnie Nelson [Member] Restricted Common Stock [Member] Number of assets. Digital Art [Member] Sanctum Agreement [Member] Gross revenue description. ILO and Multi Agreement [Member] Exclusive License Options Year One [Member] PIP Agreement [Member] Gross sales customary percentage. Tokens issued during period shares new issues. Token price. Tokens issued during period shares new issues value Purchase of vaults description. Generation Power Group Limited [Member] Mr Walton [Member] Cash placement fee rate. Exclusive License Options Year Five [Member] Debt prepayment percentage. May 31, 2022 to July 30, 2022 [Member] July 31, 2022 to October 28, 2022 [Member] October 29, 2022 to November 27, 2022 [Member] Sale of Tokens [Member] Two Customers [Member] Five Customers [Member] Diagonal Lending [Member] Share-Based Compensation Award Tranche Four [Member] Mr. Compton [Member] Net investment threshold limit for salary payment. Net income threshold limit for salary payment Sale of Tokens - Related Party [Member] Convertible loans [Text Block] Assets [Default Label] Other Notes Payable Liabilities, Current Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense Nonoperating Income (Expense) Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense Increase (Decrease) in Inventories Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Shares, Outstanding APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Adjustments to Additional Paid in Capital, Other Equity [Text Block] Inventory, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Convertible Debt Interest Payable, Current Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture Payments to Acquire Businesses, Gross Sale of Stock, Number of Shares Issued in Transaction EX-101.PRE 9 bopo-20230531_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover - shares
6 Months Ended
May 31, 2023
Aug. 22, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date May 31, 2023  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --11-30  
Entity File Number 000-53274  
Entity Registrant Name BioPower Operations Corporation  
Entity Central Index Key 0001510832  
Entity Tax Identification Number 27-4460232  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 20801 Biscayne Blvd  
Entity Address, Address Line Two Suite 403  
Entity Address, City or Town Aventura  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33180  
City Area Code (786)  
Local Phone Number 923-0272  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   47,538,859
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Balance Sheets - USD ($)
May 31, 2023
Nov. 30, 2022
Current assets    
Cash and cash equivalents $ 825
Accounts receivable 331 331
Inventory 12,893 12,893
Total assets 13,224 14,049
Current liabilities    
Cash overdraft 245
Deferred revenue 375,000 375,000
Convertible debt variable priced conversion 211,750 157,167
Notes payable 193,667 193,667
Derivative liability 313,464 262,050
Total current liabilities 6,889,184 5,953,792
Commitments and Contingencies (Note 9)
Stockholders’ deficit    
Common Stock owed 125,000 125,000
Common stock, $.0001 par value: 500,000,000 authorized;45,867,915 and 45,625,000 issued and outstanding on May 31 2023 and November 30, 2022, respectively 4,588 4,564
Additional paid-in capital 8,730,014 4,279,317
Accumulated deficit (15,736,462) (10,349,524)
Total stockholders ‘deficit (6,875,960) (5,939,743)
Total liabilities and stockholders’ deficit 13,224 14,049
Series A Preferred Stock [Member]    
Stockholders’ deficit    
Preferred stock , value
Series C Preferred Stock [Member]    
Stockholders’ deficit    
Preferred stock , value 900 900
Nonrelated Party [Member]    
Current liabilities    
Accounts payable and accrued expenses 1,275,421 451,846
Notes payable 130,671 130,671
Convertible debt 368,031 368,031
Related Party [Member]    
Current liabilities    
Accounts payable and accrued expenses 2,300,788 2,295,213
Notes payable 1,320,700 1,320,700
Convertible debt $ 399,447 $ 399,447
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Balance Sheets (Parenthetical) - $ / shares
May 31, 2023
Nov. 30, 2022
May 31, 2022
Nov. 30, 2021
Jul. 28, 2021
Jul. 27, 2021
Jun. 29, 2021
Preferred stock, par value       $ 0.0001 $ 0.0001 $ 1.00  
Preferred stock, shares authorized       5,000,000 5,000,000 10,000  
Preferred stock, shares issued 900,000 1 900,000 1      
Preferred stock, shares outstanding 900,000 0 900,000 0      
Common stock, par value $ 0.0001 $ 0.0001   $ 0.0001      
Common stock, shares authorized 500,000,000 500,000,000   500,000,000 500,000,000 100,000,000  
Common stock, shares issued 45,867,915 45,625,000 45,625,000 45,000,000      
Common stock, shares outstanding 45,867,915 45,625,000 45,625,000 45,000,000      
Series A Preferred Stock [Member]              
Preferred stock, par value $ 1.00 $ 1.00          
Preferred stock, shares authorized 10,000 10,000          
Preferred stock, shares issued 0 1          
Preferred stock, shares outstanding 0 1          
Series C Preferred Stock [Member]              
Preferred stock, par value $ 0.001 $ 0.001          
Preferred stock, shares authorized 5,000,000 5,000,000         900,000
Preferred stock, shares issued 900,000 0          
Preferred stock, shares outstanding 900,000 0          
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
May 31, 2023
May 31, 2022
May 31, 2023
May 31, 2022
Revenue:        
Total Revenue $ 246,700 $ 446,700
Operating expenses        
Development expense 248,773 681,139
Selling, general and administrative expenses 4,446,448 212,443 4,497,298 363,868
Total operating expenses 4,695,221 212,443 5,178,437 363,868
Income / (Loss) from operations (4,695,221) 34,257 (5,178,437) 82,832
Other expenses        
Loss on derivative (16,900) (66,590)
Total other expenses (62,110) (47,395) (208,501) (94,790)
Net loss $ (4,757,331) $ (13,138) $ (5,386,938) $ (11,958)
Net loss per common share: basic $ (0.10) $ (0.00) $ (0.12) $ (0.00)
Net loss per common share: diluted $ (0.10) $ (0.00) $ (0.12) $ (0.00)
Weighted average common shares outstanding: basic 45,867,915 45,597,826 45,762,474 45,302,198
Weighted average common shares outstanding: diluted 45,867,915 45,597,826 45,762,474 45,302,198
Nonrelated Party [Member]        
Other expenses        
Interest expense $ (24,021) $ (11,248) $ (99,533) $ (22,495)
Related Party [Member]        
Other expenses        
Interest expense (21,189) (36,147) (42,378) (72,295)
Sale of Tokens [Member]        
Revenue:        
Total Revenue 136,000 336,000
Sale of Tokens - Related Party [Member]        
Revenue:        
Total Revenue $ 110,700 $ 110,700
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
May 31, 2023
May 31, 2022
Cash flows from operating activities    
Net loss $ (5,386,938) $ (11,958)
Adjustments to reconcile net loss to net cash used in operating activities    
Stock based compensation 4,423,545
Amortization of debt discount 66,583
Loss on derivative 66,590
Changes in operating assets and liabilities    
Increase in accounts receivable (331)
Increase in prepaid expenses (77,593)
Increase in inventory   (12,983)
Accounts payable and accrued expenses 823,575 (191,071)
Accounts payable and accrued expenses - related party 5,575 470,238
Net cash used in operating activities (1,070) 176,302
Cash flow from financing activities    
Bank overdraft 245
Proceeds from issuance of common stock 249,991
Net cash provided by financing activities 245 249,991
Net increase in cash and cash equivalents (825) 426,293
Cash and cash equivalents at beginning of period 825 95,973
Cash and cash equivalents at end of period 522,266
Supplemental disclosure of cash flow information:    
Cash paid for interest
Cash paid for income taxes
Non-cash investing and financing activities:    
Conversion of Convertible debentures to common stock 12,000
Derivative resolution $ 15,176
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)
Preferred Stock [Member]
Series C Preferred Stock [Member]
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Common Stock Payable [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Nov. 30, 2021   $ 1 $ 900 $ 4,500 $ 4,140,411 $ (9,556,990) $ (5,411,178)
Balance, shares at Nov. 30, 2021   1 900,000 45,000,000      
Sale of common stock     $ 63 249,928 249,991
Sale of common stock, shares         625,000      
Net loss   (11,958) (11,958)
Balance at May. 31, 2022 $ 1 $ 900 $ 4,563 4,390,339 (9,568,948) (5,173,145)
Balance, shares at May. 31, 2022 1 900,000 45,625,000      
Balance at Feb. 28, 2022 $ 900 $ 4,500 4,140,411 (9,555,809) (5,409,998)
Balance, shares at Feb. 28, 2022   900,000 45,000,000      
Sale of common stock   $ 63 249,928 249,991
Sale of common stock, shares         625,000      
Net loss (13,138) (13,138)
Balance at May. 31, 2022 $ 1 $ 900 $ 4,563 4,390,339 (9,568,948) (5,173,145)
Balance, shares at May. 31, 2022 1 900,000 45,625,000      
Balance at Nov. 30, 2022   $ 900 $ 125,000 $ 4,564 4,279,317 (10,349,524) (5,939,743)
Balance, shares at Nov. 30, 2022   900,000 500,000 45,625,000      
Net loss   (5,386,938) (5,386,938)
Stock based compensation           4,423,545   4,423,545
Conversion of notes payable   $ 24 11,976 12,000
Conversion of notes payable, shares         242,915      
Derivative resolution   15,176 15,176
Balance at May. 31, 2023 $ 900 $ 125,000 $ 4,588 8,730,014 (15,736,462) (6,875,960)
Balance, shares at May. 31, 2023 900,000 500,000 45,867,915      
Balance at Feb. 28, 2023 $ 900 $ 125,000 $ 4,588 4,306,469 (10,979,131) (6,542,174)
Balance, shares at Feb. 28, 2023   900,000 500,000 45,867,915      
Net loss (4,757,331) (4,757,331)
Stock based compensation   4,423,545 4,423,545
Balance at May. 31, 2023 $ 900 $ 125,000 $ 4,588 $ 8,730,014 $ (15,736,462) $ (6,875,960)
Balance, shares at May. 31, 2023 900,000 500,000 45,867,915      
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Organization
6 Months Ended
May 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization

Note 1. Organization

 

BioPower Corporation (“BioPower” or the “Company”) was incorporated in the State of Florida on September 13, 2010. On January 5, 2011, the Company re-domiciled to Nevada and formed BioPower Operations Corporation, a Nevada corporation. On January 6, 2011, the shareholders of BioPower Corporation contributed their shares of BioPower Corporation to BioPower Operations Corporation and BioPower Corporation became a wholly owned subsidiary.

 

On October 24, 2014, the Company executed a Share Exchange Agreement (“SEA”) with Green3Power Holdings Company (“G3P”) to acquire G3P and its wholly owned subsidiaries Green3Power Operations Inc., a Delaware corporation (“G3P OPS”), and Green3Power International Company, a Nevis corporation (“G3PI”). This transaction was a stock for stock exchange (the “Exchange”), which was accounted for as an acquisition and recorded as an expense based on the fair value of the Company’s common stock as of the date of the exchange. Also exchanged was one share of the Company’s Series B preferred stock, which is convertible into common shares two years from the date of the SEA, if certain milestones are met as required by the SEA. No value was attributed to the preferred share. We conduct all of our operations through G3P and its subsidiaries which are primarily engaged in the development of waste-to-energy projects and services including design, permitting, equipment procurement, construction management and operations and maintenance of the intended facilities. We intend to hold equity interests in the waste-to-energy facilities on a global basis and operate and maintain the facilities. A second business unit is focused on providing waste remediation services globally.

 

The Company’s fiscal year end is November 30.

 

On January 6, 2011, we acquired 100% of BioPower Corporation (“BC”), a Florida corporation incorporated on September 13, 2010, by our then-CEO and Director contributing 100% of the outstanding shares to the Company. As a result, BC became a wholly owned subsidiary of the Company.

 

On October 24, 2014, the Company entered into the SEA with G3P to acquire G3P and its wholly owned subsidiaries, G3P OPS and G3PI through the Exchange.

 

By October 24, 2016, G3P had failed to meet the provisions of the SEA that would allow G3P to take over control of the Company. As a result, the Company’s Board of Directors tried to come to an arrangement to separate BioPower from its subsidiaries, but in the end, decided that it would be in the best interests of the Company’s shareholders to move forward looking for a new acquisition. From October 24, 2016 until February 2017, the Company continued project development of waste-to-energy projects with extremely limited funds. In February 2017, the Company ceased all operations. At that time, we became a shell company.

 

On June 29, 2021, we entered into an Asset Purchase Agreement (the “APA”) with Rafael Ben Shaya, Troy MacDonald, Adam Benchaya, Thomas Perez, Tom Saban and Edouard Pouchoy (collectively, Messrs. Ben Shaya, MacDonald, Benchaya, Perez, Saban and Pouchoy are referred to herein as the “Sellers”).

 

Pursuant to the terms of the APA, the Company agreed to acquire from the Sellers, and the Sellers agreed to sell to the Company, certain assets comprised of the goodwill, intellectual property, business proprietary know-how and trade secrets, intangible property and other assets of Sellers’ business with respect to HyFi, and any and all rights of Sellers in and to the foregoing (the “Assets”), and certain governance/utility virtual tokens (collectively, the “HyFi Tokens”) expected to be used as a means of payment on the HyFi Platform, as hereinafter defined (the “Acquisition”). The “HyFi Platform” refers to the HyFi Decentralized Finance (“DeFi”) exchange marketplace using blockchain platform technology. The DeFi principles are based on an ecosystem of financial services utilizing tokenization and non-fungible tokens (“NFTs”) in connection with qualifying products, licenses and projects.

 

 

In addition, the Sellers agreed to (i) pay to the Company, on the closing date of the Acquisition, $300,000 (the “Cash Consideration”), and (ii) transfer to the Company, on the closing date of the Acquisition, 400,000,000 HyFi Tokens (the “HyFi Token Consideration”). The Company used the Cash Consideration to bring the Company into a fully reporting status with the Securities and Exchange Commission (the “SEC”) and for public company operating expenses.

 

Pursuant to the terms of the APA, the Company agreed to file with the State of Nevada the certificate of designation for the Series C preferred stock on or before the date that is 60 calendar days after the closing of the Acquisition. In exchange for the sale of the Assets and the Cash Consideration, the Company agreed to issue to the Sellers an aggregate of 900,000 Series C preferred shares within 30 calendar days after the State of Nevada provides written confirmation of filing of the certificate of designation for the Series C preferred stock.

 

Pursuant to the terms of the APA, the parties agreed that the Series C preferred stock will have the following terms, among others:

 

1. Authorized Shares of Series C Preferred Stock. The number of authorized shares of Series C preferred stock will be 900,000.

 

2. Conversion. Subject to the other terms and conditions in the certificate of designation, a Series C preferred stockholder will have the right from time to time and at any time following the date that is one year after the date on the signature page of the certificate of designations to convert each outstanding share of Series C preferred stock into 450 shares of Company common stock. Based on the number of shares of common stock issued and outstanding as of June 29, 2021, if all of the 900,000 shares of Series C preferred stock are issued and subsequently converted, the holders of the converted stock will hold 90% of the issued and outstanding shares of common stock.

 

3. Voting. Except as otherwise set forth in the certificate of designation, each share of Series C preferred stock will, on any matter submitted to the holders of Company common stock, or any class thereof, for a vote, vote together with the common stock, or any class thereof, as applicable, as one class on such matter, and each share of Series C preferred stock will have 450 votes.

 

4. Dividends. The Series C preferred stock is not entitled to receive dividends or distributions.

 

The Acquisition closed on June 29, 2021 (the “Closing Date”). On the Closing Date, the Sellers delivered the Cash Consideration and the HyFi Token Consideration.

 

On August 27, 2021, the Company filed with the State of Nevada a certificate of designations for the Series C preferred stock.

 

Series A Preferred Stock Redemption Agreement & Senior Promissory Note

 

Also on the Closing Date, the Company and CEP entered into a share redemption agreement (the “Redemption Agreement”), dated as of June 29, 2021, pursuant to which the Company redeemed one share of the Company’s Series A preferred stock from CEP (the “Series A Share”). On the Closing Date, as provided in the Redemption Agreement, the Company issued to CEP a senior promissory note (the “Note”) in the principal amount of $1,000,000. The Series A Share will be held in escrow. If an Event of Default (as defined in the Note) occurs under the Note, then the Company will direct the escrow agent to release the Series A Share to CEP; provided, however, that CEP will also retain all rights and privileges under the Note (and the Company will remain bound to all obligations under Note) even if the Series A Share is required to be released by the escrow agent to CEP as provided in the Redemption Agreement. For the avoidance of doubt, CEP will regain all rights, title, and interest in and to the Series A Share upon the occurrence of an Event of Default under the Note, regardless of the amount of the outstanding balance owed under the Note at the time of the occurrence of an Event of Default under the Note.

 

 

On October 7, 2021, the Company filed a certificate of amendment (the “Certificate of Amendment”) to its amended and restated articles in the State of Nevada and with FINRA, in order to change its corporate name from BioPower Operations Corporation. to HyFi Corp (the “Name Change”). The State of Nevada has officially changed the name of the Company to HYFI Corp. The Name Change and stock symbol change will be effective for Securities and Exchange Commission or trading purposes until it is cleared by the Financial Industry Regulatory Authority (FINRA).

 

XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies
6 Months Ended
May 31, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

 

Management’s Representation of Interim Financial Statements

 

The accompanying unaudited consolidated financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the SEC. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These consolidated financial statements include all of the adjustments, which in the opinion of management are necessary to a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements filed as part of the Company’s Annual Report on Form 10-K with the SEC on June 15, 2023.

 

Principles of Consolidation

 

All inter-company accounts and transactions have been eliminated in consolidation.

 

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (the “ASC”) which is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with GAAP.

 

Going Concern

 

The accompanying unaudited consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these financial statements. The Company has incurred significant operating losses since inception. As of May 31, 2023, the Company had an accumulated deficit of $15,736,462 and stockholders’ deficit of $6,875,960.

 

Because the Company does not expect that existing operational cash flow will be sufficient to fund presently anticipated operations, this raises substantial doubt about the Company’s ability to continue as a going concern. Therefore, the Company will need to raise additional funds and is currently exploring alternative sources of financing. Historically, the Company has raised capital through private placements, as an interim measure to finance working capital needs and may continue to raise additional capital through the sale of common stock or other securities and obtaining some short-term loans. The Company will be required to continue to so until its operations become profitable. Also, the Company has, in the past, paid for consulting services with its common stock to maximize working capital, and intends to continue this practice where feasible.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

 

 

Accounts Receivable

 

Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. If market conditions decline, actual collection experience may not meet expectations and may result in decreased cash flows and increased bad debt expense.

 

The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made.

 

Inventory

 

Inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out basis and net realizable value. Net realizable value is defined as sales price less cost of completion, disposition and transportation and a normal profit margin. As of May 31, 2023 and November 30, 2022, inventory amounted to $12,893 and $12,893, respectively, which consisted of finished goods.

 

Revenue Recognition

 

On July 1, 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Results for reporting periods beginning after January 1, 2018, are presented under ASC 606.

 

On June 29, 2021, the Sellers agreed to (i) pay to the Company, on the closing date of the Acquisition, $300,000 (the “Cash Consideration”), and (ii) transfer to the Company, on the closing date of the Acquisition, 400,000,000 HyFi Tokens (the “HyFi Token Consideration”). The Company used the Cash Consideration to bring the Company into a fully reporting status with the SEC and for public company operating expenses.

 

Concentration

 

Two customers, including one related party, account for 100% of sales during the three months ended May 31, 2022.

 

Five customers, including two related parties, account for 100% of sales during the six months ended May 31, 2022.

 

Cash and cash equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On May 31, 2023 the Company had a cash overdraft of $245 and on November 30, 2022, the Company’s cash equivalents totaled $825.

 

Income taxes

 

The Company accounts for income taxes under FASB ASC 740, “Accounting for Income Taxes”. Under FASB ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. FASB ASC 740-10-05, “Accounting for Uncertainty in Income Taxes,” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.

 

 

The amount recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company assesses the validity of its conclusions regarding uncertain tax positions quarterly to determine if facts or circumstances have arisen that might cause it to change its judgment regarding the likelihood of a tax position’s sustainability under audit.

 

Stock-based Compensation

 

The Company accounts for stock-based compensation using the fair value method following the guidance outlined in Section 718-10 of the ASC for disclosure about stock-based compensation. This section requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). That cost will be recognized over the period during which an employee is required to provide service in exchange for the award- the requisite service period (usually the vesting period). No compensation cost is recognized for equity instruments for which employees do not render the requisite service.

 

Net Loss per Share

 

Net loss per common share is computed by dividing net loss by the weighted average common shares outstanding during the period as defined by ASC Topic 260, “Earnings per Share.” Basic earnings per common share calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

 

Recent Accounting Pronouncements

 

In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which establishes a new lease accounting model for lessees. The updated guidance requires an entity to recognize assets and liabilities arising from financing and operating leases, along with additional qualitative and quantitative disclosures. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, with early adoption permitted. In March 2019, the FASB issued ASU 2019-01, Codification Improvements, which clarifies certain aspects of the new lease standard. The FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases in July 2018. Also in 2018, the FASB issued ASU 2018-11, Leases (Topic 842) Targeted Improvements, which provides an optional transition method whereby the new lease standard is applied at the adoption date and recognized as an adjustment to retained earnings. The amendments have the same effective date and transition requirements as the new lease standard.

 

We adopted ASC 842 on July 1, 2021. The adoption of ASC 842 did not have any impact on our financial statements.

 

Stockholders’ Equity

 

On July 28, 2021, the Company amended and restated its articles of incorporation, as amended, in order to, among other things, (i) increase the number of authorized shares of common stock from 100,000,000 to 500,000,000, (ii) increase the number of authorized shares of preferred stock from 10,000 to 5,000,000, and (iii) change the par value of the preferred stock from $1.00 par value per share to $0.0001 par value per share. As of November 30, 2021, the Company had authorized 500,000,000 shares of common stock, $0.0001 par value per share, and 5,000,000 shares of preferred stock, $0.0001 par value per share.

 

On March 4, 2022, the Company issued 625,000 shares of restricted common stock to a Canadian investor for $0.40 per share for a total purchase price of $250,000.

 

 

On February 17, 2023 Diagonal converted $12,000 of principal into 242,915 shares of common stock at the price of $0.0494. The Company recorded a dividend resolution of $15,176.

 

As of May 31, 2023, and November 30, 2022, respectively, there were 45,867,915 and 45,625,000 shares of common stock issued and outstanding, respectively, and 900,000 and 1 shares and 0 shares of preferred stock issued and outstanding, respectively.

 

XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Notes Payable and Convertible Debt
6 Months Ended
May 31, 2023
Debt Disclosure [Abstract]  
Notes Payable and Convertible Debt

Note 3. Notes Payable and Convertible Debt

 

Notes payable consists of the following:

 

   Balance   Interest Rate   Maturity 
Demand loans  $551,167    4% to 8%   Various
Reclassification of accrued compensation to notes payable  143,031    8%   December 1, 2017  
Balance –May 31, 2023 and November 30, 2022  $694,198           

 

As of May 31, 2023 and November 30, 2022, all loans are past due and in default.

 

On July 27, 2016, the Company entered into demand loan agreements with a third-party investor totaling $193,667 at 4% interest, payable upon demand.

 

Between October 28, 2011 and January 7, 2012, the Company issued a total of $70,000 in notes payable, due May 31, 2012. Interest on the notes is payable at 4%. The lender may elect to convert the loan before maturity at a conversion price of $0.25 per share. The loans are currently past due.

 

On December 3, 2013, the Company entered into convertible debt agreements with a third-party investor totaling $62,500 at 8% interest, payable upon demand. The debt is convertible into shares of common stock at a conversion price of $0.10 per share, for any amount up to 50% of the original amount of the notes. As of May 31, 2023 and November 30, 2022, the note was in default.

 

On July 30, 2015, the Company entered into convertible debt agreements with a third-party investor totaling $200,000 at 8% interest, due on December 31, 2015. The debt is convertible into shares of common stock at a conversion price of $0.15 per share. As of May 31, 2023 and November 30, 2022, the note was in default.

 

On May 23, 2016, the Company entered into convertible debt agreements with a third-party investor totaling $25,000 at 8% interest, due on May 23, 2018. The debt is convertible into shares of common stock at a conversion price of $0.10 per share. As of May 31, 2023 and November 30, 2022, the note was in default.

 

On July 30, 2015, the Company entered into convertible debt agreements with a third-party investor totaling $15,000 at 8% interest, due on May 23, 2018. The debt is convertible into shares of common stock at a conversion price of $0.15 per share. As of May 31, 2023 and November 30, 2022, the note was in default.

 

On July 30, 2015, the Company entered into convertible debt agreements with a third-party investor totaling $15,000 at 8% interest, due on May 23, 2018. The debt is convertible into shares of common stock at a conversion price of $0.15 per share. As of May 31, 2023 and November 30, 2022, the note was in default.

 

Between December 3, 2014 and July 28, 2015, the Company issued a total of $113,031 in notes payable. Interest on the notes is payable at 8%. The loans were due prior to December 31, 2015 and are past due.

 

Accrued interest on notes payable and convertible debt at May 31, 2023 and November 30, 2022 amounted to $365,107 and $275,071, respectively, which is included as a component of accounts payable and accrued expenses.

 

Interest expense on notes payable and convertible debt with third parties amounted to $11,247, $22,494, $11,247 and $22,494 for the three and six months ended May 31, 2023 and May 31, 2022 respectively.

 

 

XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Related Party Transactions
6 Months Ended
May 31, 2023
Related Party Transactions [Abstract]  
Related Party Transactions

Note 4. Related Party Transactions

 

On May 27, 2016, the former Chief Executive Officer, now our Chief Financial Officer, agreed to reduce his accrued compensation by $206,250 as a contribution to additional paid in capital. He also agreed to reclassify $874,000 in accrued compensation to long term debt upon the issuance of a non-convertible 4% interest bearing note with a maturity date of December 1, 2017. The compensation included was accrued during the period from January 2, 2011 to February 29, 2016. This compensation will be paid as bonuses out of future income only and is further subject to a cap of 20% of operating net cash flow in any given period. If bonuses are paid, accrued compensation will be paid with an amount decided by the Board. On June 1, 2016, he agreed to reduce his accrued compensation by $25,000 as a contribution to additional paid in capital. He also agreed to reduce his long term note by $214,000 as a contribution to additional paid in capital. As the Company was not funded prior to December 1, 2016, the Board of Directors reversed the contribution of accrued salaries. As of May 31, 2023 and November 30, 2022, the Chief Financial Officer was owed $445,250 and $445,250, respectively, of accrued compensation and accrued salary was reduced by $15,722.47. As of May 31, 2023 and November 30, 2022, the Chief Financial Officer was owed $805,637 and $805,637, respectively, of notes payable and accrued interest.

 

On May 27, 2016, the Director of Strategy agreed to reduce her accrued compensation by $206,250 as a contribution to additional paid in capital. She also agreed to reclassify $660,000 in accrued compensation to long term debt upon the issuance of a non-convertible 4% interest bearing note with a maturity date of December 1, 2017. The total principal amount of $710,000 included three different notes totaling $50,000@ 8% interest. The compensation included was accrued during the period from January 2, 2011 to February 29, 2016. This compensation will be paid as bonuses out of future income only and is further subject to a cap of 20% of operating net cash flow in any given period. If bonuses are paid, accrued compensation will be paid with an amount decided by the Board. On June 1, 2016, she agreed to reduce her accrued compensation by $225,000 as a contribution to additional paid in capital. She also agreed to reduce her long term note by $9,583 as a contribution to additional paid in capital. As the Company was not funded prior to December 1, 2016, the Board of Directors reversed the contribution of accrued salaries. As of May 31, 2023 and November 30, 2022, the Director was owed a total of $440,833 and $440,833, respectively, of accrued compensation. As of May 31, 2023 and November 30, 2022, the Director was owed a total of $883,791 and $883,791, respectively, of notes payable and accrued interest. There was a reduction in the liability by share issuance of $27,308.

 

As of November 30, 2016, a related party investor advanced a total of $99,448 due on or before June 15, 2016. Pursuant to the agreement, the investor is allowed to convert 100% of the debt at a share price of $0.15. As of May 31, 2023 and November 30, 2022, the note was in default.

 

In March 2016, the Chief Operating Officer loaned to the Company $100,000. The loan bears interest at 8% and is due on or before March 2, 2018. Pursuant to the agreement, the investor is allowed to convert 100% of the debt on the maturity date at a share price of $0.15. The Company accounted for the conversion of loan in accordance with ASC 470, “Debt with Conversion and Other Options”. The fair market value of the shares on March 2, 2016 was $0.10 per share and, accordingly, there was deemed to be no Beneficial Conversion Factor. On May 18, 2016, the Chief Operating Officer loaned the Company an additional $50,000 with conversion rights at $0.10 per share. Therefore, effective May 18, 2016, $50,000 of the Chief Operating Officer’s note payable had conversion rights of $0.10 per share. The Company accounted for the conversion of loan in accordance with ASC 470, “Debt with Conversion and Other Options”. The fair market value of the shares on May 18, 2016 was $0.10 per share and accordingly there was deemed to be no Beneficial Conversion Factor. On May 23, 2016, a third-party investor loaned the Company $25,000 with conversion rights at $0.10 per share. Therefore, effective May 23, 2016, an additional $25,000 of the Chief Operating Officer’s $100,000 note payable had conversion rights of $0.10 per share. The Company accounted for the conversion of loan in accordance with ASC 470, “Debt with Conversion and Other Options”. The fair market value of the shares on May 18, 2016 was $0.10 per share and accordingly, was deemed to have no Beneficial Conversion Factor. As of May 31, 2023 and November 30, 2022, the note was in default.

 

In May 2016, the Chief Operating Officer made a loan of $50,000, bearing interest at 8% and due on or before May 18, 2018. The debt is convertible into shares of common stock at a conversion price of $0.10 per share. As of May 31, 2023 and November 30, 2022, the note was in default.

 

 

In July 2016, the Chief Operating Officer made a loan of $50,000 as collateral, bearing interest at 8% and due on or before July 31, 2018. The debt is convertible into shares of common stock at a conversion price of $0.10 per share. As of May 31, 2023 and November 30, 2022, the note was in default.

 

On June 29, 2021 the Company entered into an employment agreement with Robert Kohn. The Company agreed to an annual salary of $150,000 beginning on September 30, 2021. Mr. Kohn resigned on November 15, 2022. As of May 31, 2023 and November 30, 2022 the Company accrued $168,750 and $168,750, respectively.

 

During the year ended November 30, 2021 the Company issued 17,500,000 HyFi Tokens to related parties for the purchase of technology. The Technology has a historical value of $0. In addition, the Company issued Troy MacDonald 175,000 HyFi Tokens as consideration for his sale of HyFi tokens at 5% of the related token sales.

 

Accrued interest on related party notes payable and convertible debt at May 31, 2023 and November 30, 2022, amounted to $611,290 and $568,912, respectively, and is a component of accounts payable and accrued expenses – related parties.

 

The Company has separated accounts payable and accrued expenses on the balance sheet to reflect amounts due to related parties primarily consisting of officer compensation, health insurance, interest on notes and reimbursable expenses to officers for travel, meals and entertainment, vehicle and other related business expenses.

 

Convertible Loans – variable priced conversion

 

XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Convertible loans
6 Months Ended
May 31, 2023
Convertible Loans  
Convertible loans

Note 5. Convertible loans

 

Diagonal Lending Securities Purchase Agreement & Convertible Note

 

On May 31, 2022, the Company entered into a Securities Purchase Agreement (the “Diagonal Lending SPA”) by and between the Company and 1800 Diagonal Lending LLC (“Diagonal Lending”). Pursuant to the terms of the Diagonal Lending SPA, the Company agreed to sell, and Diagonal Lending agreed to purchase, a convertible note of the Company in the aggregate principal amount of $90,000. On August 5, 2022 the Company borrowed an additional $78,750 with similar terms. On September 26, 2022 the Company borrowed an additional $55,000 with similar terms

 

On May 31, 2022 ,August 5, 2022 and September 26, 2022, pursuant to the terms of the Diagonal Lending SPA, the Company issued to Diagonal Lending a convertible promissory note (the “Diagonal Lending Note”) in the principal amount of $90,000, $78,750 and $55,000, respectively. The Diagonal Lending Note was funded on June 23, 2022, August 5th, 2022 and November 6, 2022. The Diagonal Lending Note bears interest at a rate of 10% per annum and matures 180 days after issuance. The Diagonal Lending Note may not be prepaid in whole or in part except as otherwise explicitly set forth in the Diagonal Lending Note. Any amount of principal or interest which is not paid when due will bear interest at a rate of 22% per annum.

 

Diagonal Lending has the right from time to time, and at any time following November 27, 2022 and ending on the earlier of (i) payment of all amounts due under the Diagonal Lending Note, (ii) May 31, 2023, if all amounts are repaid in full at such time, or (iii) the date full repayment of all indebtedness to convert all or any part of the indebtedness into common stock subject to the terms of the Digital Lending Note at the Conversion Price (as hereinafter defined). The “Conversion Price” means 65% multiplied by the lowest trading price for the Company’s common stock during the 10 trading day period ending on the latest complete trading day prior to the conversion date, subject to a 4.99% equity blocker and subject to the terms of the Diagonal Lending Note.

 

The Diagonal Lending Note may be prepaid; provided, however, that if the Company exercises its right to prepay, the Company will make payment to Diagonal Lending of an amount in cash equal to the percentage as set forth in the table below, multiplied by the sum of: (w) the then outstanding principal amount of the Diagonal Lending Note, plus (x) accrued and unpaid interest on the unpaid principal amount of the Diagonal Lending Note, plus (y) default interest, if any, on the amounts referred to in clauses (w) and (x) plus (z) certain other amounts owed to Diagonal Lending pursuant to the terms of the Diagonal Lending Note.

 

 

Prepayment Period  Prepayment Percentage 
May 31, 2022 to July 30, 2022   120%
July 31, 2022 to October 28, 2022   125%
October 29, 2022 to November 27, 2022   130%

 

After November 27, 2022, prepayment will be subject to agreement of the parties with respect to the applicable prepayment percentage.

 

On February 17, 2023 Diagonal converted $12,000 of principal into 242,915 shares of common stock at the price of $0.0494. The Company recorded dividend resolution of $15,176.

 

XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Senior Promissory Note – related party
6 Months Ended
May 31, 2023
Senior Promissory Note Related Party  
Senior Promissory Note – related party

Note 6. Senior Promissory Note – related party

 

On June 29, 2021, the Closing Date, the Company and CEP entered into the Redemption Agreement, dated as of June 29, 2021, pursuant to which the Company redeemed the Series A Share. On the Closing Date, as provided in the Redemption Agreement, the Company issued to CEP the Note in the principal amount of $1,000,000 with an interest rate of 6% per annum. The Series A Share will be held in escrow. If an Event of Default (as defined in the Note) occurs under the Note, then the Company will direct the escrow agent to release the Series A Share to CEP; provided, however, that CEP will also retain all rights and privileges under the Note (and the Company will remain bound to all obligations under Note) even if the Series A Share is required to be released by the escrow agent to CEP as provided in the Redemption Agreement. For the avoidance of doubt, CEP will regain all rights, title, and interest in and to the Series A Share upon the occurrence of an Event of Default under the Note, regardless of the amount of the outstanding balance owed under the Note at the time of the occurrence of an Event of Default under the Note.

 

On June 22, 2022, the Company entered into the Addendum and Amendment of Promissory Note (the “Note Amendment”) by and between the Company and China Energy Partners, LLC (“China Energy”). Pursuant to the terms of the Note Amendment, the Company and China Energy agreed to amend the Senior Promissory Note issued by the Company to China Energy on June 29, 2021 (the “China Energy Note”) such that (i) the principal amount and accrued interest under the China Energy Note will be repaid in full on or before June 28, 2022, with $800,000 to be paid in cash and $200,000 to be paid via the transfer to China Energy of tokens to an electronic wallet; and (ii) the parties agree that $60,000 in interest previously accrued under the China Energy Note was satisfied via the transfer by the Company to China Energy of 53 HyFi NFT Athena vaults.

 

On June 28, 2022, the China Energy Note, as amended by the Note Amendment, was paid in full.

 

XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ deficit
6 Months Ended
May 31, 2023
Equity [Abstract]  
Stockholders’ deficit

Note 6. Stockholders’ deficit

 

On August 5, 2021, Company effected the following share issuances:

 

The Company issued 50,000 shares of common stock valued at $2,500 ($0.05 per share) to a consultant.

 

The Company issued 750,000 shares of common stock valued at $37,500 ($0.05 per share) to Baruch Halpern for severance compensation.

 

The Company issued 546,160 shares of common stock valued at $27,307 ($0.05 per share) to Robert Kohn for partial conversion of accrued compensation.

 

The Company issued 546,160 shares of common stock valued at $27,307 ($0.05 per share) to Bonnie Nelson for partial conversion of accrued compensation.

 

On the Closing Date, the Company and CEP entered into the Redemption Agreement, dated as of June 29, 2021, pursuant to which the Company redeemed the Series A Share. On the Closing Date, as provided in the Redemption Agreement, the Company issued to CEP the Note in the principal amount of $1,000,000 with an interest rate of 6% per annum. The Series A Share will be held in escrow. If an Event of Default (as defined in the Note) occurs under the Note, then the Company will direct the escrow agent to release the Series A Share to CEP; provided, however, that CEP will also retain all rights and privileges under the Note (and the Company will remain bound to all obligations under Note) even if the Series A Share is required to be released by the escrow agent to CEP as provided in the Redemption Agreement. For the avoidance of doubt, CEP will regain all rights, title, and interest in and to the Series A Share upon the occurrence of an Event of Default under the Note, regardless of the amount of the outstanding balance owed under the Note at the time of the occurrence of an Event of Default under the Note.

 

 

On June 29, 2021, the Sellers agreed to (i) pay to the Company, on the closing date of the Acquisition, $300,000 (the “Cash Consideration”), and (ii) transfer to the Company, on the closing date of the Acquisition, 400,000,000 HyFi Tokens (the “HyFi Token Consideration”). The Company used the Cash Consideration to bring the Company into a fully reporting status with the SEC and for public company operating expenses.

 

In exchange for the sale of the Assets and the Cash Consideration, the Company agreed to issue to the Sellers an aggregate of 900,000 Series C preferred shares within 30 calendar days after the State of Nevada provides written confirmation of filing of the certificate of designation for the Series C preferred stock.

 

Pursuant to the terms of the APA, the parties agreed that the Series C preferred stock will have the following terms, among others:

 

1. Authorized Shares of Series C Preferred Stock. The number of authorized shares of Series C preferred stock will be 900,000.

 

2. Conversion. Subject to the other terms and conditions in the certificate of designation, a Series C preferred stock holder will have the right from time to time and at any time following the date that is one year after the date on the signature page of the certificate of designations to convert each outstanding share of Series C preferred stock into 450 shares of Company common stock. Based on the number of shares of common stock issued and outstanding as of November 30, 2021, if all of the 900,000 shares of Series C preferred stock are issued and subsequently converted, the holders of the converted stock will hold 90% of the issued and outstanding shares of common stock.

 

3. Voting. Except as otherwise set forth in the certificate of designation, each share of Series C preferred stock will, on any matter submitted to the holders of Company common stock, or any class thereof, for a vote, vote together with the common stock, or any class thereof, as applicable, as one class on such matter, and each share of Series C preferred stock will have 450 votes.

 

4. Dividends. The Series C preferred stock is not entitled to receive dividends or distributions.

 

On August 27, 2021, the Company filed with the State of Nevada a certificate of designations for the Series C preferred stock.

 

On July 28, 2021, the Company amended and restated its articles of incorporation, as amended, in order to, among other things, (i) increase the number of authorized shares of common stock from 100,000,000 to 500,000,000, (ii) increase the number of authorized shares of preferred stock from 10,000 to 5,000,000, and (iii) change the par value of the preferred stock from $1.00 par value per share to $0.0001 par value per share. As of November 30, 2021, the Company had authorized 500,000,000 shares of common stock, $0.0001 par value per share, and 5,000,000 shares of preferred stock, $0.0001 par value per share. As of May 31, 2022, and November 30, 2021, respectively, there were 45,625,000 and 45,000,000 shares of common stock issued and outstanding, and 900,000 and 1 shares and 0 shares of preferred stock issued and outstanding, respectively.

 

On March 5, 2022, the Company entered into a Stock Purchase Agreement (the “Compton SPA”) by and between the Company and Clarke Compton. Pursuant to the terms of the Compton SPA, the Company agreed to sell, and Mr. Compton agreed to purchase 625,000 shares of the Company’s common stock for a total purchase price of $250,000.

 

On June 26, 2022 PIP agreed to purchase, and the Company agreed to sell 500,000 shares of restricted common stock at a purchase price of $0.25 per share. As of May 31, 2023 and November 30, 2022 the shares have not been issued by the transfer agent

 

 

On April 21, 2023 the Company awarded 112,346 of the Company’s ‘C’ class preference shares to an employe the vesting schedule is :

 

On signing this agreement (April 21, 2023)   28,088 ‘C’ class preference shares
After 6 months (October 21, 2023)   28,086 ‘C’ class preference shares
After 12 months (April 21, 2024)   28,086 ‘C’ class preference shares
After 18 months (October 21, 2024)   28,086 ‘C’ class preference shares

 

During the three months ended May 31, 2023 the Company recorded an expense of $4,423,545 for the vested portion of the awards. The remaining unamortized amount of $7,709,607 will be amortized over the vesting period.

 

XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies
6 Months Ended
May 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 8. Commitments and Contingencies

 

Commitments

 

On April 6, 2022, the Company entered into an agreement (the “Sanctum Agreement”) with Sanctum Studios (“Sanctum”) relating to The Athena Project. Pursuant to the terms of the Sanctum Agreement, Sanctum agreed to conceptualize, create and produce a collection of 20,000 digital art assets based on the Greek Goddess Athena, in exchange for payment by the Company of $121,000 and certain variable rate payments depending on the number of vaults sold by the Company. The $121,000 is payable by the Company in three equal installments of $40,333.33 due on April 4, 2022, May 19, 2022 and July 1, 2022. The Company paid all installments due through August 31, 2022. The Sanctum deliverables are due by July 1, 2022 or earlier, as set forth in the Sanctum Agreement. The Company announced this material definitive agreement and associated Press Release, incorporated by reference, on a Current Report on Form 8-K which was filed with the SEC on April 7, 2022.

 

PIP North America ILO and Multi-Agreement

 

On June 26, 2022 , the Company entered into an ILO and Multi-Agreement (the “PIP Agreement”) with PIP North America Inc. (“PIP”). Pursuant to the terms of the PIP Agreement, the parties agreed as follows:

 

1. The Company agreed to provide PIP the exclusivity to list the first initial license offering (“ILO”) for a minimum of 90 days. PIP can mutually agree to allow the Company to list another ILO during this period and PIP will receive 50% of gross revenues.

 

2. PIP will not pay any listing fee for its first three ILOs, and the Company will provide free consulting services to help structure the ILOs.

 

3. The Company agreed to provide services necessary from Super How for the customization of the HyFi technology for the first three PIP ILOs, including smart contracts for each listing.

 

4. The Company agreed to provide, at the Company’s cost, Prime Trust for anti-money laundering (AML) and know your customer (KYC) services, including processing of the payments, conversion of tokens to fiat currency for the use by the ILO issuer and all other services necessary for any ILOs, projects or bridge loans that PIP agrees to list on HyFi marketplaces to raise capital.

 

5. The Company agreed to provide PIP with Exclusive License options for one-year $1 million an option for an additional year for $10 million for the agriculture category on the HyFi DeFi marketplaces. Whoever brings the issuer will receive 75% of the gross revenues and whoever does not bring the issuer will receive 25% of the gross revenues. The option for the one-year exclusive must be exercised while the first PIP ILO is listed on the HyFi ILO marketplace and, once exercised, will last for one year. Within 90 days of the expiration of the one-year exclusive license, PIP must exercise the license for the second year.

 

 

6. PIP agreed to pay the Company 5% of gross sales of PIP vaults plus usual and customary percentages charged by third party vendors for the vault program.

 

7. PIP agreed to purchase, and the Company agreed to sell 500,000 shares of restricted common stock at a purchase price of $0.25 per share. As of November 30, 2022 the shares have not been issued by the transfer agent.

 

8. PIP agreed to purchase, and the Company agreed to sell 3,125,000 HyFi tokens at a purchase price of $0.04 per token for $125,000. The HyFi tokens can be used as utility tokens in conjunction with HyFi DeFi marketplace fees and services, HyFi vaults, HyFi memberships and any other HyFi fees and services. As of November 30, 2022 the HyFi tokens have not been delivered.

 

9. The Company agreed to grant PIP an option to purchase up to 50 HyFi vaults for $1,000. The option will expire on August 30, 2022.

 

10. The Company agreed to provide a license for the HyFi Vault Program, a blockchain promotional and marketing program, and services necessary from third party vendors, including Super How and Sanctum Studios.

 

11. In exchange for the above, PIP agreed to pay to the Company $500,000. The Company agreed to use this payment as part of the payments to retire the China Energy Note, as amended.

 

On November 11, 2022, the Company entered into an agreement with Generation Power Group Limited. The Company agreed to act as a non-exclusive placement agent in connection with an offering to investors of up to an aggregate of $100,000,000 of securities. The Company will receive the following:

 

  (a) Company Onboarding & Due Diligence Fee. The Company will receive a non-refundable Onboarding fee of $125,000 upon execution of this Agreement.

 

  (b) Placement Fee. The Company will receive a cash placement fee equal to 4% of the aggregate gross proceeds received from Investors that the Company originated. The Company will receive placement fee equal to 2% of the aggregate gross proceeds received from Investors that Generation Power Group Limited originate.

 

  (c) Expenses. The Company will receive promptly reimburse upon request for reasonable out-of-pocket expenses incurred by the Company in connection with the services provided hereunder, including, without limitation, travel costs, Site maintenance, and other customary expenses for this type of engagement, including, without limitation, out-of-pocket legal or regulatory fees, costs and expenses (including without limitation, any Offering-related regulatory filing fees and reasonable out-of-pocket counsel or consultant fees, related to the review of Offering Materials for compliance with applicable SEC/FINRA rules).

 

  (d) All fees and expenses payable hereunder are net of all applicable withholding and similar taxes.

 

The term of this Agreement shall be from the date hereof until the earlier of: (i) 12 months from the date hereof; or (ii) the date of the closing of the Offering as agreed by HYFI and the Company. The engagement hereunder will commence upon the execution of this Agreement by both parties, and shall be terminable by either party, with or without cause, on 30 days’ prior written notice to the other.

 

As of November 30, 2022, the Company has recorded the Onboarding & Due Diligence Fee as deferred revenue.

 

On November 15, 2022, Robert Kohn resigned as Chief Financial Officer of the Company and as a member of the Company’s Board of Directors, effective immediately. Mr. Kohn’s resignation was not because of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Effective November 15, 2022, the Board appointed Paul Christopher Walton to serve as the Company’s Chief Operating Officer, as well as the Company’s principal financial officer and principal accounting officer.

 

 

Mr.Walton, Since September 2022, Mr. Walton has served as Chief Operating Officer of HyFi, helping to review its security token and renewable green energy financing business. He is responsible for developing the regulated financial infrastructure which will enable HyFi to raise capital for its clients, as well as attending to key operational responsibilities.

 

For the past five years Mr. Walton advised several start-up fintech businesses to raise capital, arrange operations and develop business invest management and alternative investing markets. This work involved regulated blockchain and cryptocurrency businesses as well as style-based investment technology. At Optimal Asset Management, Mr. Walton grew assets and helped to develop a business which was eventually sold to BNY Mellon.

 

Prior to this, Mr. Walton advised on a substantial portion of new technology and new product development at the London Stock Exchange’s New York operation, FTSE Russell for two periods between 2009 and 2017. Mr. Walton also ran business development for renowned economist, Mr. Stephen Ross, at his Ross, Jeffrey and Antle hedge fund, for a four-year period, helping to grow assets substantially.

 

Mr. Walton worked for a number of leading investment banks in London over three decades from the 1980s to the early 2000’s. In this work, Mr. Walton was a highly rated financial analyst and investment strategist at the Warburg’s private bank, Schroders private bank, Goldman Sachs, Schroder Salomon Smith Barney, and Merrill Lynch.

 

Mr. Walton received a Master’s Degree in Economics from the University of London and Bachelor’s Degree in Economics from the Victoria University of Manchester. Mr. Walton studied advanced management principles at the UK-based Ashridge Business School. For most of his career, Mr. Walton held regulatory qualifications administered by the then UK supervisory body, Financial Services Authority.

 

Effective April 21, 2023 The Company and Paul Walton entered into a one year employment agreement.

 

The Company shall pay the Executive as compensation for his services during the first twelve (12) months of his Employment a base salary at a gross annual rate of $180,000. Such salary shall be payable either when:

 

i.the Company receives net investment of at least $1,000,000 or,
ii.the Company receives net income of at least $1,000,000.

 

Mr. Walton shall be awarded 112,346 of the Company’s ‘C’ class preference shares on signing this agreement according to the following vesting schedule:

 

On signing this agreement (April 21, 2023)   28,088 ‘C’ class preference shares
After 6 months (October 21, 2023)   28,086 ‘C’ class preference shares
After 12 months (April 21, 2024)   28,086 ‘C’ class preference shares
After 18 months (October 21, 2024)   28,086 ‘C’ class preference shares

 

During the three months ended May 31, 2023 the Company recorded an expense of $4,423,545 for the vested portion of the awards. The remaining unamortized amount of $7,709,607 will be amortized over the vesting period.

 

Contingencies

 

From time to time, the Company may be involved in legal matters arising in the ordinary course of business. While the Company believes that such matters are currently not material, there can be no assurance that matters arising in the ordinary course of business for which the Company is, or could be, involved in litigation, will not have a material adverse effect on its business, financial condition or results of operations.

 

XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Subsequent Events
6 Months Ended
May 31, 2023
Subsequent Events [Abstract]  
Subsequent Events

Note 9. Subsequent Events

 

On June 22, 2023 Diagonal converted $25,000 of principal into 253,036 shares of common stock at the price of $0.0988.

 

On June 27, 2023 Diagonal converted $25,000 of principal into 300,120 shares of common stock at the price of $0.0833.

 

On July 12, 2023 Diagonal converted $22,000 of principal into 637,019 shares of common stock at the price of $0.0416.

 

On July 14, 2023 Diagonal converted $20,000 of principal into 480,769 shares of common stock at the price of $0.0416.

 

On June 28, 2023, the Company entered into a Securities Purchase Agreement by and between the Company and Fast Capital LLC. Pursuant to the terms of the Diagonal Lending SPA, the Company agreed to sell, and Diagonal Lending agreed to purchase, a convertible note of the Company in the aggregate principal amount of $75,000. The Note is convertible at 65% of the lowest trading price of the Common Stock as reported on the National Quotations Bureau OTC.

 

On July 17, 2023, the Company entered into a Securities Purchase Agreement by and between the Company and 1800 Diagonal Lending LLC. Pursuant to the terms of the Diagonal Lending SPA, the Company agreed to sell, and Diagonal Lending agreed to purchase, a convertible note of the Company in the aggregate principal amount of $55,000. See note 5 for terms.

 

On August 21, 2023, the Company entered into a Securities Purchase Agreement by and between the Company and 1800 Diagonal Lending LLC. Pursuant to the terms of the Diagonal Lending SPA, the Company agreed to sell, and Diagonal Lending agreed to purchase, a convertible note of the Company in the aggregate principal amount of $10,000. See note 5 for terms.

XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
May 31, 2023
Accounting Policies [Abstract]  
Principles of Consolidation

Principles of Consolidation

 

All inter-company accounts and transactions have been eliminated in consolidation.

 

Basis of Presentation

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (the “ASC”) which is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with GAAP.

 

Going Concern

Going Concern

 

The accompanying unaudited consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these financial statements. The Company has incurred significant operating losses since inception. As of May 31, 2023, the Company had an accumulated deficit of $15,736,462 and stockholders’ deficit of $6,875,960.

 

Because the Company does not expect that existing operational cash flow will be sufficient to fund presently anticipated operations, this raises substantial doubt about the Company’s ability to continue as a going concern. Therefore, the Company will need to raise additional funds and is currently exploring alternative sources of financing. Historically, the Company has raised capital through private placements, as an interim measure to finance working capital needs and may continue to raise additional capital through the sale of common stock or other securities and obtaining some short-term loans. The Company will be required to continue to so until its operations become profitable. Also, the Company has, in the past, paid for consulting services with its common stock to maximize working capital, and intends to continue this practice where feasible.

 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

 

 

Accounts Receivable

Accounts Receivable

 

Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. If market conditions decline, actual collection experience may not meet expectations and may result in decreased cash flows and increased bad debt expense.

 

The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made.

 

Inventory

Inventory

 

Inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out basis and net realizable value. Net realizable value is defined as sales price less cost of completion, disposition and transportation and a normal profit margin. As of May 31, 2023 and November 30, 2022, inventory amounted to $12,893 and $12,893, respectively, which consisted of finished goods.

 

Revenue Recognition

Revenue Recognition

 

On July 1, 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Results for reporting periods beginning after January 1, 2018, are presented under ASC 606.

 

On June 29, 2021, the Sellers agreed to (i) pay to the Company, on the closing date of the Acquisition, $300,000 (the “Cash Consideration”), and (ii) transfer to the Company, on the closing date of the Acquisition, 400,000,000 HyFi Tokens (the “HyFi Token Consideration”). The Company used the Cash Consideration to bring the Company into a fully reporting status with the SEC and for public company operating expenses.

 

Concentration

Concentration

 

Two customers, including one related party, account for 100% of sales during the three months ended May 31, 2022.

 

Five customers, including two related parties, account for 100% of sales during the six months ended May 31, 2022.

 

Cash and cash equivalents

Cash and cash equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On May 31, 2023 the Company had a cash overdraft of $245 and on November 30, 2022, the Company’s cash equivalents totaled $825.

 

Income taxes

Income taxes

 

The Company accounts for income taxes under FASB ASC 740, “Accounting for Income Taxes”. Under FASB ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. FASB ASC 740-10-05, “Accounting for Uncertainty in Income Taxes,” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.

 

 

The amount recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company assesses the validity of its conclusions regarding uncertain tax positions quarterly to determine if facts or circumstances have arisen that might cause it to change its judgment regarding the likelihood of a tax position’s sustainability under audit.

 

Stock-based Compensation

Stock-based Compensation

 

The Company accounts for stock-based compensation using the fair value method following the guidance outlined in Section 718-10 of the ASC for disclosure about stock-based compensation. This section requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). That cost will be recognized over the period during which an employee is required to provide service in exchange for the award- the requisite service period (usually the vesting period). No compensation cost is recognized for equity instruments for which employees do not render the requisite service.

 

Net Loss per Share

Net Loss per Share

 

Net loss per common share is computed by dividing net loss by the weighted average common shares outstanding during the period as defined by ASC Topic 260, “Earnings per Share.” Basic earnings per common share calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which establishes a new lease accounting model for lessees. The updated guidance requires an entity to recognize assets and liabilities arising from financing and operating leases, along with additional qualitative and quantitative disclosures. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, with early adoption permitted. In March 2019, the FASB issued ASU 2019-01, Codification Improvements, which clarifies certain aspects of the new lease standard. The FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases in July 2018. Also in 2018, the FASB issued ASU 2018-11, Leases (Topic 842) Targeted Improvements, which provides an optional transition method whereby the new lease standard is applied at the adoption date and recognized as an adjustment to retained earnings. The amendments have the same effective date and transition requirements as the new lease standard.

 

We adopted ASC 842 on July 1, 2021. The adoption of ASC 842 did not have any impact on our financial statements.

 

Stockholders’ Equity

Stockholders’ Equity

 

On July 28, 2021, the Company amended and restated its articles of incorporation, as amended, in order to, among other things, (i) increase the number of authorized shares of common stock from 100,000,000 to 500,000,000, (ii) increase the number of authorized shares of preferred stock from 10,000 to 5,000,000, and (iii) change the par value of the preferred stock from $1.00 par value per share to $0.0001 par value per share. As of November 30, 2021, the Company had authorized 500,000,000 shares of common stock, $0.0001 par value per share, and 5,000,000 shares of preferred stock, $0.0001 par value per share.

 

On March 4, 2022, the Company issued 625,000 shares of restricted common stock to a Canadian investor for $0.40 per share for a total purchase price of $250,000.

 

 

On February 17, 2023 Diagonal converted $12,000 of principal into 242,915 shares of common stock at the price of $0.0494. The Company recorded a dividend resolution of $15,176.

 

As of May 31, 2023, and November 30, 2022, respectively, there were 45,867,915 and 45,625,000 shares of common stock issued and outstanding, respectively, and 900,000 and 1 shares and 0 shares of preferred stock issued and outstanding, respectively.

XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Notes Payable and Convertible Debt (Tables)
6 Months Ended
May 31, 2023
Debt Disclosure [Abstract]  
Schedule of Notes Payable

Notes payable consists of the following:

 

   Balance   Interest Rate   Maturity 
Demand loans  $551,167    4% to 8%   Various
Reclassification of accrued compensation to notes payable  143,031    8%   December 1, 2017  
Balance –May 31, 2023 and November 30, 2022  $694,198           
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Convertible loans (Tables)
6 Months Ended
May 31, 2023
Convertible Loans  
Schedule of Amount Owed on Prepayment of Diagonal Lending Note

 

Prepayment Period  Prepayment Percentage 
May 31, 2022 to July 30, 2022   120%
July 31, 2022 to October 28, 2022   125%
October 29, 2022 to November 27, 2022   130%
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ deficit (Tables)
6 Months Ended
May 31, 2023
Equity [Abstract]  
Schedule of Preference Shares Awarded to an Employee

 

On signing this agreement (April 21, 2023)   28,088 ‘C’ class preference shares
After 6 months (October 21, 2023)   28,086 ‘C’ class preference shares
After 12 months (April 21, 2024)   28,086 ‘C’ class preference shares
After 18 months (October 21, 2024)   28,086 ‘C’ class preference shares
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies (Tables)
6 Months Ended
May 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Preference Shares Awarded

 

On signing this agreement (April 21, 2023)   28,088 ‘C’ class preference shares
After 6 months (October 21, 2023)   28,086 ‘C’ class preference shares
After 12 months (April 21, 2024)   28,086 ‘C’ class preference shares
After 18 months (October 21, 2024)   28,086 ‘C’ class preference shares
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Organization (Details Narrative) - USD ($)
Jun. 29, 2021
Sep. 13, 2010
May 31, 2023
Nov. 30, 2022
Nov. 30, 2021
Jul. 28, 2021
Jul. 27, 2021
Jan. 06, 2011
Preferred stock, shares authorized         5,000,000 5,000,000 10,000  
Common Stock [Member]                
Stock conversion, issued shares 450              
Series C Preferred Stock [Member]                
Preferred stock, shares authorized 900,000   5,000,000 5,000,000        
Stock conversion, issued shares 900,000              
Preferred stock, conversion basis subsequently converted, the holders of the converted stock will hold 90% of the issued and outstanding shares of common stock              
Preferred stock, voting rights Except as otherwise set forth in the certificate of designation, each share of Series C preferred stock will, on any matter submitted to the holders of Company common stock, or any class thereof, for a vote, vote together with the common stock, or any class thereof, as applicable, as one class on such matter, and each share of Series C preferred stock will have 450 votes.              
Series A Preferred Stock [Member]                
Preferred stock, shares authorized     10,000 10,000        
Series A Preferred Stock [Member] | China Energy Partners LLC [Member] | Redemption Agreement [Member]                
Debt instrument, principal amount $ 1,000,000              
HyFi [Member]                
Cash consideration, acquisition $ 300,000              
Number of consideration shares 400,000,000              
Business combination description Pursuant to the terms of the APA, the Company agreed to file with the State of Nevada the certificate of designation for the Series C preferred stock on or before the date that is 60 calendar days after the closing of the Acquisition. In exchange for the sale of the Assets and the Cash Consideration, the Company agreed to issue to the Sellers an aggregate of 900,000 Series C preferred shares within 30 calendar days after the State of Nevada provides written confirmation of filing of the certificate of designation for the Series C preferred stock              
HyFi [Member] | HyFi Tokens [Member]                
Number of consideration shares 400,000,000              
BioPower Corporation [Member]                
Ownership, percentage               100.00%
Chief Executive Officer and Director [Member]                
Outstanding shares, percentage   100.00%            
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Feb. 17, 2023
Mar. 04, 2022
Jun. 29, 2021
May 31, 2022
May 31, 2022
May 31, 2023
Feb. 28, 2023
Nov. 30, 2022
Feb. 28, 2022
Nov. 30, 2021
Jul. 28, 2021
Jul. 27, 2021
Product Information [Line Items]                        
Accumulated deficit           $ 15,736,462   $ 10,349,524        
Stockholders' deficit       $ 5,173,145 $ 5,173,145 6,875,960 $ 6,542,174 5,939,743 $ 5,409,998 $ 5,411,178    
Inventory           12,893   12,893        
Cash overdraft           245          
Cash equivalents             $ 825        
Common stock, shares authorized           500,000,000   500,000,000   500,000,000 500,000,000 100,000,000
Preferred stock, shares authorized                   5,000,000 5,000,000 10,000
Preferred stock, par value                   $ 0.0001 $ 0.0001 $ 1.00
Common stock, par value           $ 0.0001   $ 0.0001   $ 0.0001    
Common stock, shares issued       45,625,000 45,625,000 45,867,915   45,625,000   45,000,000    
Common stock, shares outstanding       45,625,000 45,625,000 45,867,915   45,625,000   45,000,000    
Preferred stock, shares issued       900,000 900,000 900,000   1   1    
Preferred stock, shares outstanding       900,000 900,000 900,000   0   0    
Diagonal Lending [Member]                        
Product Information [Line Items]                        
Debt principal amount converted $ 12,000                      
Common stock issued in conversion 242,915                      
Debt conversion price $ 0.0494                      
Dividend resolution $ 15,176                      
Canadian Investor [Member]                        
Product Information [Line Items]                        
Restricted common stock issued, shares   625,000                    
Share issued price per share   $ 0.40                    
Restricted common stock issued   $ 250,000                    
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Two Customers [Member]                        
Product Information [Line Items]                        
Concentration risk, percentage       100.00%                
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Five Customers [Member]                        
Product Information [Line Items]                        
Concentration risk, percentage         100.00%              
HyFi [Member]                        
Product Information [Line Items]                        
Cash consideration, acquisition     $ 300,000                  
Number of consideration shares     400,000,000                  
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Notes Payable (Details) - USD ($)
6 Months Ended
May 31, 2023
Nov. 30, 2022
Jul. 28, 2015
Short-Term Debt [Line Items]      
Balance $ 694,198 $ 694,198 $ 113,031
Interest rate     8.00%
Demand Loans [Member]      
Short-Term Debt [Line Items]      
Balance $ 551,167    
Maturity date Various    
Demand Loans [Member] | Minimum [Member]      
Short-Term Debt [Line Items]      
Interest rate 4.00%    
Demand Loans [Member] | Maximum [Member]      
Short-Term Debt [Line Items]      
Interest rate 8.00%    
Reclassification of Accrued Compensation To Notes Payable [Member]      
Short-Term Debt [Line Items]      
Balance $ 143,031    
Interest rate 8.00%    
Maturity date December 1, 2017    
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Notes Payable and Convertible Debt (Details Narrative) - USD ($)
2 Months Ended 3 Months Ended 6 Months Ended
May 23, 2016
Jul. 30, 2015
Jan. 07, 2012
May 31, 2023
May 31, 2022
May 31, 2023
May 31, 2022
Nov. 30, 2022
Jul. 27, 2016
Jul. 28, 2015
Dec. 03, 2013
Short-Term Debt [Line Items]                      
Notes payable       $ 694,198   $ 694,198   $ 694,198   $ 113,031  
Debt instrument, interest                   8.00%  
Accrued interest       365,107   365,107   $ 275,071      
Third Party Investor [Member]                      
Short-Term Debt [Line Items]                      
Conversion price per share $ 0.10                    
Lender [Member]                      
Short-Term Debt [Line Items]                      
Notes payable     $ 70,000                
Debt instrument, interest     4.00%                
Debt Instrument, Maturity Date     May 31, 2012                
Conversion price per share     $ 0.25                
Third Parties [Member] | Convertible Debt [Member]                      
Short-Term Debt [Line Items]                      
Interest expense       $ 11,247 $ 11,247 $ 22,494 $ 22,494        
Demand Loan Agreements [Member] | Third Party Investor [Member]                      
Short-Term Debt [Line Items]                      
Notes payable                 $ 193,667    
Debt instrument, interest                 4.00%    
Convertible Debt Agreement [Member] | Third Party Investor [Member]                      
Short-Term Debt [Line Items]                      
Debt instrument, interest 8.00%                   8.00%
Debt Instrument, Maturity Date May 23, 2018                    
Conversion price per share $ 0.10                   $ 0.10
Convertible debt $ 25,000                   $ 62,500
Debt instrument, original percentage                     50.00%
Convertible Debt Agreement [Member] | Third Party Investor One [Member]                      
Short-Term Debt [Line Items]                      
Debt instrument, interest   8.00%                  
Debt Instrument, Maturity Date   Dec. 31, 2015                  
Conversion price per share   $ 0.15                  
Convertible debt   $ 200,000                  
Convertible Debt Agreement [Member] | Third Party Investor Two [Member]                      
Short-Term Debt [Line Items]                      
Debt instrument, interest   8.00%                  
Debt Instrument, Maturity Date   May 23, 2018                  
Conversion price per share   $ 0.15                  
Convertible debt   $ 15,000                  
Convertible Debt Agreement [Member] | Third Party Investor Three [Member]                      
Short-Term Debt [Line Items]                      
Debt instrument, interest   8.00%                  
Debt Instrument, Maturity Date   May 23, 2018                  
Conversion price per share   $ 0.15                  
Convertible debt   $ 15,000                  
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Related Party Transactions (Details Narrative)
1 Months Ended 6 Months Ended 12 Months Ended
Nov. 30, 2016
USD ($)
$ / shares
Jul. 31, 2016
USD ($)
$ / shares
Jun. 02, 2016
USD ($)
Jun. 01, 2016
USD ($)
May 31, 2016
USD ($)
May 27, 2016
USD ($)
Mar. 31, 2016
USD ($)
$ / shares
May 31, 2023
USD ($)
Nov. 30, 2021
USD ($)
Integer
Nov. 30, 2022
USD ($)
Jun. 29, 2021
USD ($)
May 23, 2016
USD ($)
$ / shares
May 18, 2016
USD ($)
$ / shares
Mar. 02, 2016
$ / shares
Jul. 28, 2015
USD ($)
Related Party Transaction [Line Items]                              
Debt instrument, interest rate                             8.00%
Notes payable               $ 694,198   $ 694,198         $ 113,031
Related Party [Member]                              
Related Party Transaction [Line Items]                              
Accrued interest               611,290 $ 568,912            
Related Party [Member] | Technology [Member]                              
Related Party Transaction [Line Items]                              
Value of purchased assets                 $ 0            
Related party token sales, rate                 5.00%            
Related Party [Member] | HyFi Tokens [Member] | Technology [Member]                              
Related Party Transaction [Line Items]                              
Number of tokens, issued | Integer                 17,500,000            
Third Party Investor [Member]                              
Related Party Transaction [Line Items]                              
Debt instrument, conversion price | $ / shares                       $ 0.10      
Robert Kohn [Member]                              
Related Party Transaction [Line Items]                              
Accrued salary               168,750   168,750 $ 150,000        
Troy Mac Donald [Member] | HyFi Tokens [Member] | Technology [Member]                              
Related Party Transaction [Line Items]                              
Number of tokens, issued | Integer                 175,000            
Chief Financial Officer [Member]                              
Related Party Transaction [Line Items]                              
Reduction in accrued compensation       $ 25,000   $ 206,250                  
Long term debt           $ 874,000                  
Debt instrument, interest rate           400.00%                  
Debt instrument, maturity date           Dec. 01, 2017                  
Debt instrument, description           The compensation included was accrued during the period from January 2, 2011 to February 29, 2016. This compensation will be paid as bonuses out of future income only and is further subject to a cap of 20% of operating net cash flow in any given period. If bonuses are paid, accrued compensation will be paid with an amount decided by the Board.                  
Reduction in long term debt       214,000                      
Accrued compensation               445,250   445,250          
Decrease in accrued salaries               15,722.47              
Notes payable               805,637   805,637          
Director Of Business Strategy [Member]                              
Related Party Transaction [Line Items]                              
Reduction in accrued compensation     $ 225,000     $ 206,250                  
Long term debt           $ 660,000                  
Debt instrument, interest rate           4.00%                  
Debt instrument, maturity date           Dec. 01, 2017                  
Debt instrument, description           The compensation included was accrued during the period from January 2, 2011 to February 29, 2016. This compensation will be paid as bonuses out of future income only and is further subject to a cap of 20% of operating net cash flow in any given period. If bonuses are paid, accrued compensation will be paid with an amount decided by the Board.                  
Reduction in long term debt       $ 9,583                      
Accrued compensation               440,833   440,833          
Notes payable               883,791   $ 883,791          
Debt instrument, face amount           $ 710,000                  
Reduction in liability insurance               $ 27,308              
Director Of Business Strategy [Member] | Three Notes [Member]                              
Related Party Transaction [Line Items]                              
Debt instrument, interest rate           8.00%                  
Debt instrument, face amount           $ 50,000                  
Investor [Member] | Related Party [Member]                              
Related Party Transaction [Line Items]                              
Debt instrument, maturity date Jun. 15, 2016                            
Notes payable $ 99,448                            
Debt instrument, conversion rate 100.00%                            
Debt instrument, conversion price | $ / shares $ 0.15                            
Chief Operating Officer [Member]                              
Related Party Transaction [Line Items]                              
Debt instrument, interest rate   8.00%     8.00%   8.00%                
Debt instrument, maturity date   Jul. 31, 2018     May 18, 2018   Mar. 02, 2018                
Notes payable                       $ 100,000 $ 50,000    
Debt instrument, conversion rate             100.00%                
Debt instrument, conversion price | $ / shares   $ 0.10         $ 0.15         $ 0.10 $ 0.10    
Loans payable   $ 50,000     $ 50,000   $ 100,000         $ 25,000 $ 50,000    
Share price | $ / shares                         $ 0.10 $ 0.10  
Third Party Investor [Member]                              
Related Party Transaction [Line Items]                              
Loans payable                       $ 25,000      
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Amount Owed on Prepayment of Diagonal Lending Note (Details)
May 31, 2023
May 31, 2022 to July 30, 2022 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Prepayment, rate 120.00%
July 31, 2022 to October 28, 2022 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Prepayment, rate 125.00%
October 29, 2022 to November 27, 2022 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Prepayment, rate 130.00%
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Convertible loans (Details Narrative) - USD ($)
Feb. 17, 2023
May 31, 2022
Sep. 26, 2022
Aug. 05, 2022
Jul. 28, 2015
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Debt instrument, interest rate         8.00%
Diagonal Lending [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Debt principal amount converted $ 12,000        
Common stock issued in conversion 242,915        
Debt conversion price $ 0.0494        
Dividend resolution $ 15,176        
Securities Purchase Agreement [Member] | Convertible Debt [Member] | Diagonal Lending [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Debt instrument, principal amount   $ 90,000      
Securities Purchase Agreement [Member] | Convertible Notes Payable [Member] | Diagonal Lending [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Debt instrument, principal amount     $ 55,000 $ 78,750  
Debt instrument, interest rate   10.00%      
Debt instrument, term   180 days      
Debt default, interest rate   22.00%      
Debt instrument, description   Diagonal Lending has the right from time to time, and at any time following November 27, 2022 and ending on the earlier of (i) payment of all amounts due under the Diagonal Lending Note, (ii) May 31, 2023, if all amounts are repaid in full at such time, or (iii) the date full repayment of all indebtedness to convert all or any part of the indebtedness into common stock subject to the terms of the Digital Lending Note at the Conversion Price (as hereinafter defined). The “Conversion Price” means 65% multiplied by the lowest trading price for the Company’s common stock during the 10 trading day period ending on the latest complete trading day prior to the conversion date, subject to a 4.99% equity blocker and subject to the terms of the Diagonal Lending Note      
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Senior Promissory Note – related party (Details Narrative)
Jun. 29, 2021
USD ($)
China Energy Partners Note Amendment [Member]  
Principal amount $ 800,000
Debt transfer amount 200,000
Accurued interest 60,000
China Energy Partners LLC [Member] | Redemption Agreement [Member] | Series A Preferred Stock [Member]  
Principal amount $ 1,000,000
Debt instrument, interest rate 6.00%
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Preference Shares Awarded to an Employee (Details) - Series C Preferred Stock [Member]
Apr. 21, 2023
shares
Class of Stock [Line Items]  
Number of shares awarded 112,346
Share-Based Payment Arrangement, Tranche One [Member]  
Class of Stock [Line Items]  
Vesting schedule On signing this agreement (April 21, 2023)
Number of shares awarded 28,088
Share-Based Payment Arrangement, Tranche Two [Member]  
Class of Stock [Line Items]  
Vesting schedule After 6 months (October 21, 2023)
Number of shares awarded 28,086
Share-Based Payment Arrangement, Tranche Three [Member]  
Class of Stock [Line Items]  
Vesting schedule After 12 months (April 21, 2024)
Number of shares awarded 28,086
Share-Based Compensation Award Tranche Four [Member]  
Class of Stock [Line Items]  
Vesting schedule After 18 months (October 21, 2024)
Number of shares awarded 28,086
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ deficit (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Apr. 21, 2023
Jun. 26, 2022
Mar. 05, 2022
Aug. 05, 2021
Jun. 29, 2021
May 31, 2023
May 31, 2022
May 31, 2022
Nov. 30, 2022
Nov. 30, 2021
Jul. 28, 2021
Jul. 27, 2021
Class of Stock [Line Items]                        
Value of shares issued             $ 249,991 $ 249,991        
Preferred stock, shares authorized                   5,000,000 5,000,000 10,000
Common stock, shares authorized           500,000,000     500,000,000 500,000,000 500,000,000 100,000,000
Preferred stock, par value                   $ 0.0001 $ 0.0001 $ 1.00
Common stock, par value           $ 0.0001     $ 0.0001 $ 0.0001    
Common stock, shares issued           45,867,915 45,625,000 45,625,000 45,625,000 45,000,000    
Common stock, shares outstanding           45,867,915 45,625,000 45,625,000 45,625,000 45,000,000    
Preferred stock, shares issued           900,000 900,000 900,000 1 1    
Preferred stock, shares outstanding           900,000 900,000 900,000 0 0    
Share-based compensation expense           $ 4,423,545            
Unamortized expense amount           $ 7,709,607            
HyFi [Member]                        
Class of Stock [Line Items]                        
Cash consideration, acquisition         $ 300,000              
Number of consideration shares         400,000,000              
HyFi [Member] | HyFi Tokens [Member]                        
Class of Stock [Line Items]                        
Number of consideration shares         400,000,000              
Series A Preferred Stock [Member]                        
Class of Stock [Line Items]                        
Preferred stock, shares authorized           10,000     10,000      
Preferred stock, par value           $ 1.00     $ 1.00      
Preferred stock, shares issued           0     1      
Preferred stock, shares outstanding           0     1      
Series C Preferred Stock [Member]                        
Class of Stock [Line Items]                        
Number of shares awarded 112,346                      
Preferred stock, shares authorized         900,000 5,000,000     5,000,000      
Conversion of stock, description         Subject to the other terms and conditions in the certificate of designation, a Series C preferred stock holder will have the right from time to time and at any time following the date that is one year after the date on the signature page of the certificate of designations to convert each outstanding share of Series C preferred stock into 450 shares of Company common stock. Based on the number of shares of common stock issued and outstanding as of November 30, 2021, if all of the 900,000 shares of Series C preferred stock are issued and subsequently converted, the holders of the converted stock will hold 90% of the issued and outstanding shares of common stock              
Conversion of stock shares issued         900,000              
Preferred stock voting rights         Except as otherwise set forth in the certificate of designation, each share of Series C preferred stock will, on any matter submitted to the holders of Company common stock, or any class thereof, for a vote, vote together with the common stock, or any class thereof, as applicable, as one class on such matter, and each share of Series C preferred stock will have 450 votes.              
Preferred stock, par value           $ 0.001     $ 0.001      
Preferred stock, shares issued           900,000     0      
Preferred stock, shares outstanding           900,000     0      
Series C Preferred Stock [Member] | HyFi [Member]                        
Class of Stock [Line Items]                        
Number of shares issued as consideration         900,000              
Restricted Common Stock [Member]                        
Class of Stock [Line Items]                        
Shares of restriced common stock   500,000                    
Share price   $ 0.25                    
China Energy Partners LLC [Member] | Redemption Agreement [Member] | Series A Preferred Stock [Member]                        
Class of Stock [Line Items]                        
Debt instrument, principal amount         $ 1,000,000              
Debt instrument, interest rate         6.00%              
Consultant [Member]                        
Class of Stock [Line Items]                        
Number of shares issued       50,000                
Value of shares issued       $ 2,500                
Issue price per share       $ 0.05                
Baruch Halpern [Member]                        
Class of Stock [Line Items]                        
Issue price per share       $ 0.05                
Number of shares awarded       750,000                
Value of shares issued       $ 37,500                
Robert Kohn [Member]                        
Class of Stock [Line Items]                        
Issue price per share       $ 0.05                
Number of shares awarded       546,160                
Value of shares issued       $ 27,307                
Bonnie Nelson [Member]                        
Class of Stock [Line Items]                        
Issue price per share       $ 0.05                
Number of shares awarded       546,160                
Value of shares issued       $ 27,307                
Mr. Compton [Member]                        
Class of Stock [Line Items]                        
Number of shares issued     625,000                  
Share purchase price     $ 250,000                  
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Preference Shares Awarded (Details) - Series C Preferred Stock [Member]
Apr. 21, 2023
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of shares awarded 112,346
Share-Based Payment Arrangement, Tranche One [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Vesting schedule On signing this agreement (April 21, 2023)
Number of shares awarded 28,088
Share-Based Payment Arrangement, Tranche One [Member] | Mr Walton [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Vesting schedule On signing this agreement (April 21, 2023)
Number of shares awarded 28,088
Share-Based Payment Arrangement, Tranche Two [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Vesting schedule After 6 months (October 21, 2023)
Number of shares awarded 28,086
Share-Based Payment Arrangement, Tranche Two [Member] | Mr Walton [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Vesting schedule After 6 months (October 21, 2023)
Number of shares awarded 28,086
Share-Based Payment Arrangement, Tranche Three [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Vesting schedule After 12 months (April 21, 2024)
Number of shares awarded 28,086
Share-Based Payment Arrangement, Tranche Three [Member] | Mr Walton [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Vesting schedule After 12 months (April 21, 2024)
Number of shares awarded 28,086
Share-Based Compensation Award Tranche Four [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Vesting schedule After 18 months (October 21, 2024)
Number of shares awarded 28,086
Share-Based Compensation Award Tranche Four [Member] | Mr Walton [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Vesting schedule After 18 months (October 21, 2024)
Number of shares awarded 28,086
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies (Details Narrative)
3 Months Ended 6 Months Ended
Apr. 21, 2023
USD ($)
shares
Nov. 11, 2022
USD ($)
Jul. 01, 2022
USD ($)
Jun. 26, 2022
USD ($)
$ / shares
shares
Jun. 26, 2022
USD ($)
$ / shares
shares
May 19, 2022
USD ($)
Apr. 06, 2022
USD ($)
Integer
Apr. 04, 2022
USD ($)
May 31, 2023
USD ($)
May 31, 2022
USD ($)
May 31, 2022
USD ($)
Product Liability Contingency [Line Items]                      
Offering to investors                   $ 249,991 $ 249,991
Cash placement fee rate   4.00%                  
Base salary annual rate $ 180,000                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized | shares 112,346                    
Share-based compensation expense                 $ 4,423,545    
Unamortized expense amount                 7,709,607    
Mr Walton [Member]                      
Product Liability Contingency [Line Items]                      
Share-based compensation expense                 4,423,545    
Unamortized expense amount                 $ 7,709,607    
Mr Walton [Member] | Minimum [Member]                      
Product Liability Contingency [Line Items]                      
Net investment threshold limit for salary payment $ 1,000,000                    
Net income threshold limit for salary payment $ 1,000,000                    
Generation Power Group Limited [Member]                      
Product Liability Contingency [Line Items]                      
Offering to investors   $ 100,000,000                  
Onboarding fee   $ 125,000                  
Restricted Common Stock [Member]                      
Product Liability Contingency [Line Items]                      
Shares issued, shares | shares       500,000              
Share price | $ / shares       $ 0.25 $ 0.25            
ILO and Multi Agreement [Member]                      
Product Liability Contingency [Line Items]                      
Gross revenue, description         PIP can mutually agree to allow the Company to list another ILO during this period and PIP will receive 50% of gross revenues.            
PIP Agreement [Member]                      
Product Liability Contingency [Line Items]                      
Gross revenue, description         Whoever brings the issuer will receive 75% of the gross revenues and whoever does not bring the issuer will receive 25% of the gross revenues            
Gross sales percentage       0.05 0.05            
PIP Agreement [Member] | Restricted Common Stock [Member]                      
Product Liability Contingency [Line Items]                      
Shares issued, shares | shares       500,000              
Share price | $ / shares       $ 0.25 $ 0.25            
Tokens issued during period shares | shares       3,125,000              
Token price | shares       0.04 0.04            
Tokens issued during period value new issues       $ 125,000              
Purchase of vaults, description       The Company agreed to grant PIP an option to purchase up to 50 HyFi vaults for $1,000. The option will expire on August 30, 2022              
Debt payment amount       $ 500,000 $ 500,000            
PIP Agreement [Member] | Exclusive License Options Year One [Member]                      
Product Liability Contingency [Line Items]                      
Exclusive license Amount       1,000,000 1,000,000            
PIP Agreement [Member] | Exclusive License Options Year Five [Member]                      
Product Liability Contingency [Line Items]                      
Exclusive license Amount       $ 10,000,000 $ 10,000,000            
Digital Art [Member] | Sanctum Agreement [Member]                      
Product Liability Contingency [Line Items]                      
Number of assets | Integer             20,000        
Payment of exchange     $ 40,333.33     $ 40,333.33 $ 121,000 $ 40,333.33      
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Subsequent Events (Details Narrative) - Diagonal Lending [Member] - USD ($)
Aug. 21, 2023
Jul. 28, 2023
Jul. 17, 2023
Jul. 14, 2023
Jul. 12, 2023
Jun. 27, 2023
Jun. 22, 2023
Feb. 17, 2023
Subsequent Event [Line Items]                
Debt principal amount converted               $ 12,000
Common stock issued in conversion               242,915
Debt conversion price               $ 0.0494
Subsequent Event [Member]                
Subsequent Event [Line Items]                
Debt principal amount converted       $ 20,000 $ 22,000 $ 25,000 $ 25,000  
Common stock issued in conversion       480,769 637,019 300,120 253,036  
Debt conversion price       $ 0.0416 $ 0.0416 $ 0.0833 $ 0.0988  
Subsequent Event [Member] | Securities Purchase Agreement [Member]                
Subsequent Event [Line Items]                
Debt principal amount converted $ 10,000 $ 75,000 $ 55,000          
Debt principal amount, conversion rate   65.00%            
XML 43 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001510832 2022-12-01 2023-05-31 0001510832 2023-08-22 0001510832 2023-05-31 0001510832 2022-11-30 0001510832 us-gaap:NonrelatedPartyMember 2023-05-31 0001510832 us-gaap:NonrelatedPartyMember 2022-11-30 0001510832 us-gaap:RelatedPartyMember 2023-05-31 0001510832 us-gaap:RelatedPartyMember 2022-11-30 0001510832 us-gaap:SeriesAPreferredStockMember 2023-05-31 0001510832 us-gaap:SeriesAPreferredStockMember 2022-11-30 0001510832 us-gaap:SeriesCPreferredStockMember 2023-05-31 0001510832 us-gaap:SeriesCPreferredStockMember 2022-11-30 0001510832 2023-03-01 2023-05-31 0001510832 2022-03-01 2022-05-31 0001510832 2021-12-01 2022-05-31 0001510832 BOPO:SaleOfTokensMember 2023-03-01 2023-05-31 0001510832 BOPO:SaleOfTokensMember 2022-03-01 2022-05-31 0001510832 BOPO:SaleOfTokensMember 2022-12-01 2023-05-31 0001510832 BOPO:SaleOfTokensMember 2021-12-01 2022-05-31 0001510832 BOPO:SaleOfTokensRelatedPartyMember 2023-03-01 2023-05-31 0001510832 BOPO:SaleOfTokensRelatedPartyMember 2022-03-01 2022-05-31 0001510832 BOPO:SaleOfTokensRelatedPartyMember 2022-12-01 2023-05-31 0001510832 BOPO:SaleOfTokensRelatedPartyMember 2021-12-01 2022-05-31 0001510832 us-gaap:NonrelatedPartyMember 2023-03-01 2023-05-31 0001510832 us-gaap:NonrelatedPartyMember 2022-03-01 2022-05-31 0001510832 us-gaap:NonrelatedPartyMember 2022-12-01 2023-05-31 0001510832 us-gaap:NonrelatedPartyMember 2021-12-01 2022-05-31 0001510832 us-gaap:RelatedPartyMember 2023-03-01 2023-05-31 0001510832 us-gaap:RelatedPartyMember 2022-03-01 2022-05-31 0001510832 us-gaap:RelatedPartyMember 2022-12-01 2023-05-31 0001510832 us-gaap:RelatedPartyMember 2021-12-01 2022-05-31 0001510832 2021-11-30 0001510832 2022-05-31 0001510832 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-02-28 0001510832 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-02-28 0001510832 us-gaap:PreferredStockMember 2022-02-28 0001510832 BOPO:CommonStockPayableMember 2022-02-28 0001510832 us-gaap:CommonStockMember 2022-02-28 0001510832 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0001510832 us-gaap:RetainedEarningsMember 2022-02-28 0001510832 2022-02-28 0001510832 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-02-28 0001510832 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-02-28 0001510832 us-gaap:PreferredStockMember 2023-02-28 0001510832 BOPO:CommonStockPayableMember 2023-02-28 0001510832 us-gaap:CommonStockMember 2023-02-28 0001510832 us-gaap:AdditionalPaidInCapitalMember 2023-02-28 0001510832 us-gaap:RetainedEarningsMember 2023-02-28 0001510832 2023-02-28 0001510832 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-11-30 0001510832 us-gaap:PreferredStockMember 2021-11-30 0001510832 BOPO:CommonStockPayableMember 2021-11-30 0001510832 us-gaap:CommonStockMember 2021-11-30 0001510832 us-gaap:AdditionalPaidInCapitalMember 2021-11-30 0001510832 us-gaap:RetainedEarningsMember 2021-11-30 0001510832 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-11-30 0001510832 us-gaap:PreferredStockMember 2022-11-30 0001510832 BOPO:CommonStockPayableMember 2022-11-30 0001510832 us-gaap:CommonStockMember 2022-11-30 0001510832 us-gaap:AdditionalPaidInCapitalMember 2022-11-30 0001510832 us-gaap:RetainedEarningsMember 2022-11-30 0001510832 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-03-01 2022-05-31 0001510832 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-03-01 2022-05-31 0001510832 us-gaap:PreferredStockMember 2022-03-01 2022-05-31 0001510832 BOPO:CommonStockPayableMember 2022-03-01 2022-05-31 0001510832 us-gaap:CommonStockMember 2022-03-01 2022-05-31 0001510832 us-gaap:AdditionalPaidInCapitalMember 2022-03-01 2022-05-31 0001510832 us-gaap:RetainedEarningsMember 2022-03-01 2022-05-31 0001510832 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-03-01 2023-05-31 0001510832 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-03-01 2023-05-31 0001510832 us-gaap:PreferredStockMember 2023-03-01 2023-05-31 0001510832 BOPO:CommonStockPayableMember 2023-03-01 2023-05-31 0001510832 us-gaap:CommonStockMember 2023-03-01 2023-05-31 0001510832 us-gaap:AdditionalPaidInCapitalMember 2023-03-01 2023-05-31 0001510832 us-gaap:RetainedEarningsMember 2023-03-01 2023-05-31 0001510832 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-01 2022-05-31 0001510832 us-gaap:PreferredStockMember 2021-12-01 2022-05-31 0001510832 BOPO:CommonStockPayableMember 2021-12-01 2022-05-31 0001510832 us-gaap:CommonStockMember 2021-12-01 2022-05-31 0001510832 us-gaap:AdditionalPaidInCapitalMember 2021-12-01 2022-05-31 0001510832 us-gaap:RetainedEarningsMember 2021-12-01 2022-05-31 0001510832 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-01 2023-05-31 0001510832 us-gaap:PreferredStockMember 2022-12-01 2023-05-31 0001510832 BOPO:CommonStockPayableMember 2022-12-01 2023-05-31 0001510832 us-gaap:CommonStockMember 2022-12-01 2023-05-31 0001510832 us-gaap:AdditionalPaidInCapitalMember 2022-12-01 2023-05-31 0001510832 us-gaap:RetainedEarningsMember 2022-12-01 2023-05-31 0001510832 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-05-31 0001510832 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-05-31 0001510832 us-gaap:PreferredStockMember 2022-05-31 0001510832 BOPO:CommonStockPayableMember 2022-05-31 0001510832 us-gaap:CommonStockMember 2022-05-31 0001510832 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001510832 us-gaap:RetainedEarningsMember 2022-05-31 0001510832 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2023-05-31 0001510832 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-05-31 0001510832 us-gaap:PreferredStockMember 2023-05-31 0001510832 BOPO:CommonStockPayableMember 2023-05-31 0001510832 us-gaap:CommonStockMember 2023-05-31 0001510832 us-gaap:AdditionalPaidInCapitalMember 2023-05-31 0001510832 us-gaap:RetainedEarningsMember 2023-05-31 0001510832 BOPO:BioPowerCorporationMember 2011-01-06 0001510832 BOPO:ChiefExecutiveOfficerAndDirectorMember 2010-09-12 2010-09-13 0001510832 BOPO:HyFiMember 2021-06-28 2021-06-29 0001510832 BOPO:HyFiMember BOPO:HyFiTokensMember 2021-06-28 2021-06-29 0001510832 us-gaap:SeriesCPreferredStockMember 2021-06-29 0001510832 us-gaap:CommonStockMember 2021-06-28 2021-06-29 0001510832 us-gaap:SeriesCPreferredStockMember 2021-06-28 2021-06-29 0001510832 us-gaap:SeriesAPreferredStockMember BOPO:RedemptionAgreementMember BOPO:ChinaEnergyPartnersLLCMember 2021-06-29 0001510832 BOPO:TwoCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-03-01 2022-05-31 0001510832 BOPO:FiveCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-12-01 2022-05-31 0001510832 2021-07-27 0001510832 2021-07-28 0001510832 BOPO:CanadianInvestorMember 2022-03-03 2022-03-04 0001510832 BOPO:CanadianInvestorMember 2022-03-04 0001510832 BOPO:DiagonalLendingMember 2023-02-17 2023-02-17 0001510832 BOPO:DiagonalLendingMember 2023-02-17 0001510832 BOPO:DemandLoansMember 2023-05-31 0001510832 srt:MinimumMember BOPO:DemandLoansMember 2023-05-31 0001510832 srt:MaximumMember BOPO:DemandLoansMember 2023-05-31 0001510832 BOPO:DemandLoansMember 2022-12-01 2023-05-31 0001510832 BOPO:ReclassificationOfAccruedCompensationToNotesPayableMember 2023-05-31 0001510832 BOPO:ReclassificationOfAccruedCompensationToNotesPayableMember 2022-12-01 2023-05-31 0001510832 BOPO:ThirdPartyInvestorMember BOPO:DemandLoanAgreementsMember 2016-07-27 0001510832 BOPO:LenderMember 2012-01-07 0001510832 BOPO:LenderMember 2011-10-28 2012-01-07 0001510832 BOPO:ThirdPartyInvestorMember BOPO:ConvertibleDebtAgreementMember 2013-12-03 0001510832 BOPO:ThirdPartyInvestorOneMember BOPO:ConvertibleDebtAgreementMember 2015-07-30 0001510832 BOPO:ThirdPartyInvestorOneMember BOPO:ConvertibleDebtAgreementMember 2015-07-29 2015-07-30 0001510832 BOPO:ThirdPartyInvestorMember BOPO:ConvertibleDebtAgreementMember 2016-05-23 0001510832 BOPO:ThirdPartyInvestorMember BOPO:ConvertibleDebtAgreementMember 2016-05-22 2016-05-23 0001510832 BOPO:ThirdPartyInvestorTwoMember BOPO:ConvertibleDebtAgreementMember 2015-07-30 0001510832 BOPO:ThirdPartyInvestorTwoMember BOPO:ConvertibleDebtAgreementMember 2015-07-29 2015-07-30 0001510832 BOPO:ThirdPartyInvestorThreeMember BOPO:ConvertibleDebtAgreementMember 2015-07-30 0001510832 BOPO:ThirdPartyInvestorThreeMember BOPO:ConvertibleDebtAgreementMember 2015-07-29 2015-07-30 0001510832 2015-07-28 0001510832 BOPO:ThirdPartiesMember us-gaap:ConvertibleDebtMember 2023-03-01 2023-05-31 0001510832 BOPO:ThirdPartiesMember us-gaap:ConvertibleDebtMember 2022-12-01 2023-05-31 0001510832 BOPO:ThirdPartiesMember us-gaap:ConvertibleDebtMember 2022-03-01 2022-05-31 0001510832 BOPO:ThirdPartiesMember us-gaap:ConvertibleDebtMember 2021-12-01 2022-05-31 0001510832 srt:ChiefFinancialOfficerMember 2016-05-26 2016-05-27 0001510832 srt:ChiefFinancialOfficerMember 2016-05-27 0001510832 srt:ChiefFinancialOfficerMember 2016-06-01 2016-06-01 0001510832 srt:ChiefFinancialOfficerMember 2023-05-31 0001510832 srt:ChiefFinancialOfficerMember 2022-11-30 0001510832 srt:ChiefFinancialOfficerMember 2022-12-01 2023-05-31 0001510832 BOPO:DirectorOfBusinessStrategyMember 2016-05-26 2016-05-27 0001510832 BOPO:DirectorOfBusinessStrategyMember 2016-05-27 0001510832 BOPO:DirectorOfBusinessStrategyMember BOPO:ThreeNotesMember 2016-05-27 0001510832 BOPO:DirectorOfBusinessStrategyMember 2016-06-01 2016-06-02 0001510832 BOPO:DirectorOfBusinessStrategyMember 2016-06-01 2016-06-01 0001510832 BOPO:DirectorOfBusinessStrategyMember 2023-05-31 0001510832 BOPO:DirectorOfBusinessStrategyMember 2022-11-30 0001510832 BOPO:DirectorOfBusinessStrategyMember 2022-12-01 2023-05-31 0001510832 us-gaap:InvestorMember us-gaap:RelatedPartyMember 2016-11-30 0001510832 us-gaap:InvestorMember us-gaap:RelatedPartyMember 2016-11-29 2016-11-30 0001510832 srt:ChiefOperatingOfficerMember 2016-03-31 0001510832 srt:ChiefOperatingOfficerMember 2016-03-01 2016-03-31 0001510832 srt:ChiefOperatingOfficerMember 2016-03-02 0001510832 srt:ChiefOperatingOfficerMember 2016-05-18 0001510832 BOPO:ThirdPartyInvestorMember 2016-05-23 0001510832 BOPO:ThirdPartyInvestorMember 2016-05-23 0001510832 srt:ChiefOperatingOfficerMember 2016-05-23 0001510832 srt:ChiefOperatingOfficerMember 2016-05-31 0001510832 srt:ChiefOperatingOfficerMember 2016-05-31 2016-05-31 0001510832 srt:ChiefOperatingOfficerMember 2016-07-31 0001510832 srt:ChiefOperatingOfficerMember 2016-07-31 2016-07-31 0001510832 BOPO:RobertKohnMember 2021-06-29 0001510832 BOPO:RobertKohnMember 2023-05-31 0001510832 BOPO:RobertKohnMember 2022-11-30 0001510832 BOPO:HyFiTokensMember BOPO:TechnologyMember us-gaap:RelatedPartyMember 2020-12-01 2021-11-30 0001510832 BOPO:TechnologyMember us-gaap:RelatedPartyMember 2021-11-30 0001510832 BOPO:HyFiTokensMember BOPO:TechnologyMember BOPO:TroyMacDonaldMember 2020-12-01 2021-11-30 0001510832 BOPO:TechnologyMember us-gaap:RelatedPartyMember 2020-12-01 2021-11-30 0001510832 us-gaap:RelatedPartyMember 2021-11-30 0001510832 us-gaap:ConvertibleDebtMember BOPO:DiagonalLendingMember BOPO:SecuritiesPurchaseAgreementMember 2022-05-31 0001510832 us-gaap:ConvertibleNotesPayableMember BOPO:DiagonalLendingMember BOPO:SecuritiesPurchaseAgreementMember 2022-08-05 0001510832 us-gaap:ConvertibleNotesPayableMember BOPO:DiagonalLendingMember BOPO:SecuritiesPurchaseAgreementMember 2022-09-26 0001510832 us-gaap:ConvertibleNotesPayableMember BOPO:DiagonalLendingMember BOPO:SecuritiesPurchaseAgreementMember 2022-05-31 0001510832 us-gaap:ConvertibleNotesPayableMember BOPO:DiagonalLendingMember BOPO:SecuritiesPurchaseAgreementMember 2022-05-31 2022-05-31 0001510832 BOPO:PrepaymentPeriodOneMember 2023-05-31 0001510832 BOPO:PrepaymentPeriodTwoMember 2023-05-31 0001510832 BOPO:PrepaymentPeriodThreeMember 2023-05-31 0001510832 BOPO:ChinaEnergyPartnersNoteAmendmentMember 2021-06-29 0001510832 BOPO:ConsultantMember 2021-08-04 2021-08-05 0001510832 BOPO:ConsultantMember 2021-08-05 0001510832 BOPO:BaruchHalpernMember 2021-08-04 2021-08-05 0001510832 BOPO:BaruchHalpernMember 2021-08-05 0001510832 BOPO:RobertKohnMember 2021-08-04 2021-08-05 0001510832 BOPO:RobertKohnMember 2021-08-05 0001510832 BOPO:BonnieNelsonMember 2021-08-04 2021-08-05 0001510832 BOPO:BonnieNelsonMember 2021-08-05 0001510832 BOPO:HyFiMember us-gaap:SeriesCPreferredStockMember 2021-06-28 2021-06-29 0001510832 BOPO:MrComptonMember 2022-03-03 2022-03-05 0001510832 BOPO:RestrictedCommonStockMember 2022-06-25 2022-06-26 0001510832 BOPO:RestrictedCommonStockMember 2022-06-26 0001510832 us-gaap:SeriesCPreferredStockMember 2023-04-21 2023-04-21 0001510832 us-gaap:SeriesCPreferredStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-04-21 2023-04-21 0001510832 us-gaap:SeriesCPreferredStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-04-21 2023-04-21 0001510832 us-gaap:SeriesCPreferredStockMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2023-04-21 2023-04-21 0001510832 us-gaap:SeriesCPreferredStockMember BOPO:ShareBasedCompensationAwardTrancheFourMember 2023-04-21 2023-04-21 0001510832 BOPO:DigitalArtMember BOPO:SanctumAgreementMember 2022-04-05 2022-04-06 0001510832 BOPO:DigitalArtMember BOPO:SanctumAgreementMember 2022-04-04 2022-04-04 0001510832 BOPO:DigitalArtMember BOPO:SanctumAgreementMember 2022-05-19 2022-05-19 0001510832 BOPO:DigitalArtMember BOPO:SanctumAgreementMember 2022-07-01 2022-07-01 0001510832 BOPO:ILOAndMultiAgreementMember 2022-06-26 2022-06-26 0001510832 BOPO:ExclusiveLicenseOptionsYearOneMember BOPO:PIPAgreementMember 2022-06-26 0001510832 BOPO:ExclusiveLicenseOptionsYearFiveMember BOPO:PIPAgreementMember 2022-06-26 0001510832 BOPO:PIPAgreementMember 2022-06-26 2022-06-26 0001510832 BOPO:PIPAgreementMember 2022-06-26 0001510832 BOPO:RestrictedCommonStockMember BOPO:PIPAgreementMember 2022-06-25 2022-06-26 0001510832 BOPO:RestrictedCommonStockMember BOPO:PIPAgreementMember 2022-06-26 0001510832 BOPO:GenerationPowerGroupLimitedMember 2022-11-10 2022-11-11 0001510832 2022-11-10 2022-11-11 0001510832 2023-04-21 2023-04-21 0001510832 srt:MinimumMember BOPO:MrWaltonMember 2023-04-21 2023-04-21 0001510832 BOPO:MrWaltonMember 2023-03-01 2023-05-31 0001510832 BOPO:MrWaltonMember 2023-05-31 0001510832 BOPO:MrWaltonMember us-gaap:SeriesCPreferredStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-04-21 2023-04-21 0001510832 BOPO:MrWaltonMember us-gaap:SeriesCPreferredStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-04-21 2023-04-21 0001510832 BOPO:MrWaltonMember us-gaap:SeriesCPreferredStockMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2023-04-21 2023-04-21 0001510832 BOPO:MrWaltonMember us-gaap:SeriesCPreferredStockMember BOPO:ShareBasedCompensationAwardTrancheFourMember 2023-04-21 2023-04-21 0001510832 BOPO:DiagonalLendingMember us-gaap:SubsequentEventMember 2023-06-21 2023-06-22 0001510832 BOPO:DiagonalLendingMember us-gaap:SubsequentEventMember 2023-06-22 0001510832 BOPO:DiagonalLendingMember us-gaap:SubsequentEventMember 2023-06-26 2023-06-27 0001510832 BOPO:DiagonalLendingMember us-gaap:SubsequentEventMember 2023-06-27 0001510832 BOPO:DiagonalLendingMember us-gaap:SubsequentEventMember 2023-07-11 2023-07-12 0001510832 BOPO:DiagonalLendingMember us-gaap:SubsequentEventMember 2023-07-12 0001510832 BOPO:DiagonalLendingMember us-gaap:SubsequentEventMember 2023-07-13 2023-07-14 0001510832 BOPO:DiagonalLendingMember us-gaap:SubsequentEventMember 2023-07-14 0001510832 BOPO:DiagonalLendingMember us-gaap:SubsequentEventMember BOPO:SecuritiesPurchaseAgreementMember 2023-07-27 2023-07-28 0001510832 BOPO:DiagonalLendingMember us-gaap:SubsequentEventMember BOPO:SecuritiesPurchaseAgreementMember 2023-07-16 2023-07-17 0001510832 BOPO:DiagonalLendingMember us-gaap:SubsequentEventMember BOPO:SecuritiesPurchaseAgreementMember 2023-08-20 2023-08-21 iso4217:USD shares iso4217:USD shares BOPO:Integer pure 0001510832 false --11-30 Q2 10-Q true 2023-05-31 2023 false 000-53274 BioPower Operations Corporation NV 27-4460232 20801 Biscayne Blvd Suite 403 Aventura FL 33180 (786) 923-0272 Yes Yes Non-accelerated Filer true false false 47538859 825 331 331 12893 12893 13224 14049 245 1275421 451846 2300788 2295213 2300788 2295213 375000 375000 130671 130671 211750 157167 368031 368031 399447 399447 399447 399447 193667 193667 1320700 1320700 1320700 1320700 313464 262050 6889184 5953792 1.00 1.00 10000 10000 0 0 1 1 0.001 0.001 5000000 5000000 900000 900000 0 0 900 900 900 900 125000 125000 0.0001 0.0001 500000000 500000000 45867915 45867915 45625000 45625000 4588 4564 8730014 4279317 -15736462 -10349524 -6875960 -5939743 13224 14049 136000 336000 110700 110700 246700 446700 248773 681139 4446448 212443 4497298 363868 4695221 212443 5178437 363868 -4695221 34257 -5178437 82832 -16900 -66590 24021 11248 99533 22495 21189 36147 42378 72295 21189 36147 42378 72295 -62110 -47395 -208501 -94790 -4757331 -13138 -5386938 -11958 -0.10 -0.10 -0.00 -0.00 -0.12 -0.12 -0.00 -0.00 45867915 45867915 45597826 45597826 45762474 45762474 45302198 45302198 -5386938 -11958 4423545 66583 -66590 331 77593 12983 823575 -191071 5575 470238 -1070 176302 245 249991 245 249991 -825 426293 825 95973 522266 12000 15176 900000 900 45000000 4500 4140411 -9555809 -5409998 625000 63 249928 249991 -13138 -13138 1 900000 900 45625000 4563 4390339 -9568948 -5173145 900000 900 500000 125000 45867915 4588 4306469 -10979131 -6542174 4423545 4423545 -4757331 -4757331 900000 900 500000 125000 45867915 4588 8730014 -15736462 -6875960 1 1 900000 900 45000000 4500 4140411 -9556990 -5411178 625000 63 249928 249991 -11958 -11958 1 1 900000 900 45625000 4563 4390339 -9568948 -5173145 900000 900 500000 125000 45625000 4564 4279317 -10349524 -5939743 900000 900 500000 125000 45625000 4564 4279317 -10349524 -5939743 242915 24 11976 12000 15176 15176 4423545 4423545 -5386938 -5386938 -5386938 -5386938 900000 900 500000 125000 45867915 4588 8730014 -15736462 -6875960 900000 900 500000 125000 45867915 4588 8730014 -15736462 -6875960 <p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z6ZXrb6sxNY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 1. <span id="xdx_821_z6Znzzrnl7P8">Organization</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioPower Corporation (“BioPower” or the “Company”) was incorporated in the State of Florida on September 13, 2010. On January 5, 2011, the Company re-domiciled to Nevada and formed BioPower Operations Corporation, a Nevada corporation. On January 6, 2011, the shareholders of BioPower Corporation contributed their shares of BioPower Corporation to BioPower Operations Corporation and BioPower Corporation became a wholly owned subsidiary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 24, 2014, the Company executed a Share Exchange Agreement (“SEA”) with Green3Power Holdings Company (“G3P”) to acquire G3P and its wholly owned subsidiaries Green3Power Operations Inc., a Delaware corporation (“G3P OPS”), and Green3Power International Company, a Nevis corporation (“G3PI”). This transaction was a stock for stock exchange (the “Exchange”), which was accounted for as an acquisition and recorded as an expense based on the fair value of the Company’s common stock as of the date of the exchange. Also exchanged was one share of the Company’s Series B preferred stock, which is convertible into common shares two years from the date of the SEA, if certain milestones are met as required by the SEA. No value was attributed to the preferred share. We conduct all of our operations through G3P and its subsidiaries which are primarily engaged in the development of waste-to-energy projects and services including design, permitting, equipment procurement, construction management and operations and maintenance of the intended facilities. We intend to hold equity interests in the waste-to-energy facilities on a global basis and operate and maintain the facilities. A second business unit is focused on providing waste remediation services globally.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s fiscal year end is November 30.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 6, 2011, we acquired <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20110106__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BioPowerCorporationMember_zI0ysT2QKKu8" title="Ownership, percentage">100</span>% of BioPower Corporation (“BC”), a Florida corporation incorporated on September 13, 2010, by our then-CEO and Director contributing <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20100912__20100913__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ChiefExecutiveOfficerAndDirectorMember_zDdndffQRo6" title="Outstanding shares, percentage">100</span>% of the outstanding shares to the Company. As a result, BC became a wholly owned subsidiary of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 24, 2014, the Company entered into the SEA with G3P to acquire G3P and its wholly owned subsidiaries, G3P OPS and G3PI through the Exchange.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By October 24, 2016, G3P had failed to meet the provisions of the SEA that would allow G3P to take over control of the Company. As a result, the Company’s Board of Directors tried to come to an arrangement to separate BioPower from its subsidiaries, but in the end, decided that it would be in the best interests of the Company’s shareholders to move forward looking for a new acquisition. From October 24, 2016 until February 2017, the Company continued project development of waste-to-energy projects with extremely limited funds. In February 2017, the Company ceased all operations. At that time, we became a shell company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 29, 2021, we entered into an Asset Purchase Agreement (the “APA”) with Rafael Ben Shaya, Troy MacDonald, Adam Benchaya, Thomas Perez, Tom Saban and Edouard Pouchoy (collectively, Messrs. Ben Shaya, MacDonald, Benchaya, Perez, Saban and Pouchoy are referred to herein as the “Sellers”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the APA, the Company agreed to acquire from the Sellers, and the Sellers agreed to sell to the Company, certain assets comprised of the goodwill, intellectual property, business proprietary know-how and trade secrets, intangible property and other assets of Sellers’ business with respect to HyFi, and any and all rights of Sellers in and to the foregoing (the “Assets”), and certain governance/utility virtual tokens (collectively, the “HyFi Tokens”) expected to be used as a means of payment on the HyFi Platform, as hereinafter defined (the “Acquisition”). The “HyFi Platform” refers to the HyFi Decentralized Finance (“DeFi”) exchange marketplace using blockchain platform technology. The DeFi principles are based on an ecosystem of financial services utilizing tokenization and non-fungible tokens (“NFTs”) in connection with qualifying products, licenses and projects.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Sellers agreed to (i) pay to the Company, on the closing date of the Acquisition, $<span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20210628__20210629__us-gaap--BusinessAcquisitionAxis__custom--HyFiMember_znty21BkzB54" title="Cash consideration, acquisition">300,000</span> (the “Cash Consideration”), and (ii) transfer to the Company, on the closing date of the Acquisition, <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210628__20210629__us-gaap--BusinessAcquisitionAxis__custom--HyFiMember__us-gaap--FinancialInstrumentAxis__custom--HyFiTokensMember_zI34Sqd69MR8" title="Number of consideration shares">400,000,000</span> HyFi Tokens (the “HyFi Token Consideration”). The Company used the Cash Consideration to bring the Company into a fully reporting status with the Securities and Exchange Commission (the “SEC”) and for public company operating expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--BusinessAcquisitionDescriptionOfAcquiredEntity_c20210628__20210629__us-gaap--BusinessAcquisitionAxis__custom--HyFiMember_zoIZJFn2LiNf" title="Business combination description">Pursuant to the terms of the APA, the Company agreed to file with the State of Nevada the certificate of designation for the Series C preferred stock on or before the date that is 60 calendar days after the closing of the Acquisition. In exchange for the sale of the Assets and the Cash Consideration, the Company agreed to issue to the Sellers an aggregate of <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210629__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zepY1ZhzFO19" title="Preferred stock, shares authorized">900,000</span> Series C preferred shares within 30 calendar days after the State of Nevada provides written confirmation of filing of the certificate of designation for the Series C preferred stock</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the APA, the parties agreed that the Series C preferred stock will have the following terms, among others:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. Authorized Shares of Series C Preferred Stock. The number of authorized shares of Series C preferred stock will be <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210629__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z7TVJYV7lI34" title="Preferred stock, shares authorized">900,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. Conversion. Subject to the other terms and conditions in the certificate of designation, a Series C preferred stockholder will have the right from time to time and at any time following the date that is one year after the date on the signature page of the certificate of designations to convert each outstanding share of Series C preferred stock into <span id="xdx_906_eus-gaap--ConversionOfStockSharesIssued1_pid_c20210628__20210629__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7QVZgH200mk" title="Stock conversion, shares issued">450</span> shares of Company common stock. Based on the number of shares of common stock issued and outstanding as of June 29, 2021, if all of the <span id="xdx_90D_eus-gaap--ConversionOfStockSharesIssued1_pid_c20210628__20210629__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zdr4NQ8g66I6" title="Stock conversion, issued shares">900,000</span> shares of Series C preferred stock are issued and <span id="xdx_90C_eus-gaap--PreferredStockConversionBasis_c20210628__20210629__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z29GRGeSWnyl" title="Preferred stock, conversion basis">subsequently converted, the holders of the converted stock will hold 90% of the issued and outstanding shares of common stock</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. Voting. <span id="xdx_90C_eus-gaap--PreferredStockVotingRights_pid_c20210628__20210629__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zeO10z1LUjC3" title="Preferred stock, voting rights">Except as otherwise set forth in the certificate of designation, each share of Series C preferred stock will, on any matter submitted to the holders of Company common stock, or any class thereof, for a vote, vote together with the common stock, or any class thereof, as applicable, as one class on such matter, and each share of Series C preferred stock will have 450 votes.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. Dividends. The Series C preferred stock is not entitled to receive dividends or distributions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Acquisition closed on June 29, 2021 (the “Closing Date”). On the Closing Date, the Sellers delivered the Cash Consideration and the HyFi Token Consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 27, 2021, the Company filed with the State of Nevada a certificate of designations for the Series C preferred stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series A Preferred Stock Redemption Agreement &amp; Senior Promissory Note</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also on the Closing Date, the Company and CEP entered into a share redemption agreement (the “Redemption Agreement”), dated as of June 29, 2021, pursuant to which the Company redeemed one share of the Company’s Series A preferred stock from CEP (the “Series A Share”). On the Closing Date, as provided in the Redemption Agreement, the Company issued to CEP a senior promissory note (the “Note”) in the principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20210629__dei--LegalEntityAxis__custom--ChinaEnergyPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--RedemptionAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLGF879oLfUi" title="Debt instrument, principal amount">1,000,000</span>. The Series A Share will be held in escrow. If an Event of Default (as defined in the Note) occurs under the Note, then the Company will direct the escrow agent to release the Series A Share to CEP; provided, however, that CEP will also retain all rights and privileges under the Note (and the Company will remain bound to all obligations under Note) even if the Series A Share is required to be released by the escrow agent to CEP as provided in the Redemption Agreement. For the avoidance of doubt, CEP will regain all rights, title, and interest in and to the Series A Share upon the occurrence of an Event of Default under the Note, regardless of the amount of the outstanding balance owed under the Note at the time of the occurrence of an Event of Default under the Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 7, 2021, the Company filed a certificate of amendment (the “Certificate of Amendment”) to its amended and restated articles in the State of Nevada and with FINRA, in order to change its corporate name from BioPower Operations Corporation. to HyFi Corp (the “Name Change”). The State of Nevada has officially changed the name of the Company to HYFI Corp. The Name Change and stock symbol change will be effective for Securities and Exchange Commission or trading purposes until it is cleared by the Financial Industry Regulatory Authority (FINRA).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1 1 300000 400000000 Pursuant to the terms of the APA, the Company agreed to file with the State of Nevada the certificate of designation for the Series C preferred stock on or before the date that is 60 calendar days after the closing of the Acquisition. In exchange for the sale of the Assets and the Cash Consideration, the Company agreed to issue to the Sellers an aggregate of 900,000 Series C preferred shares within 30 calendar days after the State of Nevada provides written confirmation of filing of the certificate of designation for the Series C preferred stock 900000 900000 450 900000 subsequently converted, the holders of the converted stock will hold 90% of the issued and outstanding shares of common stock Except as otherwise set forth in the certificate of designation, each share of Series C preferred stock will, on any matter submitted to the holders of Company common stock, or any class thereof, for a vote, vote together with the common stock, or any class thereof, as applicable, as one class on such matter, and each share of Series C preferred stock will have 450 votes. 1000000 <p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zK4npBjlyOg9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 2. <span id="xdx_821_zRJ1LflFmEO4">Summary of Significant Accounting Policies</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Management’s Representation of Interim Financial Statements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited consolidated financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the SEC. Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These consolidated financial statements include all of the adjustments, which in the opinion of management are necessary to a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements filed as part of the Company’s Annual Report on Form 10-K with the SEC on June 15, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_z6OcLqMKheD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_867_zMZ0hbFTzXS9">Principles of Consolidation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All inter-company accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zhuko9nsnbB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_862_zb4dVaIpfm4g">Basis of Presentation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (the “ASC”) which is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with GAAP.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_ecustom--GoingConcernPolicyTextBlock_zDgdnoYj1m0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zSMGs4injEsh">Going Concern</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these financial statements. The Company has incurred significant operating losses since inception. As of May 31, 2023, the Company had an accumulated deficit of $<span id="xdx_90D_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20230531_zjHm3KEIH0Ti" title="Accumulated deficit">15,736,462</span> and stockholders’ deficit of $<span id="xdx_90F_eus-gaap--StockholdersEquity_iNI_pp0p0_di_c20230531_zIC7Wv9shDAj" title="Stockholders' deficit">6,875,960</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because the Company does not expect that existing operational cash flow will be sufficient to fund presently anticipated operations, this raises substantial doubt about the Company’s ability to continue as a going concern. Therefore, the Company will need to raise additional funds and is currently exploring alternative sources of financing. Historically, the Company has raised capital through private placements, as an interim measure to finance working capital needs and may continue to raise additional capital through the sale of common stock or other securities and obtaining some short-term loans. The Company will be required to continue to so until its operations become profitable. Also, the Company has, in the past, paid for consulting services with its common stock to maximize working capital, and intends to continue this practice where feasible.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--UseOfEstimates_zBQPh8yZxuKi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_869_ze3o4CzsBXGh">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zmsv3neIPmrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_868_zgIiDYM3EV66">Accounts Receivable</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. If market conditions decline, actual collection experience may not meet expectations and may result in decreased cash flows and increased bad debt expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--InventoryPolicyTextBlock_zYFjJL1kWOJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86D_zzmAUS18Ye61">Inventory</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out basis and net realizable value. Net realizable value is defined as sales price less cost of completion, disposition and transportation and a normal profit margin. As of May 31, 2023 and November 30, 2022, inventory amounted to $<span id="xdx_90E_eus-gaap--InventoryNet_iI_c20230531_zCV8qpU3MMP7" title="Inventory">12,893</span> and $<span id="xdx_907_eus-gaap--InventoryNet_iI_c20221130_zgoR5Tek0Gtk" title="Inventory">12,893</span>, respectively, which consisted of finished goods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z97QpihlEp08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86D_zMnZXLKq1F21">Revenue Recognition</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 1, 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Results for reporting periods beginning after January 1, 2018, are presented under ASC 606.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 29, 2021, the Sellers agreed to (i) pay to the Company, on the closing date of the Acquisition, $<span id="xdx_905_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20210628__20210629__us-gaap--BusinessAcquisitionAxis__custom--HyFiMember_zjOKKyetfNK8" title="Cash consideration, acquisition">300,000</span> (the “Cash Consideration”), and (ii) transfer to the Company, on the closing date of the Acquisition, <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210628__20210629__us-gaap--BusinessAcquisitionAxis__custom--HyFiMember_zQwg01c8IJAi" title="Number of consideration shares">400,000,000</span> HyFi Tokens (the “HyFi Token Consideration”). The Company used the Cash Consideration to bring the Company into a fully reporting status with the SEC and for public company operating expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_z1Ij1WPAG0W6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_86C_ziiriS69ETd6">Concentration</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two customers, including one related party, account for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220301__20220531__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zWIyJBmmOHlb" title="Concentration risk, percentage">100</span>% of sales during the three months ended May 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five customers, including two related parties, account for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20211201__20220531__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--FiveCustomersMember_zOi348YuftH" title="Concentration risk, percentage">100</span>% of sales during the six months ended May 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zOxCOrsRrADd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_862_zZ54kBP9xiv">Cash and cash equivalents</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On May 31, 2023 the Company had a cash overdraft of $<span id="xdx_90D_eus-gaap--BankOverdrafts_iI_pp0p0_c20230531_zSwEPHwV1kib" title="Cash overdraft">245</span> and on November 30, 2022, the Company’s cash equivalents totaled $<span id="xdx_900_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20221130_zmLZg64pGxbl" title="Cash equivalents">825</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zyP9K2uBdho1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_868_zjHKdtxVXdMc">Income taxes</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes under FASB ASC 740, “Accounting for Income Taxes”. Under FASB ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. FASB ASC 740-10-05, “Accounting for Uncertainty in Income Taxes,” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company assesses the validity of its conclusions regarding uncertain tax positions quarterly to determine if facts or circumstances have arisen that might cause it to change its judgment regarding the likelihood of a tax position’s sustainability under audit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zbwrxlEqegWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zSgVEPbGdHf8">Stock-based Compensation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based compensation using the fair value method following the guidance outlined in Section 718-10 of the ASC for disclosure about stock-based compensation. This section requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). That cost will be recognized over the period during which an employee is required to provide service in exchange for the award- the requisite service period (usually the vesting period). No compensation cost is recognized for equity instruments for which employees do not render the requisite service.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zT7xg5JTwP0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86E_znG74acJmGfk">Net Loss per Share</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per common share is computed by dividing net loss by the weighted average common shares outstanding during the period as defined by ASC Topic 260, “Earnings per Share.” Basic earnings per common share calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zapjCTYLWiZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_zEmLXfkESEX9">Recent Accounting Pronouncements</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which establishes a new lease accounting model for lessees. The updated guidance requires an entity to recognize assets and liabilities arising from financing and operating leases, along with additional qualitative and quantitative disclosures. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, with early adoption permitted. In March 2019, the FASB issued ASU 2019-01, Codification Improvements, which clarifies certain aspects of the new lease standard. The FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases in July 2018. Also in 2018, the FASB issued ASU 2018-11, Leases (Topic 842) Targeted Improvements, which provides an optional transition method whereby the new lease standard is applied at the adoption date and recognized as an adjustment to retained earnings. The amendments have the same effective date and transition requirements as the new lease standard.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We adopted ASC 842 on July 1, 2021. The adoption of ASC 842 did not have any impact on our financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--StockholdersEquityPolicyTextBlock_zGzIxYwwwn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zbhfZjjebGN">Stockholders’ Equity</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 28, 2021, the Company amended and restated its articles of incorporation, as amended, in order to, among other things, (i) increase the number of authorized shares of common stock from <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20210727_zdctstAaASg2" title="Common stock, shares authorized">100,000,000</span> to <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20210728_zsmMu12Zq80f" title="Common stock, shares authorized">500,000,000</span>, (ii) increase the number of authorized shares of preferred stock from <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210727_zMfzR1z3P79g" title="Preferred stock, shares authorized">10,000</span> to <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210728_zzB8cn4TUjCe" title="Preferred stock, shares authorized">5,000,000</span>, and (iii) change the par value of the preferred stock from $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210727_zsm04kLEovZ" title="Preferred stock, par value">1.00</span> par value per share to $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210728_zGcvd6kj8AOh" title="Preferred stock, par value">0.0001</span> par value per share. As of November 30, 2021, the Company had authorized <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20211130_zVamVRpY1E1k" title="Common stock, shares authorized">500,000,000</span> shares of common stock, $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211130_z810Yar5sSze" title="Common stock, par value">0.0001</span> par value per share, and <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20211130_zykRo6oAULZ5" title="Preferred stock, shares authorized">5,000,000</span> shares of preferred stock, $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211130_zuS7oLhw4UL6" title="Preferred stock, par value">0.0001</span> par value per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 4, 2022, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20220303__20220304__srt--TitleOfIndividualAxis__custom--CanadianInvestorMember_zvetxXVScOvh" title="Restricted common stock issued, shares">625,000</span> shares of restricted common stock to a Canadian investor for $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20220304__srt--TitleOfIndividualAxis__custom--CanadianInvestorMember_zu4tuE7n5sZ7" title="Share issued price per share">0.40</span> per share for a total purchase price of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20220303__20220304__srt--TitleOfIndividualAxis__custom--CanadianInvestorMember_z7pgH3HEyKf9" title="Restricted common stock issued">250,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 17, 2023 Diagonal converted $<span id="xdx_90F_eus-gaap--DebtConversionOriginalDebtAmount1_c20230217__20230217__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zUaOuk7rPlO1" title="Debt principal amount converted">12,000</span> of principal into <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230217__20230217__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zxmesDd99Csj" title="Common stock issued in conversion">242,915</span> shares of common stock at the price of $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230217__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zDOJCU1J9FYj" title="Debt conversion price">0.0494</span>. The Company recorded a dividend resolution of $<span id="xdx_902_eus-gaap--Dividends_c20230217__20230217__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zY9Z0UUFAYh2" title="Dividend resolution">15,176</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of May 31, 2023, and November 30, 2022, respectively, there were <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20230531_z0jKPZu7dZrf" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20230531_z3Ej6SYMDlug" title="Common stock, shares outstanding">45,867,915</span></span> and <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20221130_zUZzMVZlhy9l" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20221130_zuBorpP7mail" title="Common stock, shares outstanding">45,625,000</span></span> shares of common stock issued and outstanding, respectively, and <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20230531_zXQzGLqyLN87" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20230531_z6jgrQO9tYE8" title="Preferred stock, shares outstanding">900,000</span></span> and <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_c20221130_z8KSxUNGYcra" title="Preferred stock, shares issued">1</span> shares and <span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20221130_zoTFe9fgKknl" title="Preferred stock, shares outstanding">0</span> shares of preferred stock issued and outstanding, respectively.</span></p> <p id="xdx_853_zJ4Kjr1dcBCk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ConsolidationPolicyTextBlock_z6OcLqMKheD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_867_zMZ0hbFTzXS9">Principles of Consolidation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All inter-company accounts and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zhuko9nsnbB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_862_zb4dVaIpfm4g">Basis of Presentation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (the “ASC”) which is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with GAAP.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_ecustom--GoingConcernPolicyTextBlock_zDgdnoYj1m0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zSMGs4injEsh">Going Concern</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these financial statements. The Company has incurred significant operating losses since inception. As of May 31, 2023, the Company had an accumulated deficit of $<span id="xdx_90D_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20230531_zjHm3KEIH0Ti" title="Accumulated deficit">15,736,462</span> and stockholders’ deficit of $<span id="xdx_90F_eus-gaap--StockholdersEquity_iNI_pp0p0_di_c20230531_zIC7Wv9shDAj" title="Stockholders' deficit">6,875,960</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because the Company does not expect that existing operational cash flow will be sufficient to fund presently anticipated operations, this raises substantial doubt about the Company’s ability to continue as a going concern. Therefore, the Company will need to raise additional funds and is currently exploring alternative sources of financing. Historically, the Company has raised capital through private placements, as an interim measure to finance working capital needs and may continue to raise additional capital through the sale of common stock or other securities and obtaining some short-term loans. The Company will be required to continue to so until its operations become profitable. Also, the Company has, in the past, paid for consulting services with its common stock to maximize working capital, and intends to continue this practice where feasible.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -15736462 -6875960 <p id="xdx_847_eus-gaap--UseOfEstimates_zBQPh8yZxuKi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_869_ze3o4CzsBXGh">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zmsv3neIPmrc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_868_zgIiDYM3EV66">Accounts Receivable</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. If market conditions decline, actual collection experience may not meet expectations and may result in decreased cash flows and increased bad debt expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--InventoryPolicyTextBlock_zYFjJL1kWOJi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86D_zzmAUS18Ye61">Inventory</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out basis and net realizable value. Net realizable value is defined as sales price less cost of completion, disposition and transportation and a normal profit margin. As of May 31, 2023 and November 30, 2022, inventory amounted to $<span id="xdx_90E_eus-gaap--InventoryNet_iI_c20230531_zCV8qpU3MMP7" title="Inventory">12,893</span> and $<span id="xdx_907_eus-gaap--InventoryNet_iI_c20221130_zgoR5Tek0Gtk" title="Inventory">12,893</span>, respectively, which consisted of finished goods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 12893 12893 <p id="xdx_84D_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z97QpihlEp08" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86D_zMnZXLKq1F21">Revenue Recognition</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 1, 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Results for reporting periods beginning after January 1, 2018, are presented under ASC 606.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 29, 2021, the Sellers agreed to (i) pay to the Company, on the closing date of the Acquisition, $<span id="xdx_905_eus-gaap--BusinessCombinationConsiderationTransferred1_pp0p0_c20210628__20210629__us-gaap--BusinessAcquisitionAxis__custom--HyFiMember_zjOKKyetfNK8" title="Cash consideration, acquisition">300,000</span> (the “Cash Consideration”), and (ii) transfer to the Company, on the closing date of the Acquisition, <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210628__20210629__us-gaap--BusinessAcquisitionAxis__custom--HyFiMember_zQwg01c8IJAi" title="Number of consideration shares">400,000,000</span> HyFi Tokens (the “HyFi Token Consideration”). The Company used the Cash Consideration to bring the Company into a fully reporting status with the SEC and for public company operating expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 300000 400000000 <p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_z1Ij1WPAG0W6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_86C_ziiriS69ETd6">Concentration</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two customers, including one related party, account for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220301__20220531__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zWIyJBmmOHlb" title="Concentration risk, percentage">100</span>% of sales during the three months ended May 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five customers, including two related parties, account for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20211201__20220531__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--FiveCustomersMember_zOi348YuftH" title="Concentration risk, percentage">100</span>% of sales during the six months ended May 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1 1 <p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zOxCOrsRrADd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_862_zZ54kBP9xiv">Cash and cash equivalents</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On May 31, 2023 the Company had a cash overdraft of $<span id="xdx_90D_eus-gaap--BankOverdrafts_iI_pp0p0_c20230531_zSwEPHwV1kib" title="Cash overdraft">245</span> and on November 30, 2022, the Company’s cash equivalents totaled $<span id="xdx_900_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20221130_zmLZg64pGxbl" title="Cash equivalents">825</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 245 825 <p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zyP9K2uBdho1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_868_zjHKdtxVXdMc">Income taxes</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes under FASB ASC 740, “Accounting for Income Taxes”. Under FASB ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. FASB ASC 740-10-05, “Accounting for Uncertainty in Income Taxes,” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount recognized is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company assesses the validity of its conclusions regarding uncertain tax positions quarterly to determine if facts or circumstances have arisen that might cause it to change its judgment regarding the likelihood of a tax position’s sustainability under audit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zbwrxlEqegWa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zSgVEPbGdHf8">Stock-based Compensation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock-based compensation using the fair value method following the guidance outlined in Section 718-10 of the ASC for disclosure about stock-based compensation. This section requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). That cost will be recognized over the period during which an employee is required to provide service in exchange for the award- the requisite service period (usually the vesting period). No compensation cost is recognized for equity instruments for which employees do not render the requisite service.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zT7xg5JTwP0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86E_znG74acJmGfk">Net Loss per Share</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per common share is computed by dividing net loss by the weighted average common shares outstanding during the period as defined by ASC Topic 260, “Earnings per Share.” Basic earnings per common share calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zapjCTYLWiZf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_zEmLXfkESEX9">Recent Accounting Pronouncements</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which establishes a new lease accounting model for lessees. The updated guidance requires an entity to recognize assets and liabilities arising from financing and operating leases, along with additional qualitative and quantitative disclosures. The amended guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, with early adoption permitted. In March 2019, the FASB issued ASU 2019-01, Codification Improvements, which clarifies certain aspects of the new lease standard. The FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases in July 2018. Also in 2018, the FASB issued ASU 2018-11, Leases (Topic 842) Targeted Improvements, which provides an optional transition method whereby the new lease standard is applied at the adoption date and recognized as an adjustment to retained earnings. The amendments have the same effective date and transition requirements as the new lease standard.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We adopted ASC 842 on July 1, 2021. The adoption of ASC 842 did not have any impact on our financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--StockholdersEquityPolicyTextBlock_zGzIxYwwwn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_866_zbhfZjjebGN">Stockholders’ Equity</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 28, 2021, the Company amended and restated its articles of incorporation, as amended, in order to, among other things, (i) increase the number of authorized shares of common stock from <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20210727_zdctstAaASg2" title="Common stock, shares authorized">100,000,000</span> to <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20210728_zsmMu12Zq80f" title="Common stock, shares authorized">500,000,000</span>, (ii) increase the number of authorized shares of preferred stock from <span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210727_zMfzR1z3P79g" title="Preferred stock, shares authorized">10,000</span> to <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210728_zzB8cn4TUjCe" title="Preferred stock, shares authorized">5,000,000</span>, and (iii) change the par value of the preferred stock from $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210727_zsm04kLEovZ" title="Preferred stock, par value">1.00</span> par value per share to $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210728_zGcvd6kj8AOh" title="Preferred stock, par value">0.0001</span> par value per share. As of November 30, 2021, the Company had authorized <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20211130_zVamVRpY1E1k" title="Common stock, shares authorized">500,000,000</span> shares of common stock, $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211130_z810Yar5sSze" title="Common stock, par value">0.0001</span> par value per share, and <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20211130_zykRo6oAULZ5" title="Preferred stock, shares authorized">5,000,000</span> shares of preferred stock, $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211130_zuS7oLhw4UL6" title="Preferred stock, par value">0.0001</span> par value per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 4, 2022, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20220303__20220304__srt--TitleOfIndividualAxis__custom--CanadianInvestorMember_zvetxXVScOvh" title="Restricted common stock issued, shares">625,000</span> shares of restricted common stock to a Canadian investor for $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20220304__srt--TitleOfIndividualAxis__custom--CanadianInvestorMember_zu4tuE7n5sZ7" title="Share issued price per share">0.40</span> per share for a total purchase price of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c20220303__20220304__srt--TitleOfIndividualAxis__custom--CanadianInvestorMember_z7pgH3HEyKf9" title="Restricted common stock issued">250,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 17, 2023 Diagonal converted $<span id="xdx_90F_eus-gaap--DebtConversionOriginalDebtAmount1_c20230217__20230217__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zUaOuk7rPlO1" title="Debt principal amount converted">12,000</span> of principal into <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230217__20230217__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zxmesDd99Csj" title="Common stock issued in conversion">242,915</span> shares of common stock at the price of $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230217__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zDOJCU1J9FYj" title="Debt conversion price">0.0494</span>. The Company recorded a dividend resolution of $<span id="xdx_902_eus-gaap--Dividends_c20230217__20230217__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zY9Z0UUFAYh2" title="Dividend resolution">15,176</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of May 31, 2023, and November 30, 2022, respectively, there were <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20230531_z0jKPZu7dZrf" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20230531_z3Ej6SYMDlug" title="Common stock, shares outstanding">45,867,915</span></span> and <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20221130_zUZzMVZlhy9l" title="Common stock, shares issued"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20221130_zuBorpP7mail" title="Common stock, shares outstanding">45,625,000</span></span> shares of common stock issued and outstanding, respectively, and <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20230531_zXQzGLqyLN87" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20230531_z6jgrQO9tYE8" title="Preferred stock, shares outstanding">900,000</span></span> and <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_c20221130_z8KSxUNGYcra" title="Preferred stock, shares issued">1</span> shares and <span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20221130_zoTFe9fgKknl" title="Preferred stock, shares outstanding">0</span> shares of preferred stock issued and outstanding, respectively.</span></p> 100000000 500000000 10000 5000000 1.00 0.0001 500000000 0.0001 5000000 0.0001 625000 0.40 250000 12000 242915 0.0494 15176 45867915 45867915 45625000 45625000 900000 900000 1 0 <p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zdyhjXEwouj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 3. <span id="xdx_821_zII5Ts6930gc">Notes Payable and Convertible Debt</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfDebtTableTextBlock_z95OQv2flW61" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zrISRddV48C5" style="display: none">Schedule of Notes Payable</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Balance</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Interest Rate</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Maturity</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Demand loans</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--NotesPayable_iI_c20230531__us-gaap--DebtInstrumentAxis__custom--DemandLoansMember_zKcnNADDAH2d" style="width: 12%; text-align: right" title="Balance">551,167</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230531__us-gaap--DebtInstrumentAxis__custom--DemandLoansMember__srt--RangeAxis__srt--MinimumMember_zNaVYfPYqzf" title="Interest rate">4</span>% to <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230531__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--DemandLoansMember_zByYJ5CqqhF2" title="Interest rate">8</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDateDescription_c20221201__20230531__us-gaap--DebtInstrumentAxis__custom--DemandLoansMember_z7CIQkKo56oh" title="Maturity date">Various</span></td><td style="width: 1%; text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Reclassification of accrued compensation to notes payable</td><td> </td> <td style="text-align: left"></td><td id="xdx_98D_eus-gaap--NotesPayable_iI_c20230531__us-gaap--DebtInstrumentAxis__custom--ReclassificationOfAccruedCompensationToNotesPayableMember_zttxCr93HiD1" style="text-align: right" title="Balance">143,031</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230531__us-gaap--DebtInstrumentAxis__custom--ReclassificationOfAccruedCompensationToNotesPayableMember_zVx9mQr9u7Zh" title="Interest rate">8</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateDescription_c20221201__20230531__us-gaap--DebtInstrumentAxis__custom--ReclassificationOfAccruedCompensationToNotesPayableMember_zyrXH7FO6bt7" title="Maturity date">December 1, 2017</span> </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance –May 31, 2023 and November 30, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesPayable_iI_c20230531_z2H5QVhOCdXf" style="text-align: right" title="Balance"><span id="xdx_902_eus-gaap--NotesPayable_iI_c20221130_zXPbNUfVFa08">694,198</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A7_zGbj9SO3c93i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of May 31, 2023 and November 30, 2022, all loans are past due and in default.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 27, 2016, the Company entered into demand loan agreements with a third-party investor totaling $<span id="xdx_90E_eus-gaap--NotesPayable_iI_pp0p0_c20160727__us-gaap--TypeOfArrangementAxis__custom--DemandLoanAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorMember_zbHrx3K29i26" title="Notes payable">193,667</span> at <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20160727__us-gaap--TypeOfArrangementAxis__custom--DemandLoanAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorMember_zJOshX8khnV5" title="Debt instrument, interest">4</span>% interest, payable upon demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between October 28, 2011 and January 7, 2012, the Company issued a total of $<span id="xdx_90F_eus-gaap--NotesPayable_iI_pp0p0_c20120107__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderMember_zSqa19bAhb2f" title="Notes payable">70,000</span> in notes payable, due <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_pp0p0_dd_c20111028__20120107__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderMember_z9FVEXai913c" title="Maturity date">May 31, 2012</span>. Interest on the notes is payable at <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20120107__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderMember_zIpDy5t7mgob" title="Debt instrument, interest rate, stated percentage">4</span>%. The lender may elect to convert the loan before maturity at a conversion price of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20120107__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderMember_zpVrfmeZFJ35" title="Conversion price per share">0.25</span> per share. The loans are currently past due.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 3, 2013, the Company entered into convertible debt agreements with a third-party investor totaling $<span id="xdx_90F_eus-gaap--ConvertibleDebt_iI_pp0p0_c20131203__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorMember_zG6caS1r0A3k" title="Convertible debt">62,500</span> at <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20131203__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorMember_zkTsZzSQ6XK8" title="Debt instrument, interest">8</span>% interest, payable upon demand. The debt is convertible into shares of common stock at a conversion price of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20131203__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorMember_zXMxc9miKuOf" title="Conversion price per share">0.10</span> per share, for any amount up to <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20131203__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorMember_zIPJHKHF4iD3" title="Debt instrument, original percentage">50</span>% of the original amount of the notes. As of May 31, 2023 and November 30, 2022, the note was in default.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 30, 2015, the Company entered into convertible debt agreements with a third-party investor totaling $<span id="xdx_907_eus-gaap--ConvertibleDebt_iI_pp0p0_c20150730__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorOneMember_zJ00GHEFTRx7" title="Debt instrument, interest">200,000</span> at <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20150730__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorOneMember_zY4PSgDbeTg3" title="Debt instrument, interest">8</span>% interest, due on <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20150729__20150730__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorOneMember_zOd1GLhRb0vd" title="Debt Instrument, Maturity Date">December 31, 2015</span>. The debt is convertible into shares of common stock at a conversion price of $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20150730__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorOneMember_z5ygAM0Rcyt8" title="Conversion price per share">0.15</span> per share. As of May 31, 2023 and November 30, 2022, the note was in default.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 23, 2016, the Company entered into convertible debt agreements with a third-party investor totaling $<span id="xdx_903_eus-gaap--ConvertibleDebt_iI_pp0p0_c20160523__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorMember_zAeszPknCxG4" title="Convertible debt">25,000</span> at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20160523__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorMember_z2OXmahdr6I" title="Debt instrument, interest">8</span>% interest, due on <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20160522__20160523__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorMember_zAiBN3rXaJsi" title="Debt instrument, maturity date">May 23, 2018</span>. The debt is convertible into shares of common stock at a conversion price of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20160523__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorMember_z8ktCSRlSmU" title="Conversion price per share">0.10</span> per share. As of May 31, 2023 and November 30, 2022, the note was in default.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 30, 2015, the Company entered into convertible debt agreements with a third-party investor totaling $<span id="xdx_905_eus-gaap--ConvertibleDebt_iI_pp0p0_c20150730__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorTwoMember_zhVhP1IXnlaa" title="Convertible debt">15,000</span> at <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20150730__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorTwoMember_zhKVV3RKsXad" title="Debt instrument, interest">8</span>% interest, due on <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20150729__20150730__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorTwoMember_zlkvbFL2kQla" title="Debt Instrument, Maturity Date">May 23, 2018</span>. The debt is convertible into shares of common stock at a conversion price of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20150730__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorTwoMember_zYLGD8yhSLqf" title="Conversion price per share">0.15</span> per share. As of May 31, 2023 and November 30, 2022, the note was in default.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 30, 2015, the Company entered into convertible debt agreements with a third-party investor totaling $<span id="xdx_905_eus-gaap--ConvertibleDebt_iI_pp0p0_c20150730__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorThreeMember_z3XUnqGVMkdg" title="Convertible debt">15,000</span> at <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20150730__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorThreeMember_zNGi9E3uaNFa" title="Debt instrument, interest">8</span>% interest, due on <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20150729__20150730__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorThreeMember_zQlM9xJyYdBj" title="Debt Instrument, Maturity Date">May 23, 2018</span>. The debt is convertible into shares of common stock at a conversion price of $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20150730__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorThreeMember_zhJysGVnK1m8" title="Conversion price per share">0.15</span> per share. As of May 31, 2023 and November 30, 2022, the note was in default.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between December 3, 2014 and July 28, 2015, the Company issued a total of $<span id="xdx_905_eus-gaap--NotesPayable_iI_pp0p0_c20150728_zI2DRkvgbGca" title="Notes payable">113,031</span> in notes payable. Interest on the notes is payable at <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20150728_zOUp9o0pHdbc" title="Debt instrument, interest">8</span>%. The loans were due prior to December 31, 2015 and are past due.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued interest on notes payable and convertible debt at May 31, 2023 and November 30, 2022 amounted to $<span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20230531_zwU08vWh08ai" title="Accrued interest">365,107</span> and $<span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20221130_za5hkkYOiCad" title="Accrued interest">275,071</span>, respectively, which is included as a component of accounts payable and accrued expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense on notes payable and convertible debt with third parties amounted to $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_pp0p0_c20230301__20230531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartiesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zWQ6Sue65uf9" title="Interest expense">11,247</span>, $<span id="xdx_903_eus-gaap--InterestExpenseDebt_pp0p0_c20221201__20230531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartiesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z7InfgZ2v8Mk" title="Interest expense">22,494</span>, $<span id="xdx_90D_eus-gaap--InterestExpenseDebt_pp0p0_c20220301__20220531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartiesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zJSpqnVreRQ8" title="Interest expense">11,247</span> and $<span id="xdx_90A_eus-gaap--InterestExpenseDebt_pp0p0_c20211201__20220531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartiesMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zz6dJ8td1szf" title="Interest expense">22,494</span> for the three and six months ended May 31, 2023 and May 31, 2022 respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfDebtTableTextBlock_z95OQv2flW61" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_zrISRddV48C5" style="display: none">Schedule of Notes Payable</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Balance</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Interest Rate</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Maturity</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Demand loans</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--NotesPayable_iI_c20230531__us-gaap--DebtInstrumentAxis__custom--DemandLoansMember_zKcnNADDAH2d" style="width: 12%; text-align: right" title="Balance">551,167</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230531__us-gaap--DebtInstrumentAxis__custom--DemandLoansMember__srt--RangeAxis__srt--MinimumMember_zNaVYfPYqzf" title="Interest rate">4</span>% to <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230531__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--DemandLoansMember_zByYJ5CqqhF2" title="Interest rate">8</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDateDescription_c20221201__20230531__us-gaap--DebtInstrumentAxis__custom--DemandLoansMember_z7CIQkKo56oh" title="Maturity date">Various</span></td><td style="width: 1%; text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Reclassification of accrued compensation to notes payable</td><td> </td> <td style="text-align: left"></td><td id="xdx_98D_eus-gaap--NotesPayable_iI_c20230531__us-gaap--DebtInstrumentAxis__custom--ReclassificationOfAccruedCompensationToNotesPayableMember_zttxCr93HiD1" style="text-align: right" title="Balance">143,031</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230531__us-gaap--DebtInstrumentAxis__custom--ReclassificationOfAccruedCompensationToNotesPayableMember_zVx9mQr9u7Zh" title="Interest rate">8</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateDescription_c20221201__20230531__us-gaap--DebtInstrumentAxis__custom--ReclassificationOfAccruedCompensationToNotesPayableMember_zyrXH7FO6bt7" title="Maturity date">December 1, 2017</span> </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance –May 31, 2023 and November 30, 2022</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesPayable_iI_c20230531_z2H5QVhOCdXf" style="text-align: right" title="Balance"><span id="xdx_902_eus-gaap--NotesPayable_iI_c20221130_zXPbNUfVFa08">694,198</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> 551167 0.04 0.08 Various 143031 0.08 December 1, 2017 694198 694198 193667 0.04 70000 2012-05-31 0.04 0.25 62500 0.08 0.10 0.50 200000 0.08 2015-12-31 0.15 25000 0.08 2018-05-23 0.10 15000 0.08 2018-05-23 0.15 15000 0.08 2018-05-23 0.15 113031 0.08 365107 275071 11247 22494 11247 22494 <p id="xdx_803_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zWmu0QTU5h81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 4. <span id="xdx_823_zywdc1qJEQ8l">Related Party Transactions</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 27, 2016, the former Chief Executive Officer, now our Chief Financial Officer, agreed to reduce his accrued compensation by $<span id="xdx_906_eus-gaap--IncreaseDecreaseInDeferredCompensation_pp0p0_c20160526__20160527__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zbBgvDF1Xxi" title="Reduction in accrued compensation">206,250</span> as a contribution to additional paid in capital. He also agreed to reclassify $<span id="xdx_90D_eus-gaap--LongTermDebt_iI_c20160527__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zI2p0Qgaomt9" title="Long term debt">874,000</span> in accrued compensation to long term debt upon the issuance of a non-convertible <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_c20160527__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zn4uq0tVjayl" title="Interest rate">4</span>% interest bearing note with a maturity date of <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20160526__20160527__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zNH0873eJTA1" title="Debt instrument maturity date">December 1, 2017</span>. <span id="xdx_90B_eus-gaap--DebtInstrumentDescription_c20160526__20160527__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zDPhz78VHlY1" title="Debt instrument, description">The compensation included was accrued during the period from January 2, 2011 to February 29, 2016. This compensation will be paid as bonuses out of future income only and is further subject to a cap of 20% of operating net cash flow in any given period. If bonuses are paid, accrued compensation will be paid with an amount decided by the Board.</span> On June 1, 2016, he agreed to reduce his accrued compensation by $<span id="xdx_90B_eus-gaap--IncreaseDecreaseInDeferredCompensation_pp0p0_c20160601__20160601__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zvA5F5SNJvje">25,000</span> as a contribution to additional paid in capital. He also agreed to reduce his long term note by $<span id="xdx_906_eus-gaap--IncreaseDecreaseInOtherNoncurrentLiabilities_c20160601__20160601__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zf1F8QPbjSH5" title="Reduction in long term debt">214,000</span> as a contribution to additional paid in capital. As the Company was not funded prior to December 1, 2016, the Board of Directors reversed the contribution of accrued salaries. As of May 31, 2023 and November 30, 2022, the Chief Financial Officer was owed $<span id="xdx_900_eus-gaap--WorkersCompensationLiabilityCurrentAndNoncurrent_iI_pp0p0_c20230531__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zvv84dr6APue" title="Accrued compensation">445,250</span> and $<span id="xdx_907_eus-gaap--WorkersCompensationLiabilityCurrentAndNoncurrent_iI_pp0p0_c20221130__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z3TApkrbgvta" title="Accrued compensation">445,250</span>, respectively, of accrued compensation and accrued salary was reduced by $<span id="xdx_90D_eus-gaap--IncreaseDecreaseInAccruedSalaries_pp2d_c20221201__20230531__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zjeyvOiYBMu2" title="Decrease in accrued salaries">15,722.47</span>. As of May 31, 2023 and November 30, 2022, the Chief Financial Officer was owed $<span id="xdx_909_eus-gaap--NotesPayable_iI_pp0p0_c20230531__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zMAkKMV14fw" title="Notes payable to related parties">805,637</span> and $<span id="xdx_901_eus-gaap--NotesPayable_iI_pp0p0_c20221130__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z1fRqB9Jl3Yj" title="Notes payable to related parties">805,637</span>, respectively, of notes payable and accrued interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 27, 2016, the Director of Strategy agreed to reduce her accrued compensation by $<span id="xdx_901_eus-gaap--IncreaseDecreaseInDeferredCompensation_pp0p0_c20160526__20160527__srt--TitleOfIndividualAxis__custom--DirectorOfBusinessStrategyMember_z6LvGwtsiwMc">206,250</span> as a contribution to additional paid in capital. She also agreed to reclassify $<span id="xdx_90A_eus-gaap--LongTermDebt_iI_c20160527__srt--TitleOfIndividualAxis__custom--DirectorOfBusinessStrategyMember_zYRYvkWXRSX" title="Long term debt">660,000</span> in accrued compensation to long term debt upon the issuance of a non-convertible <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20160527__srt--TitleOfIndividualAxis__custom--DirectorOfBusinessStrategyMember_zcEpIVfkbiqe" title="Debt instrument, interest">4</span>% interest bearing note with a maturity date of <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20160526__20160527__srt--TitleOfIndividualAxis__custom--DirectorOfBusinessStrategyMember_z1EA330GE1M9">December 1, 2017</span>. The total principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20160527__srt--TitleOfIndividualAxis__custom--DirectorOfBusinessStrategyMember_zztupcwKCZSb" title="Debt instrument, face amount">710,000</span> included three different notes totaling $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20160527__srt--TitleOfIndividualAxis__custom--DirectorOfBusinessStrategyMember__us-gaap--DebtInstrumentAxis__custom--ThreeNotesMember_zkPsVM2Rep96" title="Debt instrument, face amount">50,000</span>@ <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20160527__srt--TitleOfIndividualAxis__custom--DirectorOfBusinessStrategyMember__us-gaap--DebtInstrumentAxis__custom--ThreeNotesMember_z6LHCyoitoGa">8</span>% interest. <span id="xdx_90A_eus-gaap--DebtInstrumentDescription_c20160526__20160527__srt--TitleOfIndividualAxis__custom--DirectorOfBusinessStrategyMember_za2gRsYFAR7k" title="Debt instrument, description">The compensation included was accrued during the period from January 2, 2011 to February 29, 2016. This compensation will be paid as bonuses out of future income only and is further subject to a cap of 20% of operating net cash flow in any given period. If bonuses are paid, accrued compensation will be paid with an amount decided by the Board. </span>On June 1, 2016, she agreed to reduce her accrued compensation by $<span id="xdx_908_eus-gaap--IncreaseDecreaseInDeferredCompensation_pp0p0_c20160601__20160602__srt--TitleOfIndividualAxis__custom--DirectorOfBusinessStrategyMember_zhkljMrj6xZf">225,000</span> as a contribution to additional paid in capital. She also agreed to reduce her long term note by $<span id="xdx_905_eus-gaap--IncreaseDecreaseInOtherNoncurrentLiabilities_c20160601__20160601__srt--TitleOfIndividualAxis__custom--DirectorOfBusinessStrategyMember_z4zWxsgUyfBf">9,583</span> as a contribution to additional paid in capital. As the Company was not funded prior to December 1, 2016, the Board of Directors reversed the contribution of accrued salaries. As of May 31, 2023 and November 30, 2022, the Director was owed a total of $<span id="xdx_901_eus-gaap--WorkersCompensationLiabilityCurrentAndNoncurrent_iI_pp0p0_c20230531__srt--TitleOfIndividualAxis__custom--DirectorOfBusinessStrategyMember_zjRcBK1B6uqg" title="Accrued compensation">440,833</span> and $<span id="xdx_90F_eus-gaap--WorkersCompensationLiabilityCurrentAndNoncurrent_iI_pp0p0_c20221130__srt--TitleOfIndividualAxis__custom--DirectorOfBusinessStrategyMember_zEpGconAaHZi" title="Accrued compensation">440,833</span>, respectively, of accrued compensation. As of May 31, 2023 and November 30, 2022, the Director was owed a total of $<span id="xdx_905_eus-gaap--NotesPayable_iI_pp0p0_c20230531__srt--TitleOfIndividualAxis__custom--DirectorOfBusinessStrategyMember_zHdAbTGXvBh6" title="Notes payable, related parties">883,791</span> and $<span id="xdx_905_eus-gaap--NotesPayable_iI_pp0p0_c20221130__srt--TitleOfIndividualAxis__custom--DirectorOfBusinessStrategyMember_z1nvDG3Wkj11" title="Notes payable, related parties">883,791</span>, respectively, of notes payable and accrued interest. There was a reduction in the liability by share issuance of $<span id="xdx_90F_ecustom--ReductionInLiabilityShareIssurance_c20221201__20230531__srt--TitleOfIndividualAxis__custom--DirectorOfBusinessStrategyMember_z9ZZkrYrhpvc" title="Reduction in liability insurance">27,308</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of November 30, 2016, a related party investor advanced a total of $<span id="xdx_90F_eus-gaap--NotesPayable_iI_pp0p0_c20161130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zyi4spuHAuS3" title="Notes payable to related parties">99,448</span> due on or before <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_pp0p0_dd_c20161129__20161130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_z30PfOVjyjj">June 15, 2016</span>. Pursuant to the agreement, the investor is allowed to convert <span id="xdx_900_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20161129__20161130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zi2XwYnneeBh" title="Debt instrument, conversion percentage">100</span>% of the debt at a share price of $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20161130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zGoF2CsXX8a2" title="Debt instrument, convertible, conversion price">0.15</span>. As of May 31, 2023 and November 30, 2022, the note was in default.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2016, the Chief Operating Officer loaned to the Company $<span id="xdx_908_eus-gaap--LoansPayable_iI_pp0p0_c20160331__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zB4AKU8qtkd2" title="Loan amount">100,000</span>. The loan bears interest at <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20160331__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zv9nbVuzToS8" title="Debt instrument bearing interest">8</span>% and is due on or before <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20160301__20160331__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zyYaXL9TRRgf" title="Debt instrument, maturity date">March 2, 2018</span>. Pursuant to the agreement, the investor is allowed to convert <span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20160301__20160331__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zhereVbNp7wf" title="Debt instrument, conversion rate">100</span>% of the debt on the maturity date at a share price of $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20160331__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zhSswUAVQjXa" title="Debt instrument, price per share">0.15</span>. The Company accounted for the conversion of loan in accordance with ASC 470, “Debt with Conversion and Other Options”. The fair market value of the shares on March 2, 2016 was $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20160302__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zmXuDrEVcZn8" title="Share price">0.10</span> per share and, accordingly, there was deemed to be no Beneficial Conversion Factor. On May 18, 2016, the Chief Operating Officer loaned the Company an additional $<span id="xdx_90D_eus-gaap--LoansPayable_iI_pp0p0_c20160518__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zkkTBevsiG42" title="Loans payable">50,000</span> with conversion rights at $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20160518__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zI9BXSo02F18" title="Debt instrument, price per share">0.10</span> per share. Therefore, effective May 18, 2016, $<span id="xdx_905_eus-gaap--NotesPayable_iI_pp0p0_c20160518__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zQnpfoLeT1Xh">50,000</span> of the Chief Operating Officer’s note payable had conversion rights of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20160518__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zaf4KqVud74j" title="Debt instrument, price per share">0.10</span> per share. The Company accounted for the conversion of loan in accordance with ASC 470, “Debt with Conversion and Other Options”. The fair market value of the shares on May 18, 2016 was $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20160518__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_z1vWyI48xLc8" title="Share price">0.10</span> per share and accordingly there was deemed to be no Beneficial Conversion Factor. On May 23, 2016, a third-party investor loaned the Company $<span id="xdx_90B_eus-gaap--LoansPayable_iI_pp0p0_c20160523__srt--TitleOfIndividualAxis__custom--ThirdPartyInvestorMember_z1jney9s79Pj" title="Convertible notes payable to related parties">25,000</span> with conversion rights at $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20160523__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyInvestorMember_zXGjwlOOvDXk">0.10</span> per share. Therefore, effective May 23, 2016, an additional $<span id="xdx_902_eus-gaap--LoansPayable_iI_pp0p0_c20160523__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zE2hm1EPBzn7">25,000</span> of the Chief Operating Officer’s $<span id="xdx_908_eus-gaap--NotesPayable_iI_pp0p0_c20160523__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zbacr4oRF8Pk" title="Notes payable">100,000</span> note payable had conversion rights of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20160523__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_z8ddSIPlsk5f" title="Debt instrument, conversion price">0.10</span> per share. The Company accounted for the conversion of loan in accordance with ASC 470, “Debt with Conversion and Other Options”. The fair market value of the shares on May 18, 2016 was $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20160518__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_z6SRv5NLksLj" title="Share price">0.10</span> per share and accordingly, was deemed to have no Beneficial Conversion Factor. As of May 31, 2023 and November 30, 2022, the note was in default.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2016, the Chief Operating Officer made a loan of $<span id="xdx_90F_eus-gaap--LoansPayable_iI_pp0p0_c20160531__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zQvkzjQPIyOl" title="Loans payable">50,000</span>, bearing interest at <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20160531__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zq5xwIIsDsDe" title="Debt instrument, interest rate">8</span>% and due on or before <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20160531__20160531__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zRCXzYfPD8Gb" title="Debt instrument, maturity date">May 18, 2018</span>. The debt is convertible into shares of common stock at a conversion price of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20160731__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zG6QrVUZIQHk" title="Debt instrument, price per share">0.10</span> per share. As of May 31, 2023 and November 30, 2022, the note was in default.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2016, the Chief Operating Officer made a loan of $<span id="xdx_904_eus-gaap--LoansPayable_iI_pp0p0_c20160731__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zWrdF2sZG0K7" title="Loans payable">50,000</span> as collateral, bearing interest at <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20160731__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_ze4VPevrk4Oc" title="Debt instrument, interest rate">8</span>% and due on or before <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_pid_dd_c20160731__20160731__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zBM50YPlRF1" title="Debt instrument, maturity date">July 31, 2018</span>. The debt is convertible into shares of common stock at a conversion price of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20160731__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zHYsXjmM2CH" title="Debt instrument, conversion price">0.10</span> per share. As of May 31, 2023 and November 30, 2022, the note was in default.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 29, 2021 the Company entered into an employment agreement with Robert Kohn. The Company agreed to an annual salary of $<span id="xdx_90D_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20210629__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertKohnMember_zroTQhqxYFAe" title="Accrued salary">150,000</span> beginning on September 30, 2021. Mr. Kohn resigned on November 15, 2022. As of May 31, 2023 and November 30, 2022 the Company accrued $<span id="xdx_900_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20230531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertKohnMember_zfbgVHXMjDD9" title="Accrued salary">168,750</span> and $<span id="xdx_902_eus-gaap--AccruedSalariesCurrentAndNoncurrent_iI_c20221130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertKohnMember_zG3UPpczqQO9" title="Accrued salary">168,750</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended November 30, 2021 the Company issued <span id="xdx_900_ecustom--NumberOfTokensIssuedToPurchaseAssets_pid_uInteger_c20201201__20211130__us-gaap--FinancialInstrumentAxis__custom--HyFiTokensMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TechnologyMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zcygMUSsfit" title="Number of tokens issued to purchase assets">17,500,000</span> HyFi Tokens to related parties for the purchase of technology. The Technology has a historical value of $<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentNet_iI_pid_c20211130__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TechnologyMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zzLBV88zuoU1" title="Value of purchased assets">0</span>. In addition, the Company issued Troy MacDonald <span id="xdx_901_ecustom--NumberOfTokensIssuedToPurchaseAssets_pid_uInteger_c20201201__20211130__us-gaap--FinancialInstrumentAxis__custom--HyFiTokensMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TechnologyMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TroyMacDonaldMember_z5gCj2JwZBP7" title="Number of tokens, issued">175,000</span> HyFi Tokens as consideration for his sale of HyFi tokens at <span id="xdx_90E_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20211130__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TechnologyMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zonkA2cBxHOg" title="Related party token sales, rate">5</span>% of the related token sales.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued interest on related party notes payable and convertible debt at May 31, 2023 and November 30, 2022, amounted to $<span id="xdx_90A_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20230531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1rcsYZbOkT" title="Accrued interest">611,290</span> and $<span id="xdx_90F_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20211130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zdU6e9WM8004" title="Accrued interest">568,912</span>, respectively, and is a component of accounts payable and accrued expenses – related parties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has separated accounts payable and accrued expenses on the balance sheet to reflect amounts due to related parties primarily consisting of officer compensation, health insurance, interest on notes and reimbursable expenses to officers for travel, meals and entertainment, vehicle and other related business expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible Loans – variable priced conversion</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 206250 874000 4 2017-12-01 The compensation included was accrued during the period from January 2, 2011 to February 29, 2016. This compensation will be paid as bonuses out of future income only and is further subject to a cap of 20% of operating net cash flow in any given period. If bonuses are paid, accrued compensation will be paid with an amount decided by the Board. 25000 214000 445250 445250 15722.47 805637 805637 206250 660000 0.04 2017-12-01 710000 50000 0.08 The compensation included was accrued during the period from January 2, 2011 to February 29, 2016. This compensation will be paid as bonuses out of future income only and is further subject to a cap of 20% of operating net cash flow in any given period. If bonuses are paid, accrued compensation will be paid with an amount decided by the Board. 225000 9583 440833 440833 883791 883791 27308 99448 2016-06-15 1 0.15 100000 0.08 2018-03-02 1 0.15 0.10 50000 0.10 50000 0.10 0.10 25000 0.10 25000 100000 0.10 0.10 50000 0.08 2018-05-18 0.10 50000 0.08 2018-07-31 0.10 150000 168750 168750 17500000 0 175000 0.05 611290 568912 <p id="xdx_80C_ecustom--DisclosureOfConvertibleLoansTextBlock_zyMSXnOurvi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 5. <span id="xdx_821_zvasszQh8Z37">Convertible loans</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diagonal Lending Securities Purchase Agreement &amp; Convertible Note</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 31, 2022, the Company entered into a Securities Purchase Agreement (the “Diagonal Lending SPA”) by and between the Company and 1800 Diagonal Lending LLC (“Diagonal Lending”). Pursuant to the terms of the Diagonal Lending SPA, the Company agreed to sell, and Diagonal Lending agreed to purchase, a convertible note of the Company in the aggregate principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zQbRfHWue7S8" title="Debt instrument, principal amount">90,000</span>. On August 5, 2022 the Company borrowed an additional $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20220805__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zupaihzGmnz3" title="Debt instrument, principal amount">78,750</span> with similar terms. On September 26, 2022 the Company borrowed an additional $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20220926__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zps3Sf7OV8yg" title="Debt instrument, principal amount">55,000</span> with similar terms</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 31, 2022 ,August 5, 2022 and September 26, 2022, pursuant to the terms of the Diagonal Lending SPA, the Company issued to Diagonal Lending a convertible promissory note (the “Diagonal Lending Note”) in the principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zDvYI7p44473" title="Debt instrument, principal amount">90,000</span>, $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20220805__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zr4zADIH8Ayf" title="Debt instrument, principal amount">78,750</span> and $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20220926__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zTRe6TxdJJfi" title="Debt instrument, principal amount">55,000</span>, respectively. The Diagonal Lending Note was funded on June 23, 2022, August 5th, 2022 and November 6, 2022. The Diagonal Lending Note bears interest at a rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zcBp4ZxBWH5i" title="Debt instrument, interest rate">10</span>% per annum and matures <span id="xdx_904_eus-gaap--DebtInstrumentTerm_pid_dtD_uPure_c20220531__20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zOBUQIUHGji5" title="Debt instrument, term">180</span> days after issuance. The Diagonal Lending Note may not be prepaid in whole or in part except as otherwise explicitly set forth in the Diagonal Lending Note. Any amount of principal or interest which is not paid when due will bear interest at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20220531__20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zGo3e1T3ip21" title="Debt default, interest rate">22</span>% per annum.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DebtInstrumentDescription_c20220531__20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zBV02Mx7xC0c" title="Debt instrument, description">Diagonal Lending has the right from time to time, and at any time following November 27, 2022 and ending on the earlier of (i) payment of all amounts due under the Diagonal Lending Note, (ii) May 31, 2023, if all amounts are repaid in full at such time, or (iii) the date full repayment of all indebtedness to convert all or any part of the indebtedness into common stock subject to the terms of the Digital Lending Note at the Conversion Price (as hereinafter defined). The “Conversion Price” means 65% multiplied by the lowest trading price for the Company’s common stock during the 10 trading day period ending on the latest complete trading day prior to the conversion date, subject to a 4.99% equity blocker and subject to the terms of the Diagonal Lending Note</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Diagonal Lending Note may be prepaid; provided, however, that if the Company exercises its right to prepay, the Company will make payment to Diagonal Lending of an amount in cash equal to the percentage as set forth in the table below, multiplied by the sum of: (w) the then outstanding principal amount of the Diagonal Lending Note, plus (x) accrued and unpaid interest on the unpaid principal amount of the Diagonal Lending Note, plus (y) default interest, if any, on the amounts referred to in clauses (w) and (x) plus (z) certain other amounts owed to Diagonal Lending pursuant to the terms of the Diagonal Lending Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p id="xdx_894_ecustom--ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteTableTextBlock_zWCSuhDNMk0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_z4Q3fKFI6BVi" style="display: none">Schedule of Amount Owed on Prepayment of Diagonal Lending Note</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Prepayment Period</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Prepayment Percentage</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%">May 31, 2022 to July 30, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 24%; text-align: right"><span id="xdx_901_ecustom--DebtInstrumentPrepaymentPercentage_iI_pid_dp_uPure_c20230531__us-gaap--AwardTypeAxis__custom--PrepaymentPeriodOneMember_zNjTyYjXhJnb" title="Prepayment, rate">120</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>July 31, 2022 to October 28, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--DebtInstrumentPrepaymentPercentage_iI_pid_dp_uPure_c20230531__us-gaap--AwardTypeAxis__custom--PrepaymentPeriodTwoMember_zcSZPrUF2Cqj" title="Prepayment, rate">125</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>October 29, 2022 to November 27, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--DebtInstrumentPrepaymentPercentage_iI_pid_dp_uPure_c20230531__us-gaap--AwardTypeAxis__custom--PrepaymentPeriodThreeMember_zEeaZms3rob1" title="Prepayment, rate">130</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AB_zeaEHZCBcn1f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After November 27, 2022, prepayment will be subject to agreement of the parties with respect to the applicable prepayment percentage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 17, 2023 Diagonal converted $<span id="xdx_90E_eus-gaap--DebtConversionOriginalDebtAmount1_c20230217__20230217__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zVp6qWyadAWb" title="Debt principal amount converted">12,000</span> of principal into <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230217__20230217__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zTM1l80UYg0k" title="Common stock issued in conversion">242,915</span> shares of common stock at the price of $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230217__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zEQiFfWuZhlg" title="Debt conversion price">0.0494</span>. The Company recorded dividend resolution of $<span id="xdx_904_eus-gaap--Dividends_c20230217__20230217__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zMeD5WffmuMg" title="Dividend resolution">15,176</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 90000 78750 55000 90000 78750 55000 0.10 P180D 0.22 Diagonal Lending has the right from time to time, and at any time following November 27, 2022 and ending on the earlier of (i) payment of all amounts due under the Diagonal Lending Note, (ii) May 31, 2023, if all amounts are repaid in full at such time, or (iii) the date full repayment of all indebtedness to convert all or any part of the indebtedness into common stock subject to the terms of the Digital Lending Note at the Conversion Price (as hereinafter defined). The “Conversion Price” means 65% multiplied by the lowest trading price for the Company’s common stock during the 10 trading day period ending on the latest complete trading day prior to the conversion date, subject to a 4.99% equity blocker and subject to the terms of the Diagonal Lending Note <p id="xdx_894_ecustom--ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteTableTextBlock_zWCSuhDNMk0e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BE_z4Q3fKFI6BVi" style="display: none">Schedule of Amount Owed on Prepayment of Diagonal Lending Note</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Prepayment Period</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Prepayment Percentage</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 72%">May 31, 2022 to July 30, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 24%; text-align: right"><span id="xdx_901_ecustom--DebtInstrumentPrepaymentPercentage_iI_pid_dp_uPure_c20230531__us-gaap--AwardTypeAxis__custom--PrepaymentPeriodOneMember_zNjTyYjXhJnb" title="Prepayment, rate">120</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>July 31, 2022 to October 28, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--DebtInstrumentPrepaymentPercentage_iI_pid_dp_uPure_c20230531__us-gaap--AwardTypeAxis__custom--PrepaymentPeriodTwoMember_zcSZPrUF2Cqj" title="Prepayment, rate">125</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>October 29, 2022 to November 27, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--DebtInstrumentPrepaymentPercentage_iI_pid_dp_uPure_c20230531__us-gaap--AwardTypeAxis__custom--PrepaymentPeriodThreeMember_zEeaZms3rob1" title="Prepayment, rate">130</span></td><td style="text-align: left">%</td></tr> </table> 1.20 1.25 1.30 12000 242915 0.0494 15176 <p id="xdx_808_ecustom--SeniorPromissoryNoteRelatedPartyDisclosureTextBlock_zgEufMiMJJY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 6. <span id="xdx_82C_zdyg3xhCwzdd">Senior Promissory Note – related party</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 29, 2021, the Closing Date, the Company and CEP entered into the Redemption Agreement, dated as of June 29, 2021, pursuant to which the Company redeemed the Series A Share. On the Closing Date, as provided in the Redemption Agreement, the Company issued to CEP the Note in the principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20210629__dei--LegalEntityAxis__custom--ChinaEnergyPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--RedemptionAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMujliil6en7" title="Debt instrument, principal value">1,000,000</span> with an interest rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20210629__dei--LegalEntityAxis__custom--ChinaEnergyPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--RedemptionAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zcAHMACeaIR8" title="Debt instrument, interest rate">6</span>% per annum. The Series A Share will be held in escrow. If an Event of Default (as defined in the Note) occurs under the Note, then the Company will direct the escrow agent to release the Series A Share to CEP; provided, however, that CEP will also retain all rights and privileges under the Note (and the Company will remain bound to all obligations under Note) even if the Series A Share is required to be released by the escrow agent to CEP as provided in the Redemption Agreement. For the avoidance of doubt, CEP will regain all rights, title, and interest in and to the Series A Share upon the occurrence of an Event of Default under the Note, regardless of the amount of the outstanding balance owed under the Note at the time of the occurrence of an Event of Default under the Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 22, 2022, the Company entered into the Addendum and Amendment of Promissory Note (the “Note Amendment”) by and between the Company and China Energy Partners, LLC (“China Energy”). Pursuant to the terms of the Note Amendment, the Company and China Energy agreed to amend the Senior Promissory Note issued by the Company to China Energy on June 29, 2021 (the “China Energy Note”) such that (i) the principal amount and accrued interest under the China Energy Note will be repaid in full on or before June 28, 2022, with $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20210629__us-gaap--DebtInstrumentAxis__custom--ChinaEnergyPartnersNoteAmendmentMember_z51ibsjpdwM4" title="Principal amount">800,000</span> to be paid in cash and $<span id="xdx_906_ecustom--DebtTransferAmount_iI_c20210629__us-gaap--DebtInstrumentAxis__custom--ChinaEnergyPartnersNoteAmendmentMember_zgwGs6cHuAQ7" title="Debt transfer amount">200,000</span> to be paid via the transfer to China Energy of tokens to an electronic wallet; and (ii) the parties agree that $<span id="xdx_907_eus-gaap--InterestReceivable_iI_c20210629__us-gaap--DebtInstrumentAxis__custom--ChinaEnergyPartnersNoteAmendmentMember_zPAW1MT0WxWi" title="Accurued interest">60,000</span> in interest previously accrued under the China Energy Note was satisfied via the transfer by the Company to China Energy of 53 HyFi NFT Athena vaults.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 28, 2022, the China Energy Note, as amended by the Note Amendment, was paid in full.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1000000 0.06 800000 200000 60000 <p id="xdx_808_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zQrlLdIXsEnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 6. <span id="xdx_828_zsgCJi0fyCZj">Stockholders’ deficit</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 5, 2021, Company effected the following share issuances:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210804__20210805__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember_pdd" title="Number of shares issued">50,000</span> shares of common stock valued at $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210804__20210805__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember_pp0p0" title="Value of shares issued">2,500</span> ($<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_c20210805__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember_pdd" title="Issue price per share">0.05</span> per share) to a consultant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issued <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210804__20210805__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BaruchHalpernMember_pdd" title="Number of shares issued">750,000</span> shares of common stock valued at $<span id="xdx_904_eus-gaap--StockGrantedDuringPeriodValueSharebasedCompensation_c20210804__20210805__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BaruchHalpernMember_pp0p0" title="Value of shares issued">37,500</span> ($<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210805__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BaruchHalpernMember_zvdgay7fpDZe" title="Issue price per share">0.05</span> per share) to Baruch Halpern for severance compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issued <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210804__20210805__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertKohnMember_zpkTyIHAeQn8" title="Number of shares issued">546,160</span> shares of common stock valued at $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210804__20210805__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertKohnMember_zEvn2uePX3F2" title="Value of shares issued">27,307</span> ($<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210805__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobertKohnMember_zDXIgVP9qb46" title="Issue price per share">0.05</span> per share) to Robert Kohn for partial conversion of accrued compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issued <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210804__20210805__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BonnieNelsonMember_pdd" title="Number of shares issued">546,160</span> shares of common stock valued at $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210804__20210805__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BonnieNelsonMember_pp0p0" title="Value of shares issued">27,307</span> ($<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20210805__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BonnieNelsonMember_z2IlgG0jrDsd" title="Issue price per share">0.05</span> per share) to Bonnie Nelson for partial conversion of accrued compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On the Closing Date, the Company and CEP entered into the Redemption Agreement, dated as of June 29, 2021, pursuant to which the Company redeemed the Series A Share. On the Closing Date, as provided in the Redemption Agreement, the Company issued to CEP the Note in the principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20210629__dei--LegalEntityAxis__custom--ChinaEnergyPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--RedemptionAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zV5ES5x9qe98" title="Debt instrument, principal value">1,000,000</span> with an interest rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20210629__dei--LegalEntityAxis__custom--ChinaEnergyPartnersLLCMember__us-gaap--TypeOfArrangementAxis__custom--RedemptionAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zt0AzRTCJRCl" title="Debt instrument, interest rate">6</span>% per annum. The Series A Share will be held in escrow. If an Event of Default (as defined in the Note) occurs under the Note, then the Company will direct the escrow agent to release the Series A Share to CEP; provided, however, that CEP will also retain all rights and privileges under the Note (and the Company will remain bound to all obligations under Note) even if the Series A Share is required to be released by the escrow agent to CEP as provided in the Redemption Agreement. For the avoidance of doubt, CEP will regain all rights, title, and interest in and to the Series A Share upon the occurrence of an Event of Default under the Note, regardless of the amount of the outstanding balance owed under the Note at the time of the occurrence of an Event of Default under the Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 29, 2021, the Sellers agreed to (i) pay to the Company, on the closing date of the Acquisition, $<span id="xdx_90B_eus-gaap--PaymentsToAcquireBusinessesGross_pp0p0_c20210628__20210629__us-gaap--BusinessAcquisitionAxis__custom--HyFiMember_zU8UskDm5Zh3" title="Cash consideration, acquisition">300,000</span> (the “Cash Consideration”), and (ii) transfer to the Company, on the closing date of the Acquisition, <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210628__20210629__us-gaap--BusinessAcquisitionAxis__custom--HyFiMember__us-gaap--FinancialInstrumentAxis__custom--HyFiTokensMember_z1hrBH1JXUh8" title="Number of consideration shares">400,000,000</span> HyFi Tokens (the “HyFi Token Consideration”). The Company used the Cash Consideration to bring the Company into a fully reporting status with the SEC and for public company operating expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In exchange for the sale of the Assets and the Cash Consideration, the Company agreed to issue to the Sellers an aggregate of <span id="xdx_905_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20210628__20210629__us-gaap--BusinessAcquisitionAxis__custom--HyFiMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zk4zbBE7hCdi" title="Number of shares issued as consideration">900,000</span> Series C preferred shares within 30 calendar days after the State of Nevada provides written confirmation of filing of the certificate of designation for the Series C preferred stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the APA, the parties agreed that the Series C preferred stock will have the following terms, among others:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. Authorized Shares of Series C Preferred Stock. The number of authorized shares of Series C preferred stock will be <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20210629__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_znvd8r2AqYu1" title="Preferred stock shares authorized">900,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. Conversion. <span id="xdx_90A_eus-gaap--ConversionOfStockDescription_c20210628__20210629__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zDpwaxLLJxSl" title="Conversion of stock, description">Subject to the other terms and conditions in the certificate of designation, a Series C preferred stock holder will have the right from time to time and at any time following the date that is one year after the date on the signature page of the certificate of designations to convert each outstanding share of Series C preferred stock into 450 shares of Company common stock. Based on the number of shares of common stock issued and outstanding as of November 30, 2021, if all of the <span id="xdx_90F_eus-gaap--ConversionOfStockSharesIssued1_pid_c20210628__20210629__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_ziRGHEs42rib" title="Conversion of stock shares issued">900,000</span> shares of Series C preferred stock are issued and subsequently converted, the holders of the converted stock will hold 90% of the issued and outstanding shares of common stock</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. Voting. <span id="xdx_907_eus-gaap--PreferredStockVotingRights_c20210628__20210629__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zBvvIWkAATPb" title="Preferred stock voting rights">Except as otherwise set forth in the certificate of designation, each share of Series C preferred stock will, on any matter submitted to the holders of Company common stock, or any class thereof, for a vote, vote together with the common stock, or any class thereof, as applicable, as one class on such matter, and each share of Series C preferred stock will have 450 votes.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. Dividends. The Series C preferred stock is not entitled to receive dividends or distributions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 27, 2021, the Company filed with the State of Nevada a certificate of designations for the Series C preferred stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 28, 2021, the Company amended and restated its articles of incorporation, as amended, in order to, among other things, (i) increase the number of authorized shares of common stock from <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_c20210727_zzZmHRiiUJE" title="Common stock, shares authorized">100,000,000</span> to <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_c20210728_zvgYKPR7mnzc" title="Common stock, shares authorized">500,000,000</span>, (ii) increase the number of authorized shares of preferred stock from <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20210727_zWehUQON3UIb" title="Preferred stock, shares authorized">10,000</span> to <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20210728_zP3HvmDJrWsj" title="Preferred stock, shares authorized">5,000,000</span>, and (iii) change the par value of the preferred stock from $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210727_zcT5UqDgJAv2" title="Preferred stock, par value">1.00</span> par value per share to $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20210728_zZQUfX4blQKh" title="Preferred stock, par value">0.0001</span> par value per share. As of November 30, 2021, the Company had authorized <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20211130_zlQJQRACt1a1" title="Common stock, shares authorized">500,000,000</span> shares of common stock, $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211130_z18UHutvFVTj" title="Common stock, par value">0.0001</span> par value per share, and <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20211130_zVW5JBRs8pv5" title="Preferred stock, shares authorized">5,000,000</span> shares of preferred stock, $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211130_zFnrTFAW4ROe" title="Preferred stock, par value">0.0001</span> par value per share. As of May 31, 2022, and November 30, 2021, respectively, there were <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20220531_z4xnw4Rfbb1l" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20220531_zPGarEFbaaHd" title="Common stock, shares outstanding">45,625,000</span></span> and <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20211130_zl0DmKrDvgkc" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20211130_zC6Q0CdZWnNd" title="Common stock, shares outstanding">45,000,000</span></span> shares of common stock issued and outstanding, and <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20220531_zsKATdrfn0n1" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_c20220531_znXxvYDnAPs" title="Preferred stock, shares outstanding">900,000</span></span> and <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_c20211130_zzc3pL5nRq2l" title="Preferred stock, shares issued">1</span> shares and <span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_iI_c20211130_zyS409VQUVt" title="Preferred stock, shares outstanding">0</span> shares of preferred stock issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 5, 2022, the Company entered into a Stock Purchase Agreement (the “Compton SPA”) by and between the Company and Clarke Compton. Pursuant to the terms of the Compton SPA, the Company agreed to sell, and Mr. Compton agreed to purchase <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220303__20220305__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrComptonMember_z64jGXlYDwwl" title="Number of shares issued">625,000</span> shares of the Company’s common stock for a total purchase price of $<span id="xdx_908_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220303__20220305__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrComptonMember_zk0UQLGuPpA6" title="Share purchase price">250,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 26, 2022 PIP agreed to purchase, and the Company agreed to sell <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220625__20220626__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember_zhJe3Z4Npc6l" title="Shares of restriced common stock">500,000</span> shares of restricted common stock at a purchase price of $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20220626__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember_zvS4rwlRxIug" title="Share price">0.25</span> per share. As of May 31, 2023 and November 30, 2022 the shares have not been issued by the transfer agent</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 21, 2023 the Company awarded <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230421__20230421__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zNGxa8Z2IMjh" title="Number of shares awarded">112,346</span> of the Company’s ‘C’ class preference shares to an employe the vesting schedule is :</span></p> <p id="xdx_890_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zAsNrhSnB4Z3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zwYv3649e7wc" style="display: none">Schedule of Preference Shares Awarded to an Employee</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zSW2ssWs4rr5" title="Vesting schedule">On signing this agreement (April 21, 2023)</span></span></td> <td style="width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zh5kUbmiGZIc" title="Number of shares awarded">28,088</span> ‘C’ class preference shares</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zBEJKttTmSY5">After 6 months (October 21, 2023)</span></span></td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z5kgs9brwYp3">28,086</span> ‘C’ class preference shares</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z2E3dQf67RXe">After 12 months (April 21, 2024)</span></span></td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zmXEFLrDeYB6">28,086</span> ‘C’ class preference shares</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230421__20230421__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zHj0PBzbVANi">After 18 months (October 21, 2024)</span></span></td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230421__20230421__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zbgAnMU4V5Dl">28,086</span> ‘C’ class preference shares</span></td></tr> </table> <p id="xdx_8A0_zc07aNbTiKGi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended May 31, 2023 the Company recorded an expense of $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20230301__20230531_zOS30VsuoYTa" title="Share-based compensation expense">4,423,545</span> for the vested portion of the awards. The remaining unamortized amount of $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20230531_zARwCJD6VkEf" title="Unamortized expense amount">7,709,607</span> will be amortized over the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 50000 2500 0.05 750000 37500 0.05 546160 27307 0.05 546160 27307 0.05 1000000 0.06 300000 400000000 900000 900000 Subject to the other terms and conditions in the certificate of designation, a Series C preferred stock holder will have the right from time to time and at any time following the date that is one year after the date on the signature page of the certificate of designations to convert each outstanding share of Series C preferred stock into 450 shares of Company common stock. Based on the number of shares of common stock issued and outstanding as of November 30, 2021, if all of the 900,000 shares of Series C preferred stock are issued and subsequently converted, the holders of the converted stock will hold 90% of the issued and outstanding shares of common stock 900000 Except as otherwise set forth in the certificate of designation, each share of Series C preferred stock will, on any matter submitted to the holders of Company common stock, or any class thereof, for a vote, vote together with the common stock, or any class thereof, as applicable, as one class on such matter, and each share of Series C preferred stock will have 450 votes. 100000000 500000000 10000 5000000 1.00 0.0001 500000000 0.0001 5000000 0.0001 45625000 45625000 45000000 45000000 900000 900000 1 0 625000 250000 500000 0.25 112346 <p id="xdx_890_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zAsNrhSnB4Z3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zwYv3649e7wc" style="display: none">Schedule of Preference Shares Awarded to an Employee</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zSW2ssWs4rr5" title="Vesting schedule">On signing this agreement (April 21, 2023)</span></span></td> <td style="width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zh5kUbmiGZIc" title="Number of shares awarded">28,088</span> ‘C’ class preference shares</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zBEJKttTmSY5">After 6 months (October 21, 2023)</span></span></td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z5kgs9brwYp3">28,086</span> ‘C’ class preference shares</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z2E3dQf67RXe">After 12 months (April 21, 2024)</span></span></td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zmXEFLrDeYB6">28,086</span> ‘C’ class preference shares</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230421__20230421__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zHj0PBzbVANi">After 18 months (October 21, 2024)</span></span></td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230421__20230421__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zbgAnMU4V5Dl">28,086</span> ‘C’ class preference shares</span></td></tr> </table> On signing this agreement (April 21, 2023) 28088 After 6 months (October 21, 2023) 28086 After 12 months (April 21, 2024) 28086 After 18 months (October 21, 2024) 28086 4423545 7709607 <p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zPuVAwEqgW21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note 8. <span id="xdx_82F_zEUFydQ3wUCf">Commitments and Contingencies</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 6, 2022, the Company entered into an agreement (the “Sanctum Agreement”) with Sanctum Studios (“Sanctum”) relating to The Athena Project. Pursuant to the terms of the Sanctum Agreement, Sanctum agreed to conceptualize, create and produce a collection of <span id="xdx_903_ecustom--NumberOfAssets_c20220405__20220406__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--DigitalArtMember__us-gaap--TypeOfArrangementAxis__custom--SanctumAgreementMember_zdcNqlo96IUj" title="Number of assets">20,000</span> digital art assets based on the Greek Goddess Athena, in exchange for payment by the Company of $<span id="xdx_907_eus-gaap--PaymentsToAcquireIntangibleAssets_c20220405__20220406__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--DigitalArtMember__us-gaap--TypeOfArrangementAxis__custom--SanctumAgreementMember_ztnHWnwUJjw2" title="Payment for asset">121,000</span> and certain variable rate payments depending on the number of vaults sold by the Company. The $<span id="xdx_903_eus-gaap--PaymentsToAcquireIntangibleAssets_c20220405__20220406__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--DigitalArtMember__us-gaap--TypeOfArrangementAxis__custom--SanctumAgreementMember_zWGbdG2ZPHsh" title="Payment for asset"><span id="xdx_903_eus-gaap--PaymentsToAcquireIntangibleAssets_c20220405__20220406__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--DigitalArtMember__us-gaap--TypeOfArrangementAxis__custom--SanctumAgreementMember_zlwQrEhHWoR9" title="Payment for asset">121,000</span></span> is payable by the Company in three equal installments of $<span id="xdx_908_eus-gaap--PaymentsToAcquireIntangibleAssets_pp2d_c20220404__20220404__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--DigitalArtMember__us-gaap--TypeOfArrangementAxis__custom--SanctumAgreementMember_zNl7sSZmldLa" title="Payment of exchange"><span id="xdx_90C_eus-gaap--PaymentsToAcquireIntangibleAssets_pp2d_c20220519__20220519__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--DigitalArtMember__us-gaap--TypeOfArrangementAxis__custom--SanctumAgreementMember_z09CRRcV2rEa" title="Payment of exchange"><span id="xdx_90F_eus-gaap--PaymentsToAcquireIntangibleAssets_pp2d_c20220701__20220701__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--DigitalArtMember__us-gaap--TypeOfArrangementAxis__custom--SanctumAgreementMember_zOOWbpmtARD7" title="Payment of exchange">40,333.33</span></span></span> due on April 4, 2022, May 19, 2022 and July 1, 2022. The Company paid all installments due through August 31, 2022. The Sanctum deliverables are due by July 1, 2022 or earlier, as set forth in the Sanctum Agreement. The Company announced this material definitive agreement and associated Press Release, incorporated by reference, on a Current Report on Form 8-K which was filed with the SEC on April 7, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PIP North America ILO and Multi-Agreement</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 26, 2022 , the Company entered into an ILO and Multi-Agreement (the “PIP Agreement”) with PIP North America Inc. (“PIP”). Pursuant to the terms of the PIP Agreement, the parties agreed as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. The Company agreed to provide PIP the exclusivity to list the first initial license offering (“ILO”) for a minimum of 90 days. <span id="xdx_90C_ecustom--GrossRevenueDescription_c20220626__20220626__us-gaap--TypeOfArrangementAxis__custom--ILOAndMultiAgreementMember_z2HGqM7hyuNk" title="Gross revenue, description">PIP can mutually agree to allow the Company to list another ILO during this period and PIP will receive 50% of gross revenues.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. PIP will not pay any listing fee for its first three ILOs, and the Company will provide free consulting services to help structure the ILOs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. The Company agreed to provide services necessary from Super How for the customization of the HyFi technology for the first three PIP ILOs, including smart contracts for each listing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. The Company agreed to provide, at the Company’s cost, Prime Trust for anti-money laundering (AML) and know your customer (KYC) services, including processing of the payments, conversion of tokens to fiat currency for the use by the ILO issuer and all other services necessary for any ILOs, projects or bridge loans that PIP agrees to list on HyFi marketplaces to raise capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. The Company agreed to provide PIP with Exclusive License options for one-year $<span id="xdx_900_eus-gaap--IndefiniteLivedLicenseAgreements_iI_pn6n6_c20220626__srt--ProductOrServiceAxis__custom--ExclusiveLicenseOptionsYearOneMember__us-gaap--TypeOfArrangementAxis__custom--PIPAgreementMember_zejdQoIwSVL4" title="Exclusive license Amount">1</span> million an option for an additional year for $<span id="xdx_903_eus-gaap--IndefiniteLivedLicenseAgreements_iI_pn6n6_c20220626__srt--ProductOrServiceAxis__custom--ExclusiveLicenseOptionsYearFiveMember__us-gaap--TypeOfArrangementAxis__custom--PIPAgreementMember_zIIqgU1GHgp6" title="Exclusive license Amount">10</span> million for the agriculture category on the HyFi DeFi marketplaces. <span id="xdx_906_ecustom--GrossRevenueDescription_c20220626__20220626__us-gaap--TypeOfArrangementAxis__custom--ILOAndMultiAgreementMember__us-gaap--TypeOfArrangementAxis__custom--PIPAgreementMember_zd7zY8LbV2nb" title="Gross revenue, description">Whoever brings the issuer will receive 75% of the gross revenues and whoever does not bring the issuer will receive 25% of the gross revenues</span>. The option for the one-year exclusive must be exercised while the first PIP ILO is listed on the HyFi ILO marketplace and, once exercised, will last for one year. Within 90 days of the expiration of the one-year exclusive license, PIP must exercise the license for the second year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. PIP agreed to pay the Company <span id="xdx_907_ecustom--GrossSalesCustomaryPercentage_iI_pid_dp_uPure_c20220626__us-gaap--TypeOfArrangementAxis__custom--PIPAgreementMember_zO01MxWe79Wh" title="Gross sales percentage">5</span>% of gross sales of PIP vaults plus usual and customary percentages charged by third party vendors for the vault program.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7. PIP agreed to purchase, and the Company agreed to sell <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220625__20220626__us-gaap--TypeOfArrangementAxis__custom--PIPAgreementMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember_zQXe8FkGDh7d" title="Shares issued, shares">500,000</span> shares of restricted common stock at a purchase price of $<span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20220626__us-gaap--TypeOfArrangementAxis__custom--PIPAgreementMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember_zOSUQFb6A6X4" title="Share price">0.25</span> per share. As of November 30, 2022 the shares have not been issued by the transfer agent.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8. PIP agreed to purchase, and the Company agreed to sell <span id="xdx_90C_ecustom--TokensIssuedDuringPeriodSharesNewIssues_pid_c20220625__20220626__us-gaap--TypeOfArrangementAxis__custom--PIPAgreementMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember_zeEfFJNoO5z9" title="Tokens issued during period shares">3,125,000</span> HyFi tokens at a purchase price of $<span id="xdx_903_ecustom--TokenPrice_pid_c20220626__us-gaap--TypeOfArrangementAxis__custom--PIPAgreementMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember_zQ6QujzEVDr4" title="Token price">0.04</span> per token for $<span id="xdx_90D_ecustom--TokensIssuedDuringPeriodSharesNewIssuesValue_c20220625__20220626__us-gaap--TypeOfArrangementAxis__custom--PIPAgreementMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember_zpLjwCoqyKS7" title="Tokens issued during period value new issues">125,000</span>. The HyFi tokens can be used as utility tokens in conjunction with HyFi DeFi marketplace fees and services, HyFi vaults, HyFi memberships and any other HyFi fees and services. As of November 30, 2022 the HyFi tokens have not been delivered.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9. <span id="xdx_901_ecustom--PurchaseOfVaultsDescription_c20220625__20220626__us-gaap--TypeOfArrangementAxis__custom--PIPAgreementMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember_zNqK2f2vDVi7" title="Purchase of vaults, description">The Company agreed to grant PIP an option to purchase up to 50 HyFi vaults for $1,000. The option will expire on August 30, 2022</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10. The Company agreed to provide a license for the HyFi Vault Program, a blockchain promotional and marketing program, and services necessary from third party vendors, including Super How and Sanctum Studios.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11. In exchange for the above, PIP agreed to pay to the Company $<span id="xdx_90A_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pid_c20220626__us-gaap--TypeOfArrangementAxis__custom--PIPAgreementMember__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember_zMPBbKkQSdkc" title="Debt payment amount">500,000</span>. The Company agreed to use this payment as part of the payments to retire the China Energy Note, as amended.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 11, 2022, the Company entered into an agreement with Generation Power Group Limited. The Company agreed to act as a non-exclusive placement agent in connection with an offering to investors of up to an aggregate of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221110__20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GenerationPowerGroupLimitedMember_zTkAS3VDzh5e" title="Offering to investors">100,000,000</span> of securities. The Company will receive the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company Onboarding &amp; Due Diligence Fee</b>. The Company will receive a non-refundable Onboarding fee of $<span id="xdx_90C_eus-gaap--LegalFees_c20221110__20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GenerationPowerGroupLimitedMember_zHV8pW5KPW5f" title="Onboarding fee">125,000</span> upon execution of this Agreement.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Placement Fee</b>. The Company will receive a cash placement fee equal to <span id="xdx_90F_ecustom--CashPlacementFeeRate_dp_c20221110__20221111_zxhkXwSezsLg" title="Cash placement fee rate">4</span>% of the aggregate gross proceeds received from Investors that the Company originated. The Company will receive placement fee equal to 2% of the aggregate gross proceeds received from Investors that Generation Power Group Limited originate.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expenses</b>. The Company will receive promptly reimburse upon request for reasonable out-of-pocket expenses incurred by the Company in connection with the services provided hereunder, including, without limitation, travel costs, Site maintenance, and other customary expenses for this type of engagement, including, without limitation, out-of-pocket legal or regulatory fees, costs and expenses (including without limitation, any Offering-related regulatory filing fees and reasonable out-of-pocket counsel or consultant fees, related to the review of Offering Materials for compliance with applicable SEC/FINRA rules).</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All fees and expenses payable hereunder are net of all applicable withholding and similar taxes.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The term of this Agreement shall be from the date hereof until the earlier of: (i) 12 months from the date hereof; or (ii) the date of the closing of the Offering as agreed by HYFI and the Company. The engagement hereunder will commence upon the execution of this Agreement by both parties, and shall be terminable by either party, with or without cause, on 30 days’ prior written notice to the other.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of November 30, 2022, the Company has recorded the Onboarding &amp; Due Diligence Fee as deferred revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 15, 2022, Robert Kohn resigned as Chief Financial Officer of the Company and as a member of the Company’s Board of Directors, effective immediately. Mr. Kohn’s resignation was not because of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Effective November 15, 2022, the Board appointed Paul Christopher Walton to serve as the Company’s Chief Operating Officer, as well as the Company’s principal financial officer and principal accounting officer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.Walton, Since September 2022, Mr. Walton has served as Chief Operating Officer of HyFi, helping to review its security token and renewable green energy financing business. He is responsible for developing the regulated financial infrastructure which will enable HyFi to raise capital for its clients, as well as attending to key operational responsibilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the past five years Mr. Walton advised several start-up fintech businesses to raise capital, arrange operations and develop business invest management and alternative investing markets. This work involved regulated blockchain and cryptocurrency businesses as well as style-based investment technology. At Optimal Asset Management, Mr. Walton grew assets and helped to develop a business which was eventually sold to BNY Mellon.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to this, Mr. Walton advised on a substantial portion of new technology and new product development at the London Stock Exchange’s New York operation, FTSE Russell for two periods between 2009 and 2017. Mr. Walton also ran business development for renowned economist, Mr. Stephen Ross, at his Ross, Jeffrey and Antle hedge fund, for a four-year period, helping to grow assets substantially.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Walton worked for a number of leading investment banks in London over three decades from the 1980s to the early 2000’s. In this work, Mr. Walton was a highly rated financial analyst and investment strategist at the Warburg’s private bank, Schroders private bank, Goldman Sachs, Schroder Salomon Smith Barney, and Merrill Lynch.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Walton received a Master’s Degree in Economics from the University of London and Bachelor’s Degree in Economics from the Victoria University of Manchester. Mr. Walton studied advanced management principles at the UK-based Ashridge Business School. For most of his career, Mr. Walton held regulatory qualifications administered by the then UK supervisory body, Financial Services Authority.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective April 21, 2023 The Company and Paul Walton entered into a one year employment agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall pay the Executive as compensation for his services during the first twelve (12) months of his Employment a base salary at a gross annual rate of $<span id="xdx_900_eus-gaap--OfficersCompensation_c20230421__20230421_zCj1q7lQrRwa" title="Base salary annual rate">180,000</span>. Such salary shall be payable either when:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>i.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company receives net investment of at least $<span id="xdx_90E_ecustom--NetInvestmentThresholdLimitForSalaryPayment_c20230421__20230421__srt--TitleOfIndividualAxis__custom--MrWaltonMember__srt--RangeAxis__srt--MinimumMember_zXlPOfQ6h6Qk" title="Net investment threshold limit for salary payment">1,000,000</span> or, </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ii.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company receives net income of at least $<span id="xdx_903_ecustom--NetIncomeThresholdLimitForSalaryPayment_c20230421__20230421__srt--TitleOfIndividualAxis__custom--MrWaltonMember__srt--RangeAxis__srt--MinimumMember_zv8b7B9C5fic" title="Net income threshold limit for salary payment">1,000,000</span>. </span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Walton shall be awarded <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20230421__20230421_zSemVfoNcL85">112,346</span> of the Company’s ‘C’ class preference shares on signing this agreement according to the following vesting schedule:</span></p> <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z7NvhuQWr2tl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zoDyWctF8Qji" style="display: none">Schedule of Preference Shares Awarded</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrWaltonMember_zQEDn9MgNkV4" title="Vesting schedule">On signing this agreement (April 21, 2023)</span></span></td> <td style="width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrWaltonMember_zufXz7HnFDvf" title="Number of shares awarded">28,088</span> ‘C’ class preference shares</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrWaltonMember_z1G8USityfE1">After 6 months (October 21, 2023)</span></span></td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrWaltonMember_zvffPd9PFhW2">28,086</span> ‘C’ class preference shares</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrWaltonMember_z8AMAP3KDZSc">After 12 months (April 21, 2024)</span></span></td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrWaltonMember_zvx4FfgZWFqj">28,086</span> ‘C’ class preference shares</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230421__20230421__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrWaltonMember_zYuepuVvsrz">After 18 months (October 21, 2024)</span></span></td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230421__20230421__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrWaltonMember_zgt2h5CwUqUh">28,086</span> ‘C’ class preference shares</span></td></tr> </table> <p id="xdx_8AE_zADO2yv10Nhh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended May 31, 2023 the Company recorded an expense of $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_c20230301__20230531__srt--TitleOfIndividualAxis__custom--MrWaltonMember_zMQq5hQ6T3rg" title="Share-based compensation expense">4,423,545</span> for the vested portion of the awards. The remaining unamortized amount of $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20230531__srt--TitleOfIndividualAxis__custom--MrWaltonMember_zf29i6rWmBm2" title="Unamortized expense amount">7,709,607</span> will be amortized over the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingencies</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company may be involved in legal matters arising in the ordinary course of business. While the Company believes that such matters are currently not material, there can be no assurance that matters arising in the ordinary course of business for which the Company is, or could be, involved in litigation, will not have a material adverse effect on its business, financial condition or results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 20000 121000 121000 121000 40333.33 40333.33 40333.33 PIP can mutually agree to allow the Company to list another ILO during this period and PIP will receive 50% of gross revenues. 1000000 10000000 Whoever brings the issuer will receive 75% of the gross revenues and whoever does not bring the issuer will receive 25% of the gross revenues 0.05 500000 0.25 3125000 0.04 125000 The Company agreed to grant PIP an option to purchase up to 50 HyFi vaults for $1,000. The option will expire on August 30, 2022 500000 100000000 125000 0.04 180000 1000000 1000000 112346 <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_z7NvhuQWr2tl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zoDyWctF8Qji" style="display: none">Schedule of Preference Shares Awarded</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrWaltonMember_zQEDn9MgNkV4" title="Vesting schedule">On signing this agreement (April 21, 2023)</span></span></td> <td style="width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrWaltonMember_zufXz7HnFDvf" title="Number of shares awarded">28,088</span> ‘C’ class preference shares</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrWaltonMember_z1G8USityfE1">After 6 months (October 21, 2023)</span></span></td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrWaltonMember_zvffPd9PFhW2">28,086</span> ‘C’ class preference shares</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrWaltonMember_z8AMAP3KDZSc">After 12 months (April 21, 2024)</span></span></td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230421__20230421__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrWaltonMember_zvx4FfgZWFqj">28,086</span> ‘C’ class preference shares</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230421__20230421__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrWaltonMember_zYuepuVvsrz">After 18 months (October 21, 2024)</span></span></td> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230421__20230421__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__srt--TitleOfIndividualAxis__custom--MrWaltonMember_zgt2h5CwUqUh">28,086</span> ‘C’ class preference shares</span></td></tr> </table> On signing this agreement (April 21, 2023) 28088 After 6 months (October 21, 2023) 28086 After 12 months (April 21, 2024) 28086 After 18 months (October 21, 2024) 28086 4423545 7709607 <p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zYnYA0ZEPMmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9. <span id="xdx_824_z3E37c8e2YN5">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 22, 2023 Diagonal converted $<span id="xdx_90A_eus-gaap--DebtConversionOriginalDebtAmount1_c20230621__20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zpe1pGkNVcw7" title="Debt principal amount converted">25,000</span> of principal into <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230621__20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zred48dJuba" title="Common stock issued in conversion">253,036</span> shares of common stock at the price of $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zuneL0KvdYjc" title="Debt conversion price">0.0988</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 27, 2023 Diagonal converted $<span id="xdx_900_eus-gaap--DebtConversionOriginalDebtAmount1_c20230626__20230627__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zNq5sfMRxl0l" title="Debt principal amount converted">25,000</span> of principal into <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230626__20230627__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zslTkFlwe9Kj" title="Common stock issued in conversion">300,120</span> shares of common stock at the price of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230627__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zT12ermv5G7d" title="Debt conversion price">0.0833</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 12, 2023 Diagonal converted $<span id="xdx_903_eus-gaap--DebtConversionOriginalDebtAmount1_c20230711__20230712__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zbhdMK1sV14l" title="Debt principal amount converted">22,000</span> of principal into <span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230711__20230712__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zR5ORVgQyHMf" title="Common stock issued in conversion">637,019</span> shares of common stock at the price of $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230712__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zl8QAMG7x4Rl" title="Debt conversion price">0.0416</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 14, 2023 Diagonal converted $<span id="xdx_90D_eus-gaap--DebtConversionOriginalDebtAmount1_c20230713__20230714__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_z2ghdUSEW4dh" title="Debt principal amount converted">20,000</span> of principal into <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230713__20230714__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_ztBax1eEpQvh" title="Common stock issued in conversion">480,769</span> shares of common stock at the price of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230714__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zQuL5JHExxI3" title="Debt conversion price">0.0416</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 28, 2023, the Company entered into a Securities Purchase Agreement by and between the Company and Fast Capital LLC. Pursuant to the terms of the Diagonal Lending SPA, the Company agreed to sell, and Diagonal Lending agreed to purchase, a convertible note of the Company in the aggregate principal amount of $<span id="xdx_90F_eus-gaap--DebtConversionOriginalDebtAmount1_c20230727__20230728__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zkwaTkpP5yMb" title="Debt principal amount converted">75,000</span>. The Note is convertible at <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentRate_c20230727__20230728__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zc0GYY6gAHo9" title="Debt principal amount, conversion rate">65%</span> of the lowest trading price of the Common Stock as reported on the National Quotations Bureau OTC. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 17, 2023, the Company entered into a Securities Purchase Agreement by and between the Company and 1800 Diagonal Lending LLC. Pursuant to the terms of the Diagonal Lending SPA, the Company agreed to sell, and Diagonal Lending agreed to purchase, a convertible note of the Company in the aggregate principal amount of $<span id="xdx_90C_eus-gaap--DebtConversionOriginalDebtAmount1_c20230716__20230717__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_z0FHzomDkA4" title="Debt principal amount converted">55,000</span>. See note 5 for terms.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 21, 2023, the Company entered into a Securities Purchase Agreement by and between the Company and 1800 Diagonal Lending LLC. Pursuant to the terms of the Diagonal Lending SPA, the Company agreed to sell, and Diagonal Lending agreed to purchase, a convertible note of the Company in the aggregate principal amount of $<span id="xdx_90A_eus-gaap--DebtConversionOriginalDebtAmount1_c20230820__20230821__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DiagonalLendingMember_zUPdndn8xj5c" title="Debt principal amount converted">10,000</span>. See note 5 for terms.</span></p> 25000 253036 0.0988 25000 300120 0.0833 22000 637019 0.0416 20000 480769 0.0416 75000 0.65 55000 10000 EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 45 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 233 194 1 false 70 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://biopowercorp.co.za/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://biopowercorp.co.za/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://biopowercorp.co.za/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://biopowercorp.co.za/role/StatementsOfOperations Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://biopowercorp.co.za/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) Sheet http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization Sheet http://biopowercorp.co.za/role/Organization Organization Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Notes Payable and Convertible Debt Notes http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebt Notes Payable and Convertible Debt Notes 9 false false R10.htm 00000010 - Disclosure - Related Party Transactions Sheet http://biopowercorp.co.za/role/RelatedPartyTransactions Related Party Transactions Notes 10 false false R11.htm 00000011 - Disclosure - Convertible loans Sheet http://biopowercorp.co.za/role/ConvertibleLoans Convertible loans Notes 11 false false R12.htm 00000012 - Disclosure - Senior Promissory Note ??? related party Sheet http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedParty Senior Promissory Note ??? related party Notes 12 false false R13.htm 00000013 - Disclosure - Stockholders??? deficit Sheet http://biopowercorp.co.za/role/StockholdersDeficit Stockholders??? deficit Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://biopowercorp.co.za/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Subsequent Events Sheet http://biopowercorp.co.za/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Notes Payable and Convertible Debt (Tables) Notes http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtTables Notes Payable and Convertible Debt (Tables) Tables http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebt 17 false false R18.htm 00000018 - Disclosure - Convertible loans (Tables) Sheet http://biopowercorp.co.za/role/ConvertibleLoansTables Convertible loans (Tables) Tables http://biopowercorp.co.za/role/ConvertibleLoans 18 false false R19.htm 00000019 - Disclosure - Stockholders??? deficit (Tables) Sheet http://biopowercorp.co.za/role/StockholdersDeficitTables Stockholders??? deficit (Tables) Tables http://biopowercorp.co.za/role/StockholdersDeficit 19 false false R20.htm 00000020 - Disclosure - Commitments and Contingencies (Tables) Sheet http://biopowercorp.co.za/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://biopowercorp.co.za/role/CommitmentsAndContingencies 20 false false R21.htm 00000021 - Disclosure - Organization (Details Narrative) Sheet http://biopowercorp.co.za/role/OrganizationDetailsNarrative Organization (Details Narrative) Details http://biopowercorp.co.za/role/Organization 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesPolicies 22 false false R23.htm 00000023 - Disclosure - Schedule of Notes Payable (Details) Notes http://biopowercorp.co.za/role/ScheduleOfNotesPayableDetails Schedule of Notes Payable (Details) Details 23 false false R24.htm 00000024 - Disclosure - Notes Payable and Convertible Debt (Details Narrative) Notes http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative Notes Payable and Convertible Debt (Details Narrative) Details http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtTables 24 false false R25.htm 00000025 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://biopowercorp.co.za/role/RelatedPartyTransactions 25 false false R26.htm 00000026 - Disclosure - Schedule of Amount Owed on Prepayment of Diagonal Lending Note (Details) Sheet http://biopowercorp.co.za/role/ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteDetails Schedule of Amount Owed on Prepayment of Diagonal Lending Note (Details) Details 26 false false R27.htm 00000027 - Disclosure - Convertible loans (Details Narrative) Sheet http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative Convertible loans (Details Narrative) Details http://biopowercorp.co.za/role/ConvertibleLoansTables 27 false false R28.htm 00000028 - Disclosure - Senior Promissory Note ??? related party (Details Narrative) Sheet http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative Senior Promissory Note ??? related party (Details Narrative) Details http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedParty 28 false false R29.htm 00000029 - Disclosure - Schedule of Preference Shares Awarded to an Employee (Details) Sheet http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedToEmployeeDetails Schedule of Preference Shares Awarded to an Employee (Details) Details 29 false false R30.htm 00000030 - Disclosure - Stockholders??? deficit (Details Narrative) Sheet http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative Stockholders??? deficit (Details Narrative) Details http://biopowercorp.co.za/role/StockholdersDeficitTables 30 false false R31.htm 00000031 - Disclosure - Schedule of Preference Shares Awarded (Details) Sheet http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails Schedule of Preference Shares Awarded (Details) Details 31 false false R32.htm 00000032 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://biopowercorp.co.za/role/CommitmentsAndContingenciesTables 32 false false R33.htm 00000033 - Disclosure - Subsequent Events (Details Narrative) Sheet http://biopowercorp.co.za/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://biopowercorp.co.za/role/SubsequentEvents 33 false false All Reports Book All Reports form10-q.htm bopo-20230531.xsd bopo-20230531_cal.xml bopo-20230531_def.xml bopo-20230531_lab.xml bopo-20230531_pre.xml ex31-1.htm ex31-2.htm ex32-1.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 49 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 22, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 661, "http://xbrl.sec.gov/dei/2023": 27 }, "contextCount": 233, "dts": { "calculationLink": { "local": [ "bopo-20230531_cal.xml" ] }, "definitionLink": { "local": [ "bopo-20230531_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "bopo-20230531_lab.xml" ] }, "presentationLink": { "local": [ "bopo-20230531_pre.xml" ] }, "schema": { "local": [ "bopo-20230531.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 384, "entityCount": 1, "hidden": { "http://biopowercorp.co.za/20230531": 1, "http://fasb.org/us-gaap/2023": 104, "http://xbrl.sec.gov/dei/2023": 4, "total": 109 }, "keyCustom": 21, "keyStandard": 173, "memberCustom": 47, "memberStandard": 21, "nsprefix": "BOPO", "nsuri": "http://biopowercorp.co.za/20230531", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://biopowercorp.co.za/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "10", "role": "http://biopowercorp.co.za/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "BOPO:DisclosureOfConvertibleLoansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Convertible loans", "menuCat": "Notes", "order": "11", "role": "http://biopowercorp.co.za/role/ConvertibleLoans", "shortName": "Convertible loans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "BOPO:DisclosureOfConvertibleLoansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "BOPO:SeniorPromissoryNoteRelatedPartyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Senior Promissory Note \u2013 related party", "menuCat": "Notes", "order": "12", "role": "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedParty", "shortName": "Senior Promissory Note \u2013 related party", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "BOPO:SeniorPromissoryNoteRelatedPartyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Stockholders\u2019 deficit", "menuCat": "Notes", "order": "13", "role": "http://biopowercorp.co.za/role/StockholdersDeficit", "shortName": "Stockholders\u2019 deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "14", "role": "http://biopowercorp.co.za/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "15", "role": "http://biopowercorp.co.za/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "16", "role": "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Notes Payable and Convertible Debt (Tables)", "menuCat": "Tables", "order": "17", "role": "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtTables", "shortName": "Notes Payable and Convertible Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "BOPO:DisclosureOfConvertibleLoansTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "BOPO:ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Convertible loans (Tables)", "menuCat": "Tables", "order": "18", "role": "http://biopowercorp.co.za/role/ConvertibleLoansTables", "shortName": "Convertible loans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "BOPO:DisclosureOfConvertibleLoansTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "BOPO:ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Stockholders\u2019 deficit (Tables)", "menuCat": "Tables", "order": "19", "role": "http://biopowercorp.co.za/role/StockholdersDeficitTables", "shortName": "Stockholders\u2019 deficit (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-11-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://biopowercorp.co.za/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "20", "role": "http://biopowercorp.co.za/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-11-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Organization (Details Narrative)", "menuCat": "Details", "order": "21", "role": "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "shortName": "Organization (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-06-282021-06-29_us-gaap_CommonStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:ConversionOfStockSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "menuCat": "Details", "order": "22", "role": "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-03-032022-03-04_custom_CanadianInvestorMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Schedule of Notes Payable (Details)", "menuCat": "Details", "order": "23", "role": "http://biopowercorp.co.za/role/ScheduleOfNotesPayableDetails", "shortName": "Schedule of Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-05-31_custom_DemandLoansMember", "decimals": "0", "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Notes Payable and Convertible Debt (Details Narrative)", "menuCat": "Details", "order": "24", "role": "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative", "shortName": "Notes Payable and Convertible Debt (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-11-30", "decimals": "0", "lang": null, "name": "us-gaap:InterestPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2015-07-28", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Related Party Transactions (Details Narrative)", "menuCat": "Details", "order": "25", "role": "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-05-31_us-gaap_RelatedPartyMember", "decimals": "0", "lang": null, "name": "us-gaap:InterestPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "BOPO:ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteTableTextBlock", "BOPO:DisclosureOfConvertibleLoansTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-05-31_custom_PrepaymentPeriodOneMember", "decimals": "INF", "first": true, "lang": null, "name": "BOPO:DebtInstrumentPrepaymentPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Schedule of Amount Owed on Prepayment of Diagonal Lending Note (Details)", "menuCat": "Details", "order": "26", "role": "http://biopowercorp.co.za/role/ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteDetails", "shortName": "Schedule of Amount Owed on Prepayment of Diagonal Lending Note (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "BOPO:ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteTableTextBlock", "BOPO:DisclosureOfConvertibleLoansTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-05-31_custom_PrepaymentPeriodOneMember", "decimals": "INF", "first": true, "lang": null, "name": "BOPO:DebtInstrumentPrepaymentPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2015-07-28", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Convertible loans (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative", "shortName": "Convertible loans (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "BOPO:DisclosureOfConvertibleLoansTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-05-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_ConvertibleDebtMember_custom_DiagonalLendingMember", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "p", "BOPO:SeniorPromissoryNoteRelatedPartyDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-29_custom_ChinaEnergyPartnersNoteAmendmentMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Senior Promissory Note \u2013 related party (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative", "shortName": "Senior Promissory Note \u2013 related party (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "BOPO:SeniorPromissoryNoteRelatedPartyDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-06-29_custom_ChinaEnergyPartnersNoteAmendmentMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-212023-04-21_us-gaap_SeriesCPreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Schedule of Preference Shares Awarded to an Employee (Details)", "menuCat": "Details", "order": "29", "role": "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedToEmployeeDetails", "shortName": "Schedule of Preference Shares Awarded to an Employee (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-11-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://biopowercorp.co.za/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-03-012022-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Stockholders\u2019 deficit (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "shortName": "Stockholders\u2019 deficit (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-06-282021-06-29_custom_HyFiMember", "decimals": "0", "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-212023-04-21_us-gaap_SeriesCPreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Schedule of Preference Shares Awarded (Details)", "menuCat": "Details", "order": "31", "role": "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails", "shortName": "Schedule of Preference Shares Awarded (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-04-212023-04-21_us-gaap_ShareBasedCompensationAwardTrancheOneMember_us-gaap_SeriesCPreferredStockMember_custom_MrWaltonMember", "decimals": null, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-03-012022-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Commitments and Contingencies (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-11-102022-11-11", "decimals": "INF", "lang": null, "name": "BOPO:CashPlacementFeeRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-02-172023-02-17_custom_DiagonalLendingMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtConversionOriginalDebtAmount1", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Subsequent Events (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://biopowercorp.co.za/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-07-132023-07-14_us-gaap_SubsequentEventMember_custom_DiagonalLendingMember", "decimals": "0", "lang": null, "name": "us-gaap:DebtConversionOriginalDebtAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-03-012022-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://biopowercorp.co.za/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-03-012022-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://biopowercorp.co.za/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-11-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit", "shortName": "Consolidated Statements of Changes in Stockholders' Deficit (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-11-30_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Organization", "menuCat": "Notes", "order": "7", "role": "http://biopowercorp.co.za/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Notes Payable and Convertible Debt", "menuCat": "Notes", "order": "9", "role": "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebt", "shortName": "Notes Payable and Convertible Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-12-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 70, "tag": { "BOPO_BaruchHalpernMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Baruch Halpern [Member]", "label": "Baruch Halpern [Member]" } } }, "localname": "BaruchHalpernMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_BioPowerCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bio power corporation [Member]", "label": "BioPower Corporation [Member]" } } }, "localname": "BioPowerCorporationMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_BonnieNelsonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bonnie Nelson [Member]", "label": "Bonnie Nelson [Member]" } } }, "localname": "BonnieNelsonMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_CanadianInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Canadian investor [Member]", "label": "Canadian Investor [Member]" } } }, "localname": "CanadianInvestorMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_CashPlacementFeeRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash placement fee rate.", "label": "Cash placement fee rate" } } }, "localname": "CashPlacementFeeRate", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "BOPO_ChiefExecutiveOfficerAndDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chief Executive Officer and Director [Member]", "label": "Chief Executive Officer and Director [Member]" } } }, "localname": "ChiefExecutiveOfficerAndDirectorMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_ChinaEnergyPartnersLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "China Energy Partners LLC [Member]", "label": "China Energy Partners LLC [Member]" } } }, "localname": "ChinaEnergyPartnersLLCMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_ChinaEnergyPartnersNoteAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "China Energy Partners Note Amendment [Member]", "label": "China Energy Partners Note Amendment [Member]" } } }, "localname": "ChinaEnergyPartnersNoteAmendmentMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_CommonStockOwedValue": { "auth_ref": [], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock owed value.", "label": "Common Stock owed" } } }, "localname": "CommonStockOwedValue", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "BOPO_CommonStockPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Payable [Member]", "label": "Common Stock Payable [Member]" } } }, "localname": "CommonStockPayableMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "BOPO_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultant [Member].", "label": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_ConvertibleDebtAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Debt Agreement [Member]", "label": "Convertible Debt Agreement [Member]" } } }, "localname": "ConvertibleDebtAgreementMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_ConvertibleDebtVariablePricedConversionCurrent": { "auth_ref": [], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Convertible debt variable priced conversion current.", "label": "Convertible debt variable priced conversion" } } }, "localname": "ConvertibleDebtVariablePricedConversionCurrent", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "BOPO_DebtInstrumentPrepaymentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt prepayment percentage.", "label": "Prepayment, rate" } } }, "localname": "DebtInstrumentPrepaymentPercentage", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteDetails" ], "xbrltype": "percentItemType" }, "BOPO_DebtTransferAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt transfer amount.", "label": "Debt transfer amount" } } }, "localname": "DebtTransferAmount", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BOPO_DemandLoanAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Demand Loan Agreements [Member]", "label": "Demand Loan Agreements [Member]" } } }, "localname": "DemandLoanAgreementsMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_DemandLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Demand Loans [Member]", "label": "Demand Loans [Member]" } } }, "localname": "DemandLoansMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "BOPO_DerivativeResolution": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative resolution.", "label": "Derivative resolution" } } }, "localname": "DerivativeResolution", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "BOPO_DiagonalLendingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Diagonal Lending [Member]", "label": "Diagonal Lending [Member]" } } }, "localname": "DiagonalLendingMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative", "http://biopowercorp.co.za/role/SubsequentEventsDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_DigitalArtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Digital Art [Member]", "label": "Digital Art [Member]" } } }, "localname": "DigitalArtMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_DirectorOfBusinessStrategyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Director Of Business Strategy [Member]", "label": "Director Of Business Strategy [Member]" } } }, "localname": "DirectorOfBusinessStrategyMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_DisclosureConvertibleLoansAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Loans" } } }, "localname": "DisclosureConvertibleLoansAbstract", "nsuri": "http://biopowercorp.co.za/20230531", "xbrltype": "stringItemType" }, "BOPO_DisclosureOfConvertibleLoansTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible loans [Text Block]", "label": "Convertible loans" } } }, "localname": "DisclosureOfConvertibleLoansTextBlock", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoans" ], "xbrltype": "textBlockItemType" }, "BOPO_DisclosureSeniorPromissoryNoteRelatedPartyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Promissory Note Related Party" } } }, "localname": "DisclosureSeniorPromissoryNoteRelatedPartyAbstract", "nsuri": "http://biopowercorp.co.za/20230531", "xbrltype": "stringItemType" }, "BOPO_ExclusiveLicenseOptionsYearFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exclusive License Options Year Five [Member]", "label": "Exclusive License Options Year Five [Member]" } } }, "localname": "ExclusiveLicenseOptionsYearFiveMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_ExclusiveLicenseOptionsYearOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exclusive License Options Year One [Member]", "label": "Exclusive License Options Year One [Member]" } } }, "localname": "ExclusiveLicenseOptionsYearOneMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_FiveCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Customers [Member]", "label": "Five Customers [Member]" } } }, "localname": "FiveCustomersMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_GenerationPowerGroupLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Generation Power Group Limited [Member]", "label": "Generation Power Group Limited [Member]" } } }, "localname": "GenerationPowerGroupLimitedMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_GoingConcernPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Going Concern Policy [TextBlock]", "label": "Going Concern" } } }, "localname": "GoingConcernPolicyTextBlock", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "BOPO_GrossRevenueDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross revenue description.", "label": "Gross revenue, description" } } }, "localname": "GrossRevenueDescription", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "BOPO_GrossSalesCustomaryPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross sales customary percentage.", "label": "Gross sales percentage" } } }, "localname": "GrossSalesCustomaryPercentage", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "pureItemType" }, "BOPO_HyFiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HyFi [Member]", "label": "HyFi [Member]" } } }, "localname": "HyFiMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_HyFiTokensMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HyFi Tokens [Member]", "label": "HyFi Tokens [Member]" } } }, "localname": "HyFiTokensMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_ILOAndMultiAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ILO and Multi Agreement [Member]", "label": "ILO and Multi Agreement [Member]" } } }, "localname": "ILOAndMultiAgreementMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_LenderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lender [Member]", "label": "Lender [Member]" } } }, "localname": "LenderMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_MrComptonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr. Compton [Member]", "label": "Mr. Compton [Member]" } } }, "localname": "MrComptonMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_MrWaltonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr Walton [Member]", "label": "Mr Walton [Member]" } } }, "localname": "MrWaltonMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails" ], "xbrltype": "domainItemType" }, "BOPO_NetIncomeThresholdLimitForSalaryPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net income threshold limit for salary payment", "label": "Net income threshold limit for salary payment" } } }, "localname": "NetIncomeThresholdLimitForSalaryPayment", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BOPO_NetInvestmentThresholdLimitForSalaryPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net investment threshold limit for salary payment.", "label": "Net investment threshold limit for salary payment" } } }, "localname": "NetInvestmentThresholdLimitForSalaryPayment", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BOPO_NumberOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of assets.", "label": "Number of assets" } } }, "localname": "NumberOfAssets", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "integerItemType" }, "BOPO_NumberOfTokensIssuedToPurchaseAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of tokens issued to purchase assets.", "label": "Number of tokens, issued" } } }, "localname": "NumberOfTokensIssuedToPurchaseAssets", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "integerItemType" }, "BOPO_PIPAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PIP Agreement [Member]", "label": "PIP Agreement [Member]" } } }, "localname": "PIPAgreementMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_PrepaymentPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "May 31, 2022 to July 30, 2022 [Member]", "label": "May 31, 2022 to July 30, 2022 [Member]" } } }, "localname": "PrepaymentPeriodOneMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteDetails" ], "xbrltype": "domainItemType" }, "BOPO_PrepaymentPeriodThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "October 29, 2022 to November 27, 2022 [Member]", "label": "October 29, 2022 to November 27, 2022 [Member]" } } }, "localname": "PrepaymentPeriodThreeMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteDetails" ], "xbrltype": "domainItemType" }, "BOPO_PrepaymentPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "July 31, 2022 to October 28, 2022 [Member]", "label": "July 31, 2022 to October 28, 2022 [Member]" } } }, "localname": "PrepaymentPeriodTwoMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteDetails" ], "xbrltype": "domainItemType" }, "BOPO_PurchaseOfVaultsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase of vaults description.", "label": "Purchase of vaults, description" } } }, "localname": "PurchaseOfVaultsDescription", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "BOPO_ReclassificationOfAccruedCompensationToNotesPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reclassification Of Accrued Compensation To Notes Payable [Member]", "label": "Reclassification of Accrued Compensation To Notes Payable [Member]" } } }, "localname": "ReclassificationOfAccruedCompensationToNotesPayableMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "BOPO_RedemptionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption Agreement [Member]", "label": "Redemption Agreement [Member]" } } }, "localname": "RedemptionAgreementMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_ReductionInLiabilityShareIssurance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reduction in liability share issurance.", "label": "Reduction in liability insurance" } } }, "localname": "ReductionInLiabilityShareIssurance", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BOPO_RestrictedCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Common Stock [Member]", "label": "Restricted Common Stock [Member]" } } }, "localname": "RestrictedCommonStockMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_RobertKohnMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Robert Kohn [Member]", "label": "Robert Kohn [Member]" } } }, "localname": "RobertKohnMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_SaleOfTokensMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of Tokens [Member]", "label": "Sale of Tokens [Member]" } } }, "localname": "SaleOfTokensMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "domainItemType" }, "BOPO_SaleOfTokensRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of Tokens - Related Party [Member]", "label": "Sale of Tokens - Related Party [Member]" } } }, "localname": "SaleOfTokensRelatedPartyMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "domainItemType" }, "BOPO_SanctumAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sanctum Agreement [Member]", "label": "Sanctum Agreement [Member]" } } }, "localname": "SanctumAgreementMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Amount Owed on Prepayment of Diagonal Lending Note [TableTextBlock]", "label": "Schedule of Amount Owed on Prepayment of Diagonal Lending Note" } } }, "localname": "ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteTableTextBlock", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansTables" ], "xbrltype": "textBlockItemType" }, "BOPO_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities Purchase Agreement [Member]", "label": "Securities Purchase Agreement [Member]" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative", "http://biopowercorp.co.za/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_SeniorPromissoryNoteRelatedPartyDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Promissory Note Related Party [Disclosure Text Block]", "label": "Senior Promissory Note \u2013 related party" } } }, "localname": "SeniorPromissoryNoteRelatedPartyDisclosureTextBlock", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedParty" ], "xbrltype": "textBlockItemType" }, "BOPO_ShareBasedCompensationAwardTrancheFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Award Tranche Four [Member]", "label": "Share-Based Compensation Award Tranche Four [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheFourMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedToEmployeeDetails" ], "xbrltype": "domainItemType" }, "BOPO_TechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Technology [Member]", "label": "Technology [Member]" } } }, "localname": "TechnologyMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_ThirdPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Parties [Member]", "label": "Third Parties [Member]" } } }, "localname": "ThirdPartiesMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_ThirdPartyInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Party Investor [Member]", "label": "Third Party Investor [Member]" } } }, "localname": "ThirdPartyInvestorMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative", "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_ThirdPartyInvestorOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Party Investor One [Member]", "label": "Third Party Investor One [Member]" } } }, "localname": "ThirdPartyInvestorOneMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_ThirdPartyInvestorThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Party Investor Three [Member]", "label": "Third Party Investor Three [Member]" } } }, "localname": "ThirdPartyInvestorThreeMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_ThirdPartyInvestorTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Party Investor Two [Member]", "label": "Third Party Investor Two [Member]" } } }, "localname": "ThirdPartyInvestorTwoMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_ThreeNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Notes [Member]", "label": "Three Notes [Member]" } } }, "localname": "ThreeNotesMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_TokenPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Token price.", "label": "Token price" } } }, "localname": "TokenPrice", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "BOPO_TokensIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tokens issued during period shares new issues.", "label": "Tokens issued during period shares" } } }, "localname": "TokensIssuedDuringPeriodSharesNewIssues", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "BOPO_TokensIssuedDuringPeriodSharesNewIssuesValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tokens issued during period shares new issues value", "label": "Tokens issued during period value new issues" } } }, "localname": "TokensIssuedDuringPeriodSharesNewIssuesValue", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "BOPO_TroyMacDonaldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Troy Mac Donald [Member]", "label": "Troy Mac Donald [Member]" } } }, "localname": "TroyMacDonaldMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "BOPO_TwoCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Customers [Member]", "label": "Two Customers [Member]" } } }, "localname": "TwoCustomersMember", "nsuri": "http://biopowercorp.co.za/20230531", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r642" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r642" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r639", "r641", "r642" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r640" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r628" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r643" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r634" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r647" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r644" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r642" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r641" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r635" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r637" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biopowercorp.co.za/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r673" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ChiefOperatingOfficerMember": { "auth_ref": [ "r673", "r722" ], "lang": { "en-us": { "role": { "label": "Chief Operating Officer [Member]" } } }, "localname": "ChiefOperatingOfficerMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [ "r236", "r237", "r238" ], "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r200", "r610", "r689", "r735", "r736" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r257", "r258", "r259", "r260", "r329", "r452", "r485", "r516", "r517", "r578", "r579", "r580", "r581", "r582", "r591", "r592", "r601", "r608", "r613", "r616", "r687", "r726", "r727", "r728", "r729", "r730", "r731" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r257", "r258", "r259", "r260", "r329", "r452", "r485", "r516", "r517", "r578", "r579", "r580", "r581", "r582", "r591", "r592", "r601", "r608", "r613", "r616", "r687", "r726", "r727", "r728", "r729", "r730", "r731" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r200", "r610", "r689", "r735", "r736" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r198", "r454", "r479", "r480", "r481", "r482", "r483", "r484", "r594", "r609", "r615", "r651", "r683", "r684", "r689", "r735" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r198", "r454", "r479", "r480", "r481", "r482", "r483", "r484", "r594", "r609", "r615", "r651", "r683", "r684", "r689", "r735" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r257", "r258", "r259", "r260", "r327", "r329", "r359", "r360", "r361", "r428", "r452", "r485", "r516", "r517", "r578", "r579", "r580", "r581", "r582", "r591", "r592", "r601", "r608", "r613", "r616", "r619", "r679", "r687", "r727", "r728", "r729", "r730", "r731" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r257", "r258", "r259", "r260", "r327", "r329", "r359", "r360", "r361", "r428", "r452", "r485", "r516", "r517", "r578", "r579", "r580", "r581", "r582", "r591", "r592", "r601", "r608", "r613", "r616", "r619", "r679", "r687", "r727", "r728", "r729", "r730", "r731" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r236", "r237", "r238" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r673", "r722" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r201", "r202" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrentAndNoncurrent": { "auth_ref": [ "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.", "label": "Accrued salary" } } }, "localname": "AccruedSalariesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r82", "r614", "r738" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r365", "r366", "r367", "r504", "r669", "r670", "r671", "r717", "r740" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Adjustments to Additional Paid in Capital, Other", "verboseLabel": "Derivative resolution" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r56", "r57", "r332" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "verboseLabel": "Stock based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r363", "r372" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r6", "r65", "r91", "r292" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative", "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative", "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "http://biopowercorp.co.za/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r110", "r134", "r157", "r186", "r192", "r196", "r239", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r385", "r387", "r400", "r469", "r537", "r614", "r627", "r685", "r686", "r724" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r334", "r335", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r358", "r359", "r360", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BankOverdrafts": { "auth_ref": [ "r18", "r43" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of payments made in excess of existing cash balances, which will be honored by the bank but reflected as a loan to the entity. Overdrafts generally have a very short time frame for correction or repayment and are therefore more similar to short-term bank financing than trade financing.", "label": "Cash overdraft" } } }, "localname": "BankOverdrafts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r382", "r611", "r612" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r59", "r61", "r382", "r611", "r612" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.", "label": "Business combination description" } } }, "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Number of shares issued as consideration" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r0", "r1", "r10" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Cash consideration, acquisition" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r28", "r133", "r595" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "verboseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r28", "r93", "r153" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r2", "r93" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r128", "r135", "r136", "r137", "r157", "r176", "r177", "r179", "r181", "r184", "r185", "r239", "r261", "r263", "r264", "r265", "r268", "r269", "r301", "r302", "r305", "r308", "r315", "r400", "r496", "r497", "r498", "r499", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r525", "r546", "r569", "r583", "r584", "r585", "r586", "r587", "r648", "r664", "r672" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets", "http://biopowercorp.co.za/role/BalanceSheetsParenthetical", "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedToEmployeeDetails", "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative", "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [ "r135", "r136", "r137", "r184", "r301", "r302", "r303", "r305", "r308", "r313", "r315", "r496", "r497", "r498", "r499", "r608", "r648", "r664" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedToEmployeeDetails", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r23", "r72", "r470", "r524" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies (Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r100", "r255", "r256", "r590", "r680" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r617", "r618", "r619", "r621", "r622", "r623", "r624", "r669", "r670", "r717", "r737", "r740" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheetsParenthetical", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r81", "r525" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheetsParenthetical", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheetsParenthetical", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r11", "r81", "r525", "r543", "r740", "r741" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheetsParenthetical", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r81", "r472", "r614" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.0001 par value: 500,000,000 authorized;45,867,915 and 45,625,000 issued and outstanding on May 31 2023 and November 30, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r36", "r38", "r63", "r64", "r200", "r589" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r36", "r38", "r63", "r64", "r200", "r491", "r589" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r36", "r38", "r63", "r64", "r200", "r589", "r650" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r74", "r123" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r36", "r38", "r63", "r64", "r200" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r36", "r38", "r63", "r64", "r200", "r589" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r62", "r597" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockDescription": { "auth_ref": [ "r31", "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of stock, description" } } }, "localname": "ConversionOfStockDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r31", "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Stock conversion, issued shares", "verboseLabel": "Conversion of stock shares issued" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r14", "r113", "r734" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt", "verboseLabel": "Convertible debt" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r77" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible debt" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r102", "r271", "r272", "r282", "r283", "r284", "r288", "r289", "r290", "r291", "r292", "r603", "r604", "r605", "r606", "r607" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative", "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r77", "r111" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r37", "r200" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentRate": { "auth_ref": [ "r31", "r33" ], "lang": { "en-us": { "role": { "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.", "label": "Debt principal amount, conversion rate" } } }, "localname": "DebtConversionConvertedInstrumentRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r31", "r33" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Common stock issued in conversion" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative", "http://biopowercorp.co.za/role/SubsequentEventsDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r31", "r33" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt principal amount converted" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative", "http://biopowercorp.co.za/role/SubsequentEventsDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r101", "r155", "r270", "r276", "r277", "r278", "r279", "r280", "r281", "r286", "r293", "r294", "r296" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Notes Payable and Convertible Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "auth_ref": [ "r14" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the total principal payments made during the annual reporting period.", "label": "Debt payment amount" } } }, "localname": "DebtInstrumentAnnualPrincipalPayment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r77", "r78", "r111", "r113", "r160", "r271", "r272", "r273", "r274", "r275", "r277", "r282", "r283", "r284", "r285", "r287", "r288", "r289", "r290", "r291", "r292", "r409", "r603", "r604", "r605", "r606", "r607", "r665" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative", "http://biopowercorp.co.za/role/ScheduleOfNotesPayableDetails", "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r103", "r273" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt conversion price", "terseLabel": "Debt instrument, conversion price", "verboseLabel": "Conversion price per share" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative", "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative", "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative", "http://biopowercorp.co.za/role/SubsequentEventsDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt instrument, conversion rate" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentDescription": { "auth_ref": [ "r14", "r48", "r73", "r77", "r111", "r113" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "Debt instrument, description" } } }, "localname": "DebtInstrumentDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative", "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r66", "r68", "r271", "r409", "r604", "r605" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt instrument, principal amount", "terseLabel": "Principal amount", "verboseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative", "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative", "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r20", "r66", "r289" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt default, interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r20", "r66", "r298", "r409" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt instrument, original percentage", "verboseLabel": "Debt instrument, interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative", "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r20", "r272" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Interest rate", "terseLabel": "Debt instrument, interest rate", "verboseLabel": "Debt instrument, interest" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative", "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative", "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative", "http://biopowercorp.co.za/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r126", "r603", "r718" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "verboseLabel": "Debt instrument, maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative", "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r22", "r160", "r271", "r272", "r273", "r274", "r275", "r277", "r282", "r283", "r284", "r285", "r287", "r288", "r289", "r290", "r291", "r292", "r409", "r603", "r604", "r605", "r606", "r607", "r665" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative", "http://biopowercorp.co.za/role/ScheduleOfNotesPayableDetails", "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r659" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r716" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://biopowercorp.co.za/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Loss on derivative", "negatedLabel": "Loss on derivative" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows", "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r140" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r9", "r53" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Schedule of Preference Shares Awarded to an Employee" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r4", "r107" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividend resolution" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r148", "r166", "r167", "r168", "r169", "r170", "r174", "r176", "r179", "r180", "r181", "r182", "r398", "r399", "r467", "r478", "r599" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per common share: basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r148", "r166", "r167", "r168", "r169", "r170", "r176", "r179", "r180", "r181", "r182", "r398", "r399", "r467", "r478", "r599" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per common share: diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r34", "r35" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Loss per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r364" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unamortized expense amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r11", "r129", "r144", "r145", "r146", "r161", "r162", "r163", "r165", "r171", "r173", "r183", "r240", "r241", "r316", "r365", "r366", "r367", "r380", "r381", "r389", "r390", "r391", "r392", "r393", "r394", "r397", "r401", "r402", "r403", "r404", "r405", "r406", "r410", "r486", "r487", "r488", "r504", "r569" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Ownership, percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r295", "r313", "r395", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r477", "r602", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r674", "r675", "r676", "r677" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r143", "r374", "r375", "r376", "r377", "r378", "r379", "r495" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r5" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r5" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Accounts payable and accrued expenses - related party" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r5" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Increase in accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedSalaries": { "auth_ref": [ "r5" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in accrued salaries.", "label": "Decrease in accrued salaries" } } }, "localname": "IncreaseDecreaseInAccruedSalaries", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r5" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Reduction in accrued compensation" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r5" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Increase in inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Reduction in long term debt" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r5" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Increase in prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r253", "r254" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r42", "r98" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IndefiniteLivedLicenseAgreements": { "auth_ref": [ "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the capitalized costs to acquire rights under a license arrangement (for example, to sell specified products in a specified territory) having an indefinite period of benefit.", "label": "Exclusive license Amount" } } }, "localname": "IndefiniteLivedLicenseAgreements", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r67", "r116", "r147", "r189", "r408", "r554", "r625", "r739" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r91", "r290", "r299", "r606", "r607" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r149", "r151", "r152" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r18" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "verboseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r71", "r733" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Accrued interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivable": { "auth_ref": [ "r662", "r742" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.", "label": "Accurued interest" } } }, "localname": "InterestReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r139", "r596", "r614" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r120", "r132", "r138", "r250", "r251", "r252", "r453", "r598" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r720", "r721" ], "lang": { "en-us": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Onboarding fee" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r86", "r114", "r474", "r614", "r666", "r678", "r719" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders\u2019 Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r19", "r131", "r157", "r239", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r386", "r387", "r388", "r400", "r614", "r685", "r724", "r725" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r14", "r113", "r734" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Loans payable" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r14", "r113", "r283", "r297", "r604", "r605", "r734" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r22", "r44" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r150" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flow from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r93", "r94", "r95" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r87", "r95", "r115", "r130", "r141", "r142", "r146", "r157", "r164", "r166", "r167", "r168", "r169", "r172", "r173", "r178", "r186", "r191", "r195", "r197", "r239", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r399", "r400", "r476", "r545", "r567", "r568", "r600", "r625", "r685" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://biopowercorp.co.za/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows", "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit", "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r90" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expenses" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonrelatedPartyMember": { "auth_ref": [ "r667", "r668" ], "lang": { "en-us": { "role": { "documentation": "Party not related to reporting entity.", "label": "Nonrelated Party [Member]" } } }, "localname": "NonrelatedPartyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets", "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r14", "r113", "r734" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Balance", "verboseLabel": "Notes payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative", "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative", "http://biopowercorp.co.za/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r663" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Base salary annual rate" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://biopowercorp.co.za/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r186", "r191", "r195", "r197", "r600" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income / (Loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r76", "r109", "r492", "r493" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other expenses" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNotesPayable": { "auth_ref": [ "r14", "r113", "r734" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes payable classified as other.", "label": "Other Notes Payable", "verboseLabel": "Notes payable" } } }, "localname": "OtherNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r26", "r383" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "verboseLabel": "Cash consideration, acquisition" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payment of exchange" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConversionBasis": { "auth_ref": [ "r48", "r80" ], "lang": { "en-us": { "role": { "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.", "label": "Preferred stock, conversion basis" } } }, "localname": "PreferredStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r617", "r618", "r621", "r622", "r623", "r624", "r737", "r740" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r80", "r301" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheetsParenthetical", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r80", "r525" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheetsParenthetical", "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r80", "r301" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheetsParenthetical", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r80", "r525", "r543", "r740", "r741" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheetsParenthetical", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r80", "r471", "r614" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock , value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r48", "r80" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred stock, voting rights", "verboseLabel": "Preferred stock voting rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ProceedsFromBankDebt": { "auth_ref": [ "r27" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from bank borrowing during the year.", "label": "Bank overdraft" } } }, "localname": "ProceedsFromBankDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r3" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ProductLiabilityContingencyLineItems": { "auth_ref": [ "r259", "r681", "r682", "r683" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Liability Contingency [Line Items]" } } }, "localname": "ProductLiabilityContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ProductLiabilityContingencyTable": { "auth_ref": [ "r259", "r681", "r682", "r683" ], "lang": { "en-us": { "role": { "documentation": "Information and financial data about the reasonably possible loss or the recognized and additional reasonably possible loss from product liability related to an individual product.", "label": "Product Liability Contingency [Table]" } } }, "localname": "ProductLiabilityContingencyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r7", "r468", "r475", "r614" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Value of purchased assets" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r328", "r414", "r415", "r519", "r520", "r521", "r522", "r523", "r542", "r544", "r577" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets", "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative", "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative", "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative", "http://biopowercorp.co.za/role/StatementsOfOperations", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "http://biopowercorp.co.za/role/SubsequentEventsDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyMember": { "auth_ref": [ "r158", "r159", "r414", "r415", "r416", "r417", "r519", "r520", "r521", "r522", "r523", "r542", "r544", "r577" ], "lang": { "en-us": { "role": { "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.", "label": "Related Party [Member]" } } }, "localname": "RelatedPartyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets", "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative", "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [ "r549", "r550", "r553" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.", "label": "Related party token sales, rate" } } }, "localname": "RelatedPartyTransactionRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r328", "r414", "r415", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r519", "r520", "r521", "r522", "r523", "r542", "r544", "r577", "r723" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets", "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative", "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative", "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative", "http://biopowercorp.co.za/role/StatementsOfOperations", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "http://biopowercorp.co.za/role/SubsequentEventsDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r411", "r412", "r413", "r415", "r418", "r501", "r502", "r503", "r551", "r552", "r553", "r574", "r576" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r75", "r373", "r732" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r83", "r107", "r473", "r489", "r490", "r500", "r526", "r614" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r129", "r161", "r162", "r163", "r165", "r171", "r173", "r240", "r241", "r365", "r366", "r367", "r380", "r381", "r389", "r391", "r392", "r394", "r397", "r486", "r488", "r504", "r740" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r187", "r188", "r190", "r193", "r194", "r198", "r199", "r200", "r325", "r326", "r454" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Total Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r127", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r593" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Share purchase price" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "verboseLabel": "Number of shares issued" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r200", "r649" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Notes Payable" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r69", "r70", "r549", "r550", "r553" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r12", "r13", "r55" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Schedule of Preference Shares Awarded" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r331", "r333", "r334", "r335", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r358", "r359", "r360", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteDetails", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative", "http://biopowercorp.co.za/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r45", "r46", "r47", "r48", "r49", "r50", "r51", "r105", "r106", "r107", "r135", "r136", "r137", "r184", "r301", "r302", "r303", "r305", "r308", "r313", "r315", "r496", "r497", "r498", "r499", "r608", "r648", "r664" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedToEmployeeDetails", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r89" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r660", "r661", "r688" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets", "http://biopowercorp.co.za/role/BalanceSheetsParenthetical", "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative", "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [ "r660", "r661", "r688" ], "lang": { "en-us": { "role": { "documentation": "Series C preferred stock.", "label": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets", "http://biopowercorp.co.za/role/BalanceSheetsParenthetical", "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedToEmployeeDetails", "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r5" ], "calculation": { "http://biopowercorp.co.za/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Vesting schedule" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedToEmployeeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r331", "r333", "r334", "r335", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r358", "r359", "r360", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteDetails", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r697" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Number of shares awarded" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedToEmployeeDetails", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Outstanding shares, percentage" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r334", "r335", "r336", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r358", "r359", "r360", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfAmountOwedOnPrepaymentOfDiagonalLendingNoteDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche One [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedToEmployeeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche Three [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedToEmployeeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche Two [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedToEmployeeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r330", "r337", "r356", "r357", "r358", "r359", "r362", "r368", "r369", "r370", "r371" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Share issued price per share", "verboseLabel": "Issue price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative", "http://biopowercorp.co.za/role/ScheduleOfNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r96", "r154" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r128", "r135", "r136", "r137", "r157", "r176", "r177", "r179", "r181", "r184", "r185", "r239", "r261", "r263", "r264", "r265", "r268", "r269", "r301", "r302", "r305", "r308", "r315", "r400", "r496", "r497", "r498", "r499", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r525", "r546", "r569", "r583", "r584", "r585", "r586", "r587", "r648", "r664", "r672" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets", "http://biopowercorp.co.za/role/BalanceSheetsParenthetical", "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedToEmployeeDetails", "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative", "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r11", "r25", "r129", "r144", "r145", "r146", "r161", "r162", "r163", "r165", "r171", "r173", "r183", "r240", "r241", "r316", "r365", "r366", "r367", "r380", "r381", "r389", "r390", "r391", "r392", "r393", "r394", "r397", "r401", "r402", "r403", "r404", "r405", "r406", "r410", "r486", "r487", "r488", "r504", "r569" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r161", "r162", "r163", "r183", "r454", "r494", "r515", "r518", "r519", "r520", "r521", "r522", "r523", "r525", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r542", "r544", "r547", "r548", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r569", "r620" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets", "http://biopowercorp.co.za/role/BalanceSheetsParenthetical", "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative", "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit", "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r161", "r162", "r163", "r183", "r454", "r494", "r515", "r518", "r519", "r520", "r521", "r522", "r523", "r525", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r542", "r544", "r547", "r548", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r569", "r620" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets", "http://biopowercorp.co.za/role/BalanceSheetsParenthetical", "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative", "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit", "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "auth_ref": [ "r52", "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture", "verboseLabel": "Value of shares issued" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r31", "r32", "r33" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Conversion of Convertible debentures to common stock" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r80", "r81", "r107" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Number of consideration shares" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r11", "r24", "r48", "r107", "r287" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Conversion of notes payable, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r11", "r80", "r81", "r107", "r496", "r569", "r584" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Sale of common stock, shares", "terseLabel": "Shares issued, shares", "verboseLabel": "Shares of restriced common stock" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r11", "r80", "r81", "r107" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Restricted common stock issued, shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r11", "r25", "r107" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversion of notes payable" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Value of shares issued" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r11", "r80", "r81", "r107", "r504", "r569", "r584", "r626" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Sale of common stock", "terseLabel": "Offering to investors", "verboseLabel": "Value of shares issued" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r11", "r107" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Restricted common stock issued" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r81", "r84", "r85", "r97", "r527", "r543", "r570", "r571", "r614", "r627", "r666", "r678", "r719", "r740" ], "calculation": { "http://biopowercorp.co.za/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "negatedLabel": "Stockholders' deficit", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders \u2018deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets", "http://biopowercorp.co.za/role/StatementsOfChangesInStockholdersDeficit", "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r104", "r156", "r300", "r302", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r314", "r316", "r396", "r572", "r575", "r588" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]", "verboseLabel": "Stockholders\u2019 deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityPolicyTextBlock": { "auth_ref": [ "r8", "r573" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.", "label": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [ "r407", "r420" ], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r407", "r420" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r407", "r420" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r407", "r420" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r407", "r420" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r419", "r421" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r117", "r118", "r119", "r203", "r204", "r205" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r295", "r313", "r395", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r477", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r674", "r675", "r676", "r677" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/CommitmentsAndContingenciesDetailsNarrative", "http://biopowercorp.co.za/role/ConvertibleLoansDetailsNarrative", "http://biopowercorp.co.za/role/NotesPayableAndConvertibleDebtDetailsNarrative", "http://biopowercorp.co.za/role/OrganizationDetailsNarrative", "http://biopowercorp.co.za/role/SeniorPromissoryNoteRelatedPartyDetailsNarrative", "http://biopowercorp.co.za/role/StockholdersDeficitDetailsNarrative", "http://biopowercorp.co.za/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r39", "r40", "r41", "r121", "r122", "r124", "r125" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedToEmployeeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedDetails", "http://biopowercorp.co.za/role/ScheduleOfPreferenceSharesAwardedToEmployeeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r175", "r181" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average common shares outstanding: diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r174", "r181" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average common shares outstanding: basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WorkersCompensationLiabilityCurrentAndNoncurrent": { "auth_ref": [ "r78", "r79", "r112" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature.", "label": "Accrued compensation" } } }, "localname": "WorkersCompensationLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://biopowercorp.co.za/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org//330/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.C.Q3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480513/718-10-30-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480843/718-30-35-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r628": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r629": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r631": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r632": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r633": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r634": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r635": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r636": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r637": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r638": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r639": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r641": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r642": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r643": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r644": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r645": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r646": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r647": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 50 0001493152-23-029788-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-029788-xbrl.zip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end